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Important Definitions 
 
Acute Coronary 
Syndrome  
ACS is a series of conditions which include chest discomfort or any other 
symptoms caused by decreased oxygen supply to the myocardium.  Coronary 
artery disease caused by erosion, fissuring, or rupture of a plaque (American 
Heart Association 2004). 
Anti-Inflammatory 
Reducing inflammation by acting on body responses, without directly 
antagonizing the causative agent (WebMD, 2006). 
Atherogenesis 
Patients with occlusive atherosclerotic vascular diseases regularly develop 
collateral blood vessels that bypass areas of arterial obstructions.  The growth 
of these collateral arteries has been termed “arteriogenesis” (Cai and Schaper, 
2008). 
Atherosclerosis 
Atherosclerosis is a condition of progressive thickening and hardening of the 
walls of medium-sized and large arteries in which cholesterol, fat, calcium, and 
other substances build up in the walls of arteries (Medicinenet.com, 2011). 
Atherothrombosis 
A condition in which a thrombus originates in an atheromatous blood vessel 
(http://medicaldictionary.thefreedictionary.com, 2007). 
Coronary Artery 
Bypass Graft 
(CABG) 
Coronary artery bypass graft (CABG) surgery is a surgical procedure performed 
to alleviate angina symptoms and reduce the risk of death as a result from 
coronary artery disease.  Veins are grafted to the diseased coronary artery to 
restore coronary circulation of oxygen rich blood (Medicinenet.com, 2011). 
CABG Off-Pump 
Coronary artery bypass graft surgery done without the use of a heart-lung 
machine (Medicinenet.com, 2004). 
CABG On-Pump 
Coronary artery bypass graft surgery done with the use of a heart lung machine 
(Medicinenet.com, 2004). 
Cardiopulmonary 
Bypass 
A procedure to mechanically circulate and oxygenate the blood while surgery is 
performed on the heart, thus providing a motionless, bloodless operating field 
for the surgeon to operate.  Draining oxygen poor blood from the heart through 
the heart-lung machine, and then returning oxygen rich blood back to the body 
(Medicinenet.com, 2011). 
Clinical Outcomes 
A reflection of the data obtained from the result of a treatment procedure 
(Whitcomb, 2005). 
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Complications 
A secondary disease or problem that develops in the course of a primary 
disease or condition and arises either as a result of it or from independent 
causes (Merriam-Webster, 2011).  
Coronary Heart 
Disease 
Narrowing of the small blood vessels that supply blood and oxygen to the heart. 
Coronary heart disease is usually caused by a condition called atherosclerosis 
(MedlinePlus, 2010).  
Coronary Plaque 
A coronary plaque consists of fatty substances, cholesterol, waste products 
from the cells, calcium, and fibrin.  The plaque formation process stimulates the 
cells of the coronary artery wall to produce substances that accumulate in the 
inner layer.  Fat builds up within these cells and around them.  The inner layer 
of the artery wall thickens, decreasing the artery's diameter and blood flow and 
oxygen delivery is decreased (http://medical-dictionary.thefreedictionary.com, 
2007). 
Endothelial 
Dysfunction 
Physiological dysfunction of normal biochemical processes carried out by 
endothelial cell, the cells that line the inner surface of all blood vessels, arteries 
and veins.  Compromise of normal function of endothelial cells is characteristic 
of endothelial dysfunction.  Normal functions of endothelial cells include 
mediation of coagulation, platelet adhesion, immune function, control of volume 
and electrolyte content of the intravascular and extravascular spaces 
(www.websters-online-dictionary.org). 
Hemodynamics 
Hemodynamics is the study of all parameters influencing blood flow or 
circulation (Medilexico, 2006). 
Hyperlactatemia 
Increased levels of lactic acid in the blood (http://medical dictionary. 
thefreedictionary.com, 2007). 
Hypoperfusion 
Decreased blood flow through an organ, consequently there is a decrease in 
oxygen delivery.  If hypoperfusion is prolonged it may cause cellular 
dysfunction and even death (http://medical-dictionary.thefreedictionary.com, 
2007). 
Inflammation 
The body's response to either invading foreign substances (such as viruses or 
bacteria) or to direct injury of body tissue (http://medical-
dictionary.thefreedictionary.com, 2008). 
Morbidity 
Loss of physical or psychological well-being, resulting from disease, illness, 
injury, or sickness, especially where the affected individual is aware of their 
own state (Merriam-Webster, 2011). 
Mortality 
The state or condition of being subjected to death, a fatal outcome 
(MedicineNet.com, 2011). 
NONSTEMI These patients may have symptoms indistinguishable from Unstable Angina 
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(UA).  There will always be a significant rise in serum markers to levels that are 
diagnostic of Myocardial Infarction (MI).  This includes patients presenting with 
increased serum levels of creatine kinase, troponin I or troponin T, with no ST-
segment elevation but with ST-segment depression or T-wave inversion (Banas, 
2004). 
Pathophysiology 
The physiology of abnormal states; specifically: the functional changes that 
accompany a particular syndrome or disease (Merriam-Webster, 2011).  
Pro-Inflammatory Tending to cause inflammation (Medicinenet.com, 2003). 
STEMI 
It most often arises from the sudden, total occlusion of a coronary artery by a 
thrombus causing a trans mural Myocardial Infarction (MI) that may progress 
to infarction within 3 – 6 hours.  The presence of ST-segment elevation on the 
ECG suggests complete occlusion of a coronary artery and Q waves usually 
develops.  The management of STEMI differs dramatically from that of unstable 
angina and NONSTEMI.  The primary medical treatment of STEMI is early 
reperfusion (Dalby, 2001). 
ST Segment 
Refers to a specific portion of an electrocardiogram (ECG), which is a graphic 
representation of heart beats.  This segment on the ECG suggests that a heart 
attack is occurring when it is elevated away from the baseline (so called ST-
elevation Myocardial Infarction (MI) or STEMI) (http://medical-
dictionary.thefreedictionary.com, 2008). 
Unstable Angina 
Chest pain or discomfort that is unforeseen and usually occurs while at rest.  
The discomfort may be more severe and prolonged and it may be a person’s 
first angina.  Unstable angina is often accompanied by shortness of breath, 
indigestion and/or dizziness but is not associated with muscle damage but may 
progress rapidly to a heart attack (http://medical-
dictionary.thefreedictionary.com, 2008). 
 
 
 
 
 
 
 
 
                                                                                                      XV | P a g e  
 
 
List of Figures 
 
Figure 2.1 Pathophysiology of Atherosclerosis 7 
Figure 2.2 
The Role of the Microcirculation in Goal-Directed Circulatory 
Support 
35 
Figure 2.3 STS Adult Cardiac Database: Post-operative Complications  46 
Figure 3.1a Schematic Representation of Study Layout- Phase 1 52 
Figure 3.1b Schematic Representation of Study Layout- Phase 2 55 
Figure 3.2  Pre-operative Risk Profile 56 
Figure 3.3 
Post-operative Complications Recorded by STS Adult Cardiac 
Database 
67 
Figure 4.1 Schematic Representation of Research Objectives  71 
Figure 4.2 Gender Distributions for On-pump and Off-pump CABG Groups 72 
Figure 4.3 Ethnicity Distributions for On-pump and Off-pump CABG Patients  73 
Figure 4.4 
Medians for acid-base balance for the on-pump and off-pump 
CABG groups 
82 
Figure 4.5 
Medians for metabolites, saturation (%) and hemoglobin (Hb) for 
the on-pump and off-pump group 
83 
Figure 4.6 
Medians for electrolytes, Sodium (Na+), Chloride (Cl-), Potassium 
(K+) and Calcium (Ca++) for the on-pump and off-pump group 
84 
                                                                                                      XVI | P a g e  
 
 
Figure 4.7 
Medians for hemodynamic data and temperature during on-
pump and off-pump CABG surgery 
90 
Figure 4.8 
Medians for acid-base balance for on-pump and off-pump CABG 
groups during the first 72 hours post-operatively 
96 
Figure 4.9 
Medians for metabolites, Saturation (%) and Hemoglobin (Hb) 
for On-Pump and Off-Pump Groups During the First 72 Hours 
Post-Operatively 
97 
Figure 4.10 
Medians for electrolytes, Sodium (Na+), Potassium (K+), Calcium 
(Ca++) and Chloride (Cl-) for on-pump and off-pump group up to 
72 hours post-operatively 
98 
Figure 4.11 
Lactate<5 mmol/L and Lactate >5mmol/L irrespective of surgical 
technique 
104 
Figure 4.12 
Medians for acid-base balance during the intra-operative period 
for both lactate <5mmol/l and lactate >5mmol/L groups 
113 
Figure 4.13 
Medians for metabolites, saturation (%) and hemoglobin (Hb) 
during the Intra-operative period for both lactate <5mmol/l and 
lactate >5mmol/L groups 
114 
Figure 4.14 
Medians for electrolytes, Sodium (Na+), Potassium (K+), Calcium 
(Ca++) and Chloride (Cl-) during the intra-operative period for 
both lactate <5mmol/l and lactate >5mmol/L groups.   
115 
Figure 4.15 
Medians for hemodynamics for both lactate risk group 1 
<5mmol/L and lactate risk group 2 >5 mmol/L during CABG 
surgery 
120 
Figure 4.16 
Medians for acid-base balance during the first 72 hours post-
operatively following CABG surgery for both lactate risk group 1 
<5 (mmol/L) and lactate risk group 2 >5 (mmol/L) 
126 
Figure 4.17 
Medians for metabolites, saturation (%) and hemoglobin (Hb) 
the first 72hour post-operative period following CABG surgery 
for both lactate risk group 1 <5 (mmol/L) and lactate risk group 
2 >5 (mmol/L).   
127 
Figure 4.18 
Medians for electrolytes, Sodium (Na+), Potassium (K+), Calcium 
(Ca++) and Chloride (Cl-) following CABG surgery for both lactate 
risk group 1 <5 (mmol/L) and lactate risk group 2 >5 (mmol/L).   
128 
 
 
 
                                                                                                      XVII | P a g e  
 
 
List of Tables 
 
Table 2.1 Summary of Pharmacological Drugs 11 
Table 2.2 Meta-analyses Comparing On-Pump and Off-Pump CABG Surgery 17 
Table 2.3 The Stress Response to Surgery 18 
Table 2.4 Features of the Acute Phase Response 19 
Table 2.5 Principal Hormonal Response to Surgery  22 
Table 2.6 Pharmacological Treatment of Acute Circulatory Failure 32 
Table 2.7  References Ranges for Arterial Blood Gas Variables 42 
Table 3.1  Normal and Abnormal References Ranges for Metabolic Data  58 
Table 4.1  Demographic Data: On-pump vs. Off-pump CABG Groups 73 
Table 4.2  Pre-operative Clinical Data: On-pump vs. Off-pump Groups 75 
Table 4.3  Intra-operative Metabolic Data: On-pump CABG Group  78 
Table 4.4  Intra-operative Metabolic Data: Off-pump CABG Group 80 
Table 4.5  
P-values for Intra-operative Metabolic Data: On-pump vs. Off-
pump CABG Groups 
85 
                                                                                                      XVIII | P a g e  
 
 
Table 4.6 
Post-hoc Power Analysis: Mean Intra-operative and Post-
operative Lactate Levels for On-pump and Off-pump CABG 
Groups 
86 
Table 4.7  
Intra-operative Hemodynamic Data and Temperature: On-pump 
CABG Group 
88 
Table 4.8  
Intra-operative Hemodynamic Data and Temperature: Off-pump 
CABG Group 
89 
Table 4.9  
P-values for Intra-operative Hemodynamic Data and 
Temperature: On-pump vs. Off-pump Group 
91 
Table 4.10  Post-operative Metabolic Data: On-pump CABG Group 92 
Table 4.11  Post-operative Metabolic Data: Off-pump CABG Group 94 
Table 4.12  
P-values for Post-operative Metabolic Data: On-pump vs. Off-
pump 
100 
Table 4.13 
Clinical Outcomes/Complications: On-pump vs. Off-pump CABG 
Group 
102 
Table 4.14  Odds Ratio for Lactate Group vs. Surgical Technique 105 
Table 4.15  Demographic Data: Lactate<5 mmol/L and Lactate >5mmol/L 105 
Table 4.16  
Pre-operative Clinical Data: Lactate <5mmol/L vs. Lactate 
>5mmol/L 
107 
Table 4.17 Intra-operative Metabolic Data: Lactate <5 mmol/L 109 
Table 4.18 Intra-operative Metabolic Data: Lactate >5 mmol/L 111 
Table 4.19  
P-values for Intra-operative Metabolic Data: Lactate <5 mmol/L 
vs. Lactate >5 mmol/L 
116 
Table 4.20  
Intra-operative Hemodynamic Data and Temperature: Lactate <5 
mmol/L 
118 
Table 4.21  
Intra-operative Hemodynamic Data and Temperature: Lactate >5 
mmol/L 
119 
                                                                                                      XIX | P a g e  
 
 
Table 4.22 
Intra-operative Hemodynamic Data and Temperature: Lactate <5 
mmol/L vs. Lactate >5  
121 
Table 4.23 Post-operative Metabolic Data: Lactate <5 mmol/L 122 
Table 4.24 Post-operative Metabolic Data: Lactate >5 mmol/L 124 
Table 4.25 
P-values for Post-operative Metabolic Data: Lactate <5mmol/L 
vs. Lactate >5 mmol/ L  
129 
Table 4.26 
Clinical Outcomes/Complications between Lactate <5mmol/L vs. 
Lactate >5 mmol/ L 
130 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                                                                      XX | P a g e  
 
 
Summary 
 
The best approach to surgical myocardial revascularization remains controversial.  It is already 
known that an inflammatory response exists due to several factors related to the use of CPB.  
However, surgical trauma itself also contributes to the inflammatory response.  Thus, a 
physiological stress response which leads to an increase in pro-inflammatory markers still 
remains during OPCAB surgery. 
Cardiac surgery induces a wide range of endocrinological, metabolic, immunological, 
haematological and hemodynamic changes.  Hemodynamic and metabolic optimization is of 
daily importance in the hospital environment.   
Hypoperfusion resulting in increased lactate levels is associated with high post-operative 
morbidity and mortality.  Lactate is also often used to predict clinical outcomes and 
complications but controversy remains about using this measure because of discrepancies in 
reference intervals and cut-off points.   
The aim of the study was to evaluate how metabolic and clinical changes relate to the incidence 
of complications and clinical outcomes in ACS patients undergoing on-pump and off-pump CABG 
surgery.   
Sixty patients diagnosed with ACS who received CABG surgery were recruited to participate in 
the study (30 patients on-pump and 30 patients off-pump).  Patients not receiving isolated 
CABG surgery were excluded from the study.  Comparisons between the two groups were made 
with reference to the intra-operative and post-operative metabolic data, intra-operative 
hemodynamic data and post-operative clinical outcomes/complications.   
Irrespective of surgical technique, the 60 patients were divided into two groups, patients with 
lactate levels <5mmol/L or patients with lactate levels >5mmol/L.  Comparisons between the 
two groups were made with reference to the intra-operative and post-operative metabolic data, 
intra-operative hemodynamic data and post-operative clinical outcomes /complications.   
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Intra-operative metabolic data indicated 11 (37.0%) on-pump patients and 6 (20.0%) off-pump 
patients had peak lactate levels of >5mmol/L during cardiac surgery.  The difference between 
the proportions of on- and off-pump patients with peak lactate levels of >5mmol/L was 
statistically significant (p<0.05).  However, since the study was not powered for this 
comparison, the difference cannot be considered clinically relevant. 
Variables for the acid-base balance, HCO3- and BE (B), showed statistically significant 
differences (p<0.05) between the lactate < 5mmol/L group and the lactate > 5 mmol/L group.  
Intra-operative hemodynamic data showed statistically significant differences between the on-
pump and off-pump groups for all hemodynamic variables (p<0.05) for most part of the surgery. 
Post-operative metabolic data showed statistically significant differences (p<0.05) between the 
on-pump and off-pump groups for acid-base balance variables, pH, HCO3- and BE (B) from 
admission to ICU until 4 hours post-operatively.   
The metabolites, glucose and lactate, showed statistically significant differences (p<0.05) 
between the on-pump and off-pump groups from admission to ICU until 12 hours post-
operatively.   
Despite the fact that elevated lactate levels have been described to be associated with adverse 
outcomes in paediatric- as well as general intensive care admission, no specific lactate level has 
been identified as a reliable indicator of adverse outcomes in adult coronary artery bypass 
surgery.   
Lactate values for the on-pump group were significantly higher during the immediate post-
operative period (p<0.05).  Pulsatile flow is converted to laminar flow during on-pump CABG 
resulting in vasoconstriction and a redistribution of blood flow away from the peripheral tissue 
and the splanchnic circulation, creating an environment for increased lactate levels in the tissue.   
We hypothesized that a lactate value of >5mmol/l may provide clinicians with an early 
indication of a patient's likelihood of experiencing various complications.  Both groups 
recovered to lactate levels of <2mmol/L by the 24th hour post-operatively.  According to 
literature if a patient does not recover to a lactate level of <2mmol/L within 24 hours post-
operatively this is associated with an increased 60-day mortality.   
The study did show a statistically significant difference between the on-pump and off-pump 
group with respect to lactate values.  However, since the study was not powered for this 
comparison, the difference cannot be considered conclusive and we can only make suggestions 
as to the trends seen in the data.  Elevated lactate levels show that they may be poorly 
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correlated with clinical outcomes and in order to see a more definite relationship between peak 
lactate levels and clinical outcomes, a larger study population will be required or perhaps a 
different lactate cut-off value should be considered.  It may also be more useful to see if there is 
a positive correlation between the duration of time a patient is subjected to peak lactate levels 
of >5mmol/L and clinical outcomes.   
We recommend larger study population and change lactate cut-off value to >10mmol/L.   
Introduction                                                                                                                                           1 | P a g e  
 
Chapter 1  
Introduction 
 
The term “acute coronary syndrome (ACS)” is broadly used to describe a heterogeneous 
spectrum of clinical conditions.  These conditions are referred to as “syndromes” for 
uncertainty remains whether ACS are a collection of clinical conditions sharing similar 
pathophysiology or are each of them associated with unique disease processes (Monaco et al., 
2005).   
Coronary artery occlusion is commonly shared by these syndromes, decreasing or totally 
occluding blood flow to the myocardium causing acute myocardial ischemia resulting in chest 
pain due to insufficient blood supply to the heart muscle (Grech et al., 2003). 
Treatments for ACS includes medical treatment, percutaneous coronary intervention (PCI), and 
coronary artery bypass grafting (CABG) with or without the use of cardiopulmonary bypass 
(CPB) (Warnica, 2008).  
In an attempt to avoid some of the major adverse effects caused by CPB, off-pump coronary 
artery bypass grafting (OPCAB) has become an alternative technique for revascularisation 
(Pojar et al., 2008).  The purpose of OPCAB is to provide an alternative that is just as good, or 
even better, than conventional CABG with the use of CPB with respect to long-term clinical 
outcome. However, to date there is no clear evidence that off-pump CABG is preferable to on-
pump CABG, both techniques have positive and negative attributes (Ascione et al., 2003). 
On- and off-pump CABG surgery are associated with hemodynamic changes very specific to 
each of the surgical techniques. The hemodynamic changes could result in changes in tissue 
metabolic activity and may in due course also influence post-operative clinical outcomes (Pojar 
et al., 2008). 
Currently, it remains very difficult to assess hemodynamic alterations and fluctuations, or to 
describe metabolic changes seen during CABG surgery.  All of these alterations form a complex 
network of physiological changes and with better understanding might help clinicians to 
identify a sub-group of patients, at higher risk, requiring more intensive or more specific 
therapy to prevent other possible adverse clinical outcomes (Ngaage. 2003).   
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Glucose and lactate concentrations during the intra-operative and post-operative period may 
provide caregivers with a tool to establish whether or not metabolic demands are satisfied.  It 
may also serve as an early warning sign of metabolic imbalances that may arise due to surgery 
or due to post-operative complications (Anderson et al., 2011). 
Therefore, the aim of the study was to evaluate and compare the metabolic and clinical changes 
in ACS patients undergoing on-pump and off-pump CABG surgery.  
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Chapter 2  
Literature Review 
 
2.1 Background 
 
The prevalence of coronary artery disease (CAD) is increasing and is predicted to develop into a 
leading cause of mortality worldwide by 2020 (Ferrari et al., 2009).  Atherosclerosis, the 
beginning of CAD, is thought to underlie most acute coronary syndromes (ACS), including 
Unstable Angina (UA), Non-ST-Segment Elevation Myocardial Infarction (NONSTEMI) and ST-
Segment Elevation Myocardial Infarction (STEMI), and is thus a major cause of overall 
morbidity and mortality (Grech et al., 2009). 
ACS can be treated either medically with pharmacological drugs or by myocardial 
revascularisation (CABG surgery or PCI).  However, CABG surgery, with the use of CPB also 
known as on-pump CABG surgery, remains the golden standard as therapeutic method for 
myocardial revascularisation (Raja et al., 2004).   
Despite advances in perfusion, CPB still leads to profound physiological changes.  Off-pump 
coronary artery bypass grafting (OPCAB) has become an alternative technique for 
revascularisation and avoids some of the major side effects of CPB.  Both types of CABG surgery 
however are associated with changes in circulation.  With conventional CPB, blood flow in the 
peripheral and splanchnic circulation is redistributed, which could lead to hypoperfusion, and in 
turn lead to further post-operative complications.  Off-pump surgery requires stabilization of 
the heart and exposure of target sites, which may cause decreased blood pressure caused by 
handling of the heart.  This change in the hemodynamic state of a patient ultimately also allows 
for changes in tissue metabolic activity and may also further influence the post-operative 
clinical outcomes (Pojar et al., 2008). 
Literature implicates inflammation as being central to atherogenesis and, ultimately, 
atherothrombosis (Anwaruddin et al., 2007).  As a matter of fact, the inflammatory process 
appears to be much more extensive than previously suspected (Libby et al., 2009).   
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In order to develop an understanding of the metabolic and clinical sequelae encountered during 
on- and off-pump coronary artery bypass graft surgery (CABG), it is important to have an 
understanding of the underlying disease processes, as well as the existing treatment modalities 
for ACS. The study was designed to evaluate and compare the metabolic and clinical changes 
during off-pump CABG versus conventional on-pump CABG surgery. 
 
2.2 Acute Coronary Syndrome (ACS) 
2.2.1 Definition of ACS 
 
The term “acute coronary syndrome” is broadly used to describe a heterogeneous spectrum of 
clinical conditions.  These clinical conditions include myocardial infarction (MI), non-ST-
elevation myocardial infarction (NONSTEMI) and unstable angina (UA).  These conditions are 
classed together under the assumption that they form a spectrum of conditions with the same 
underlying pathophysiology.  These conditions are referred to as “syndromes” for uncertainty 
remains whether ACS are a collection of clinical conditions sharing similar pathophysiology or 
are each of them associated with unique disease processes (Monaco et al., 2005).   
 
Partial and/or total occlusion of the coronary artery is commonly shared by these syndromes, 
decreasing or totally occluding blood flow to the myocardium causing acute myocardial 
ischemia that result in chest pain due to insufficient blood supply to the heart muscle (Grech et 
al., 2003). 
 
2.2.2 Etiology of ACS 
 
Fibrous plaque formation or thrombosis can cause occlusion of a coronary artery thus 
decreasing or totally occluding blood flow to the myocardium.  A possible cause for the 
formation of these plaques or thrombi is atherosclerosis (Monaco et al., 2005; Singh et al., 
2005). 
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2.2.2.1 Atherosclerosis 
 
Atherosclerosis is a disease which can be asymptomatic for many decades but can lead to the 
initiation of acute manifestations like acute coronary syndromes, sudden death and stroke 
(Monaco et al., 2005; Singh et al., 2005).  Atherosclerosis is characterized by the thickening, 
hardening and the loss of elasticity of the inner arterial walls due to the formation of 
atheromatous plaques. 
 
2.2.2.2 Pathophysiology of Atherosclerosis and the Role of the 
Endothelium 
 
Atherosclerosis begins with inflammation and immune cell activation at endothelial level, which 
leads to endothelial dysfunction and eventually to arterial damage and plaque-formation 
(Kharbanda et al., 2005).   
It usually presents either with a MI, unstable angina pectoris or sudden cardiac death.  The 
cause of such acute episodes could be from a coronary thrombosis which usually originates 
from the rupture of an atheromatous plaque (Singh et al., 2005).  This process is fast tracked  by 
risk factors such as high cholesterol levels, smoking, obesity, high blood pressure, and metabolic 
syndrome (Merck ©, 2008).   
The process of plaque rupture is thought to underlie most acute coronary syndromes, including 
UA, NONSTEMI and STEMI myocardial infarctions, and is thus a major cause of overall 
morbidity and mortality (Gutstein et al., 1999). 
The atherosclerotic plaque is the origin of atherosclerosis, consisting of lipids (intracellular and 
extracellular cholesterol and phospholipids), inflammatory cells (macrophages and T cells), 
smooth muscle cells, connective tissue (collagen), thrombi and calcium deposits.  All the stages 
of atherosclerosis, starting from the initiation through to plaque formation are considered an 
inflammatory response to injury (Figure 2.1).   
Endothelial injury is considered to have a primary initiating or inciting role (Merck ©, 2008).  
Turbulent blood flow, within the coronary artery, leads to endothelial dysfunction and inhibits 
endothelial production of nitric oxide (potent vasodilator and anti-inflammatory molecule).  
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Turbulent blood flow also stimulates endothelial cells to produce adhesion molecules, which 
recruit and bind inflammatory cells.  
The net effect is endothelial binding of monocytes and T cells, migration of these cells to the 
sub-endothelial space, and the initiation and maintenance of local vascular inflammatory 
responses.  Monocytes in the sub-endothelium change into macrophages. Lipids in the blood, 
particularly low density lipoproteins (LDL), also bind to endothelial cells and are oxidized 
within the sub-endothelium. The uptake of these oxidized lipids and macrophage 
transformation into lipid-laden foam cells result in typical early atherosclerotic lesions known 
as fatty streaks (Merck ©, 2008).   
The macrophages stimulate pro-inflammatory cytokines that employ smooth muscle cell 
migration from the media that further stimulates the attraction of macrophages.  The result is a 
sub-endothelial fibrous plaque with a fibrous cap, which consists of intimal smooth muscle cells 
surrounded by connective tissue with intracellular and extracellular lipids (Faxon et al., 2004). 
There are several types of atheromatous plaques (Stary et al., 1995).   
 type I- early lesion, marked by foam cell infiltration. Early lesions develop within the 
first three decades of life in areas of turbulent blood flow.  Early lesion development is 
stimulated by conditions such as hypertension, diabetes, high cholesterol and cigarette 
smoking. 
 type II- mature into lesions with smooth muscle infiltration,  
 type III- lipid and connective tissue deposition,  
 type IV- early lesions grow into softer plaques with high extracellular lipid content,  
 type V- develop a progressively thinner fibrous cap and become more susceptible to 
rupture.   
 type VI- ruptured plaques with an overlying thrombus are known as complicated 
lesions.   
When a significant amount of stenosis without sufficient collateralization is reached, these 
lesions result in ACS (Gutstein et al., 1999). 
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Figure 2.1 Pathophysiology of Atherosclerosis. 
A, Leukocyte recruitment to the emerging atherosclerotic lesion.  Blood leukocytes adhere poorly 
to the normal endothelium. When the endothelial monolayer becomes inflamed, it expresses 
adhesion molecules that bind cognate ligands on leukocytes. Selectins mediate a rolling, or 
saltatory, interaction with the inflamed luminal endothelium.  Integrins mediate firmer 
attachment. Proinflammatory cytokines expressed within atheroma provide a chemotactic 
stimulus to the adherent leukocytes, directing their migration into the intima. Inflammatory 
mediators such as M-CSF can augment expression of macrophage scavenger receptors leading to 
uptake of modified lipoprotein particles and formation of lipid-laden macrophages. M-CSF and 
other mediators produced in plaques can promote the replication of macrophages within the 
intima as well. B, T lymphocytes join macrophages in the intima during lesion evolution. These 
leukocytes, as well as resident vascular wall cells, secrete cytokines and growth factors that can 
promote the migration and proliferation of SMCs. Medial SMCs express specialized enzymes that 
can degrade the elastin and collagen in response to inflammatory stimulation. This degradation of 
the arterial extracellular matrix permits the penetration of the SMCs through the elastic laminae 
and collagenous matrix of the growing plaque. C, eventually, inflammatory mediators can inhibit 
collagen synthesis and evoke the expression of collagenases by foam cells within the intimal lesion. 
These alterations in extracellular matrix metabolism thin the fibrous cap, rendering it weak and 
susceptible to rupture. Cross-talk between T lymphocytes and macrophages heightens the 
expression of the potent procoagulant tissue factor. Thus, when the plaque ruptures, as shown 
here, the tissue factor induced by the inflammatory signalling triggers the thrombus that causes 
most acute complications of atherosclerosis (adapted from Libby et al., 2009).  
Literature Review                                                                                                                              8 | P a g e  
 
2.2.3 Classification and Clinical Manifestation of ACS 
 
ACS includes clinical conditions that share a common end result referred to as acute myocardial 
ischemia which includes acute myocardial infarction (MI) with or without ST elevation (STEMI 
and NONSTEMI) and unstable angina (UA) (Monaco et al., 2005).  According to the American 
Heart Association (2004) patients that suffer from acute myocardial ischemia that received an 
electrocardiogram (ECG) may or may not have ST elevation (Antman et al., 2004).  Portions of 
an ECG are usually labelled P, Q, R, S and T.  If an ST-segment elevation is present a rise in a 
particular portion of the ECG graph will occur.  The majority of patients that present with an ST-
segment elevation will ultimately develop a Q-wave (transmural) acute myocardial infarction.  
On the other hand patients who have ischemic discomfort without ST-segment elevation are 
either having an unstable angina (UA) or a non-ST-segment elevation (sub-endocardial) 
myocardial infarction that usually leads to a non-Q-wave myocardial infarction (Monaco et al., 
2005). 
Therefore, ACS covers the spectrum of clinical conditions that range from UA to non-Q-wave 
myocardial infarction and Q-wave myocardial infarction. 
 
2.2.3.1 Myocardial Infarction (MI) 
 
MI is the death of myocardial cells that results from extended periods of myocardial oxygen 
deprivation.  It is a culminating lethal response to unrelieved myocardial ischemia presenting as 
an abrupt onset of chest pain that is severe and crushing in nature and usually lasts for several 
hours. MI is defined according to the changes seen on the ECG which enables distinction 
between STEMI and NONSTEMI. For instance, if an absolute occlusion of the coronary artery is 
present myocardial ischemia will occur and will result in ST-segment elevation (Sheppard et al., 
2004). 
 
 
 
 
Literature Review                                                                                                                              9 | P a g e  
 
2.2.3.2 Non-ST-Segment Elevation Myocardial Infarction 
(NONSTEMI) 
 
These patients may have symptoms indistinguishable from UA.  There will always be a 
significant rise in serum markers to levels that are diagnostic of MI.  This includes patients 
presenting with increased serum levels of creatine kinase, troponin I or troponin T, with no ST-
segment elevation but with ST-segment depression or T-wave inversion (Banas, 2004). 
NONSTEMI is usually associated with white, platelet-rich, and only partially occlusive thrombus 
formation (Grech et al., 2003). 
 
2.2.3.3 ST-Segment Elevation Myocardial Infarction (STEMI) 
 
STEMI, most often arises from the sudden, total occlusion of a coronary artery by a thrombus 
causing a transmural MI that may progress to infarction within 3 – 6 hours.  The presence of ST-
segment elevation on the ECG suggests complete occlusion of a coronary artery and Q-waves 
usually develops.  The management of STEMI differs dramatically from that of unstable angina 
and NONSTEMI and primarily involves early reperfusion (Dalby, 2001). 
 
2.2.3.4 Unstable Angina (UA) 
 
UA is a combination of stable angina and Prinzmetal’s angina and is seen in an individual with 
worsening CAD. UA is seen as a clinical state in which there is a change in the pattern of angina.  
This may be due to the onset of new symptoms, the recurrence or more severe angina and the 
development of chest pain at rest.  It appears to result from coronary atherosclerosis, 
characterized by a growing, spasm-prone thrombus.  As the thrombus continues to grow, 
episodes of UA increase in frequency and severity, therefore the individual is at increased risk of 
suffering irreversible damage.  The pathological mechanisms of UA are similar to NONSTEMI 
(Sheppard et al., 2004). Resting ECG may show ST-segment depression and/or T-wave inversion 
or transient ST-segment elevation, or may even appear normal.  The serum markers usually 
remain within normal biological ranges or increase to diagnostic levels as in the case of MI 
(Dalby, 2001). 
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Therefore, the presentation of UA, STEMI and NONSTEMI results from a variation of the same 
pathological process (Sheppard et al., 2004). 
 
2.2.4 Treatment Methods for ACS 
 
Several treatment modalities exist for the treatment of patients diagnosed with ACS.  Primarily 
there are those treatment modalities that influence the pathogenesis of the disease (anti-
platelet and anti-coagulant drugs) and there are those that provide symptomatic relief (anti-
anginal agents, analgesics and sedatives).  The majority of patients should receive aspirin, some 
should be treated in addition, with one of the heparin preparations and some of the patients 
should undergo revascularisation during treatment (Dalby, 2001).  
Revascularisation is the restitution of blood supply to the ischemic myocardium in an attempt to 
limit ongoing damage, reduce ventricular irritability, and advance short-term and long-term 
outcomes. The treatment methodologies for revascularisation include thrombolysis with 
fibrinolytic drugs (pharmacological treatment), percutaneous coronary intervention (PCI) and 
coronary artery bypass grafting (CABG) with or without the use of CPB (Merck ©, 2008). 
 
2.2.4.1 Pharmacological/Medical Treatment 
 
The stability of ACS patients can easily deteriorate, thus the need for the rapid initiation of 
medical therapy. The pharmacological treatment of patients with ACS is primarily directed at 
the dissolution of the intracoronary thrombus with the use of anti-platelet (aspirin and 
clopidogrel) and anti-coagulant (heparin) therapies.  Secondarily, the treatment modality is 
aimed at the relief of symptoms by administering anti-anginal and analgesic medications (Dalby, 
2001). 
A vast number of drugs are available and can be administered to treat ACS but the most 
commonly used drugs and their mode of action are summarized in Table 2.1 (Sheppard et al., 
2004; Dalby, 2001). 
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Table 2.1 Summary of Pharmacological Drugs Available for the Treatment of ACS 
 (Dalby, 2001; Sheppard et al., 2004). 
DRUGS ACTION DOSAGE PRECAUTIONS 
Oxygen 
There is a role for O2 in patients with 
ACS. O2 therapy should be continued 
in patients with reduced O2 
saturation. 
- - 
Aspirin 
Inhibits thromboxane formation and 
partially inhibits platelet activation 
with no effect on platelet adhesion. 
Initially 300mg 
Then 75-150mg indefinitely 
GI bleeding 
Peptic ulcer 
Aspirin allergy 
bleeding risk 
Antiplatelet therapy 
contra-indicated 
Antithrombin 
therapies-
Heparin 
In combination with aspirin 
unfractioned heparin and low weight 
heparin’s (LMWH) has shown to be 
beneficial. LMWH have a more 
predictable pharmokinetic profile, 
with a long-half life which does not 
require continuous infusion. The 
efficacy could be related to the anti-
factor Xa; anti-factor IIa ratio. 
Unfractioned heparin 60U/kg IV 
bolus to a maximum of 4000 
units 
Then 12U/kg/h infusion to a 
maximum of 1000U/h 
Low molecular weight heparin’s 
Fragman 120IU/kg subcut 12 
hrly. 
Clexane 1mg/kg subcut 12 hrly 
Any abnormal bleeding 
Thrombocytopenia- 
risk of bleeding 
Glycoprotein 
IIb/IIIa inhibitors 
Recommended in combination with 
heparin as well as aspirin as part of 
the initial treatment in high-risk 
NONSTEMI and UA patients. 
180ug/kg IV over 1-2min 
then 2ug/kg/min infusion over 
72hrs 
Bleeding disorder 
Thrombocytopenia 
Puncture of a non-
compressible vessel 
Ticlopidine & 
Clopidogrel 
Drug inhibits ADP-mediated platelet 
aggregation and therefore could 
possibly act in synergy with aspirin. 
Initially 300mg 
then 75mg daily 
Same as aspirin 
Direct 
antithrombins 
This inhibits thrombin activity. 
Initial bolus should be 60 U/kg 
and the initial infusion, 12 
U/kg/h 
Increase in the risk of 
hemorrhage 
Beta-
adrenoceptor 
blockers, nitrates 
& calcium-
channel blockers 
Anti-ischemic therapy. Nitrates used 
to relieve pain as well as a coronary 
artery vasodilator. 
Beta-adrenoceptor blockers have 
multiple effects which reduce 
ischemia rates.  In ACS they reduce 
myocardial work and O2 demands, 
and also reduce the risk of 
ventricular arrhythmias. 
Varies with the clinical 
characteristics of the patient 
Bradycardia and AV 
block 
ACS: Acute Coronary Syndrome, mg: Milligram, GI: Gastro-intestinal: increase, LMWH: Low molecular weight 
heparins, U: units, kg: Kilogram, IV: Intra-venous, hrly: Hourly, h: Hour, NONSTEMI: Non-Stemi, UA: Unstable Angina, 
min: Minute. 
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2.2.4.2 Revascularisation 
 
The indication for revascularisation in ACS patients depends on the identification of a culprit 
high-grade stenosis in a major vessel or when the coronary disease and left ventricular function 
has deteriorated dramatically. Revascularisation can be achieved by either PCI or by CABG 
surgery (Bertrand et al., 2002). 
Angiography is usually the start off point in order to make evidence based decisions about the 
revascularisation technique.  An informed decision about the optimal revascularisation 
technique can only be made after defining the anatomy and its associated risk features. 
In cases when the anatomy is unfavourable for PCI or in case of PCI failure, CABG surgery has to 
be considered especially when an exceptionally large myocardial area is in jeopardy and when 
surgical revascularisation can be completed prior to necrosis of the affected area (William et al., 
2010). 
2.2.4.3 Percutaneous Coronary Intervention (PCI) 
 
PCI offers a non-surgical alternative to CABG surgery. The introduction of a stent helps to 
mechanically stabilize the disrupted plaque at the site of the atherosclerotic lesion and helps to 
re-establish blood flow to the ischemic area (Falk et al., 1995).  Primary PCI is defined as 
percutaneous intervention in the setting of STEMI with no earlier or concomitant fibrinolytic 
treatment (William et al., 2010). 
However, in this study emphasis will be placed on CABG as the treatment modality of choice for 
patients diagnosed with ACS. 
 
2.2.4.4 Coronary Artery Bypass Graft (CABG) Surgery 
 
Cardiac surgery has been consistently performed by means of CPB ever since its clinical 
introduction during the 1950s. The first successful CPB procedure was done in 1953 and soon 
became the gold standard for all cardiac procedures (Westaby et al., 1996). 
The breakthrough in the development of CPB was not without controversy, soon issues like the 
disadvantages of laminar flow, cold myocardial ischemia, coagulation, complement activation, 
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activation of platelets and leukocytes during CPB became evident.  However, research continued 
to seek for new and more sophisticated methods to improve patient outcomes.  This led to the 
renaissance of cardiac surgery on the beating heart in the early 1980’s (Larmann et al., 2004). 
Off-pump coronary artery bypass (OPCAB) surgery is performed on a beating heart using a 
cardiac stabilizer to stabilize the coronary artery and surrounding surgical field and occluding 
the coronary artery proximal and/or distal to the stenosis with temporary ligations.  The heart 
and lungs continue to function throughout the surgery.  Only the dependent myocardial tissue is 
exposed to brief ischaemia.  Reardon and colleagues (1997) noted that in performing this 
procedure, the surgeon must consider the following: 
 the accuracy and patency of the anastomosis, 
 issues of incomplete revascularisation, 
 hemodynamic stability, and 
 long-term outcome (Stump et al., 2001). 
Today, CPB for the treatment of ACS patients can be performed in one of two ways either on-
pump (on a non-beating heart with the aid of a heart-lung machine) or off-pump (on a beating 
heart without the use of a heart lung machine) (Larmann et al., 2004). 
 
A) Coronary Artery Bypass Graft (CABG) Surgery Using Cardiopulmonary 
Bypass (CPB) 
 
CABG surgery is performed with the use of a heart-lung machine (on-pump CABG) when a 
proper medical evaluation warrants its use during cardiac surgery.  This technique assures high 
quality anastomosis with satisfactory clinical outcomes (Dybdahl et al., 2004).  Nevertheless, a 
major complication of on-pump CABG surgery is the systemic inflammatory response which can 
contribute to the increase in morbidity and mortality rates.   
The systemic inflammatory response is mainly triggered by the generation of shear forces from 
roller pumps driving blood through the bypass circuit, hypothermia as blood is expelled through 
the extracorporeal circuit, surgical trauma, ischemia and contact activation of plasma protein 
systems as circulating blood is exposed to artificial surfaces in the bypass circuit (Larmann et 
al., 2004).  CPB also initiates profound physiological alterations which include: 
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 Blood is brought into direct contact with large artificial surfaces, 
 Pulsatile flow converted to laminar flow, 
 Exposure of the heart to global ischemia with cardioplegic protection, 
 The body temperature is lowered by several degrees (Larmann et al., 2004). 
These alterations activate the inflammatory response by activating the endothelium, platelets, 
complement system, leukocytes and the coagulation cascade. Surgical trauma itself also 
contributes to the inflammatory response present after surgery (Larmann et al., 2004).   
 
B) Coronary Artery Bypass Graft (CABG) Surgery without Using 
Cardiopulmonary Bypass (CPB) 
 
Since 1960 CABG surgery has been possible without the use of CPB (Stump et al., 2001).  This 
method is technically more demanding than using CPB and requires a surgeon with an 
innovative and more flexible attitude to create optimal operative conditions. Controversy still 
remains regarding the benefits of off-pump coronary artery bypass (OPCAB) surgery when 
compared to conventional on-pump CABG surgery (Wan et al., 2004).   
The rationale for the use of OPCAB/off-pump techniques is that it should be just as good as 
conventional surgery with regards to mortality and improvement in hospital morbidity with 
maintained long-term clinical outcomes.  Therefore, OPCAB surgery has experienced a revival as 
routine heart surgery since the 1980s (Chassot et al., 2004).  
Developments in exposure techniques, together with pericardial traction sutures and slings, and 
a better perception of the hemodynamic impact of cardiac manipulation allowed broader 
application of OPCAB techniques.  However, the manipulation of the heart for anastomosis of 
the circumflex (Cx) and the posterior descending artery poses a risk of inducing hypotension, 
impaired cardiac output, and generalized hemodynamic instability with risk of cerebral 
compromise and ischemia (Murkin, 2002).  The corrective measures for this hemodynamic 
instability include an increase in volume load, use of inotropes, vasopressors, vasodilators and 
temporary suspension of cardiac manipulation.  Occasionally severe and prolonged 
deterioration and failure to recover after corrective measures may occur.  This can then result 
in the conversion to CPB (Ngaage, 2003).  
Literature Review                                                                                                                              15 | P a g e  
 
Evidence exists that OPCAB reduces postoperative morbidity, including myocardial injury, renal 
dysfunction, neurocognitive deficit, and systemic inflammatory response syndrome (SIRS).  
OPCAB cardiac surgery still results in tissue trauma, cardiac manipulation, pericardial suction 
and the administration of exogenous drugs such as heparin, protamine and many anaesthetic 
agents.  Thus, a physiological stress response which leads to an increase in pro-inflammatory 
markers still remains during OPCAB surgery (Day et al., 2005). 
With classic OPCAB for complete revascularisation, the surgical trauma experienced by the 
patient is similar to that of conventional CABG using CPB (Stump et al., 2001).  The magnitude of 
the inflammatory response, however, is significantly less than that observed when using CPB 
(Gasz et al., 2004). 
 
C) On-Pump versus Off-Pump CABG Surgery 
 
Today, cardiac surgery with- or without the use of CPB are among the most scrutinized surgical 
techniques, and continue to develop through research.   
Alterations in organ function frequently accompany anaesthesia and cardiac surgery. Most 
individuals endure these physiological changes well and recover without incident, but some 
experience significant organ dysfunction and go on to develop postoperative complications 
(Haddy et al., 1996). 
Despite improvements in the method of CPB, the disadvantages of global myocardial ischemia, 
including the systemic inflammatory response, neurologic complications, renal failure, 
hemodynamic instability, lung dysfunction, and pulsatile flow converted to laminar flow, 
complement activation, coagulation, activation of platelets and leukocytes during CPB, are still a 
major cause of concern (Racz et al., 2004).  
All inflammation associated with cardiac surgery is linked to CPB, but it is also linked to surgical 
trauma and to frequently encountered co-morbidities such as: 
 Diabetes - induces oxidative stress, paralyses of the immune system, activation and 
damaging of endothelial cells and platelets,  
 Renal failure, either chronic or acute,  
 hepatic failure,  
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 infectious diseases and,  
 in the already preoperatively critically ill, pre-existing SIRS will probably have a 
similar impact on the inflammatory response to CPB (Racz et al., 2004). 
CPB may also increase the risk for tipping the balance between the exaggerated and necessary 
inflammatory response towards the development of other inflammation-related complications.  
However, it is incredibly difficult to pinpoint the sole role of CPB and its effects on inflammation 
with respect to clinically meaningful modifications of clinical outcomes (Larmann et al., 2004).  
Off-pump CABG surgery, on the other hand, requires different surgical as well as 
anaesthesiological skills.  The major issue that remains about off-pump surgery is whether the 
need to contend with the beating heart and more blood in the operative field compromises the 
quality of distal coronary graft anastomosis and results in a less durable or less complete 
revascularisation (Cooley, 2000). 
The advantages and disadvantages of conventional on-pump CABG surgery and off-pump CABG 
surgery has, thus far, been elaborated in small detail.  Several meta-analyses have been 
performed comparing outcomes of revascularisation with- and without cardiopulmonary 
bypass (Table 2.2).  The general feedback was that improved or at least equivalent outcomes 
were observed when comparing off-pump to on-pump surgery particularly with respect to 
postoperative mortality, stroke, myocardial injury, atrial fibrillation, need for transfusion and 
hospital stay.  However, the majority of the studies performed were in highly selective and 
moderately low-risk patient groups, where mortality and morbidity rates were already low 
(Abu-Omar et al., 2009). 
Therefore, it seems that there is no clear evidence that on-pump CABG is preferable to off-pump 
CABG surgery or vice versa, both techniques have positive and negative attributes. 
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Table 2.2 Meta-analyses Comparing On-Pump and Off-Pump CABG Surgery (adapted 
 from Abu-Omar et al., 2009). 
STUDY 
NUMBER 
OF 
PATIENTS 
META-
ANALYSIS 
MAIN OUTCOMES 
Reston et al., 
2003 
39,647 
RCTs & observational 
studies 
Reduced hospital stay, operative morbidity and mortality 
for OPCAB. 
Van der 
Heijden et al., 
2004 
1584 RCTs OPCAB equivalent to conventional CABG. 
Cheng et al., 
2005 
3369 RCTs 
Reduction in the rate of atrial fibrillation, transfusion, 
inotropic requirements, respiratory infections, ventilation 
time, intensive care unit stay, hospital stay and cost for 
OPCAB. 
Parolari et al., 
2005 
1105 RCTs Reduced postoperative graft patency with OPCAB. 
Wijeysundera 
et al., 2005 
293,617 
RCTs and 
observational studies 
RCT: reduced AF and trends toward reduced 30-day 
mortality and MI Observational studies: reduced 30-day 
mortality, atrial fibrillation, stroke and myocardial 
infarction, but increased repeat revascularisation rate at 1–
2 years for OPCAB. 
Moller et al., 
2008 
5532 RCTs 
Reduced AF but similar mortality, myocardial infarction, 
stroke, and renewed coronary revascularisation rates for 
OPCAB. 
RCT: randomised controlled trial, OPCAB: Off-pump coronary artery bypass, CABG: coronary artery bypass graft, MI: 
myocardial infarction, AF: atrial fibrillation. 
 
2.3 The Stress Response to Cardiac Surgery 
 
The stress response to cardiac surgery encompasses a wide range of endocrinological, 
metabolic, immunological, haematological and hemodynamic changes induced by injury or 
trauma, and is also referred to as the systemic inflammatory response to surgery (Table 2.3). 
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Table 2.3 The Stress Responses to Surgery (adapted from Desborough, 2000). 
CONSEQUENCE OF THE STRESS RESPONSE 
Endocrine stress response 
 Pituitary hormone secretion 
 Insulin resistance 
Immunological and Haematological changes 
 Cytokine production 
 Acute phase reaction 
 Neutrophil leukocytosis  
 Lymphocyte proliferation 
Metabolic Response 
 Overall metabolic effect is one of catabolism of stored body fuels 
 Blood glucose concentrations  
 Peripheral use of glucose  
 Protein catabolism 
 Fat – increased mobilisation of triglycerides 
 Water and electrolyte – preservation of adequate body fluid volumes 
Hemodynamic Response 
 Hypertension 
 Hypotension 
 Tachycardia 
 Bradycardia 
Hypertension = Mean blood pressure>120% of baseline or >100 mmHg; Hypotension= Mean blood pressure <80% of 
baseline or <60 mmHg; Tachycardia = Heart rate >90 beats·min−1, Bradycardia= Heart rate <80% of baseline or <45
beats·min−1 
 
Inflammation is the body’s response to tissue injury and is a fast, amplified, controlled humoral 
and cellular response.  It has already been determined that cardiac surgery provokes a 
significant systemic inflammatory response, which has important clinical implications (Levy et 
al., 2003).  A patient’s risk of serious peri-operative complications are apparent as being 
somewhat preset (genotype, preoperative health status, surgical difficulty, etc.), but the degree 
to which these may be improved (e.g., hemodynamic optimization using pharmacologic or 
mechanical support) is still under assessment (Laffey et al., 2002).   
The stress response to surgery is characterized by increased secretion of different stress 
hormones such as adrenaline and cortisol, due to increased activity of the pituitary and 
activation of the sympathetic nervous system.  Changes in pituitary secretions have secondary 
effects on hormone secretions from other organs.  The overall metabolic effect of these 
hormonal changes is increased catabolism which mobilizes substrates to provide energy, retain 
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salt and water to maintain fluid volume and cardiovascular homeostasis.  Surgical patients have 
increased secretion of not just cortisol and catecholamines, but also glucagon, growth hormone 
(GH), as well as aldosterone. The mechanisms responsible for the increased synthesis are 
considered to be at least partly neuronally mediated. Afferent impulses from the site of injury 
stimulate the secretion of hypothalamic releasing factors, which then stimulate the pituitary to 
release GH and vasopressin. Adrenaline is secreted by the adrenal medulla due to the 
sympathetic nervous system activation. There is an interaction between the neuroendocrine 
stress response and the immunological response to surgical trauma (Toft et al., 2008). 
During the 1950s the speculation was that ‘wound hormones’ might be produced in injured 
tissues which activated the pituitary-adrenal axis.  However, later the idea was formed that local 
substances might influence the changes associated with surgery and this notion was confirmed 
by the discovery of cytokines (Desborough, 2000).   
The initiation of the stress response can be divided into an early/acute phase consisting of a 
number of changes that occur after tissue injury which is stimulated by cytokines and 
characterized as a hypodynamic state, a reduction in metabolic rate and depression of most of 
the physiological processes (Singh, 2003).   
During the acute phase the liver starts producing acute phase proteins (Table 2.4).  These 
proteins act as inflammatory mediators, anti-proteinases and scavengers during tissue repair.   
 
Table 2.4 Features of the Acute Phase Response (adapted from Desborough, 2000). 
Fever 
Granulocytosis 
Production of acute phase proteins in the liver 
CRP 
Fibrinogen 
α2-macroglobulin 
Changes in serum concentrations of divalent cations 
Copper increases 
Zinc and Iron decreases 
C-reactive proteins (CRP); α- alpha 
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The late/flow phase is opposite to the early phase. The body develops a hypermetabolic state 
and may last anything from a few days to weeks depending on the severity of the surgical 
trauma or occurrence of a complication.  This is also known as the period of compensation, with 
increased metabolic rate, enzyme modulation directed to glucose production and resultant 
compensation of blood volume and stimulation of the immune system (Singh, 2003). 
 
2.3.1 The Immunological Response to Cardiac Surgery 
2.3.1.1 Cytokine Production 
 
Cytokines (include interleukins (IL) and interferons) are produced from activated leukocytes, 
fibroblasts and endothelial cells as an early response to tissue injury and have a major role in 
mediating immunity and inflammation.  They act on surface receptors found on many different 
target cells and their effects are produced by influencing protein synthesis within these cells.  
After surgery the main cytokines released are IL-1, tumour necrosis factor -α (TNF- α), and IL-6. 
IL-6 is the main cytokine responsible for inducing the systemic changes known as the acute 
phase response (Desborough, 2000).   
The release of cytokines influence hemodynamic regulation, contribute to myocardial stunning 
and negatively affect both renal and lung function.  Therefore, cytokine release might also be 
involved in the development of systemic inflammatory response syndrome and multi-organ 
failure (Larmann et al., 2004). 
 
2.3.1.2 Leukocyte Production 
 
A crucial step in tissue injury and its clinical consequences is the cytokine-mediated activation 
of leukocytes (monocytes and neutrophils).  It is characterised by increased levels of neutrophil 
elastase, pro-inflammatory cytokines and the development of platelet-leukocyte conjugates.  
Leukocyte activation takes place due to increased levels of thrombin, kallikrein and C5a (Hunt et 
al., 2007).  C5a is a protein generated with the initiation of CPB that induces neutrophil 
chemotaxis, degranulation and super-oxide generation.  Leukocytes are also activated by IL-1, 
IL-8, TNF-α, C5b-9, factor XIIa and heparin.  When activated neutrophils degranulate and 
release cytotoxic enzymes, oxygen free radicals and, hydrogen peroxide, this stimulate 
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superoxides and directly activates endothelial cells.  Monocyte activation plays a very specific 
role in thrombin generation via expression of tissue factor and the release of TNF- α, IL-1 and 
IL-6 (Day et al., 2005).   
Non-specific cell mediated immunity (neutrophils, monocytes, and natural killer cells) is 
suppressed after surgical trauma.  After surgical stress leukocytosis is observed in peripheral 
blood while granulocytes accumulate in the injured area.  However, to pass through the 
endothelium into the injured area, warrants an increased expression of adhesion molecules on 
the surface of neutrophils as well as on the surface of the endothelium. 
 
2.3.2 The Endocrine Response to Cardiac Surgery 
 
Activation of the endocrine response after surgery is caused by afferent neuronal impulses from 
the site of injury.  These impulses travel along sensory nerve roots, up the spinal cord to the 
medulla to activate the hypothalamus.  The hypothalamus then stimulates the release of 
pituitary hormones (Table 2.5) (Toft et al., 2008; Desborough, 2000). 
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Table 2.5 Principal Hormonal Responses to Surgery (adapted from Desborough, 
 2000). 
ENDOCRINE GLAND HORMONES CHANGE IN SECRETION 
Anterior pituitary 
  
 
ACTH Increases 
 
Growth hormone Increases 
 
TSH May increase or decrease 
 
FSH and LH May increase or decrease 
Posterior pituitary 
  
 
AVP Increases 
Adrenal cortex 
  
 
Cortisol Increases 
 
Aldosterone Increases 
Pancreas 
  
 
Insulin Often decreases 
 
Glucagon Usually small increases 
Thyroid 
  
 
Thyroxine, tri-iodothyronine Decrease 
ACTH: adrenocorticotrophic hormone (corticotrophin), AVP: arginine vasopressin, FSH: follicle-stimulating hormone, 
LH: luteinizing hormone, TSH: thyroid-stimulating hormone (adapted from Desborough, 2000). 
 
2.3.2.1 Hypothalamic-Pituitary-Adrenal Axis 
A) Anterior Pituitary 
 
The anterior pituitary hormone secretion is stimulated by hypothalamic releasing factors.  The 
changes of pituitary secretion allows for the synthesis of corticotrophin or adrenocorticotrophic 
hormones (ACTH) as part of a larger forbearing molecule, pro-opiomelanocortin.  This molecule 
is metabolized in the pituitary into ACTH, Beta-endorphin and an N-terminal precursor (Burton 
et al., 2004).  The surgical stimulus also results in the increased secretion of GH and 
procalcitonin. 
The stress response leads to secretion of several anabolic and catabolic hormones causing 
hypermetabolism, and acceleration of biochemical reactions.  This compensatory mechanism 
ensures maximum chance of survival during increased cardiac functions, fluid preservation and 
supply of increased demands for energy generating substrates (Desborough, 2000).   
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B) Posterior Pituitary 
 
The posterior pituitary produces arginine vasopressin which has an important role as an 
antidiuretic hormone.  Arginine also has an endocrine function, acting with corticotrophin-
releasing factor (Burton et al., 2004).   
 
C) Corticotrophin 
 
Produced in the pituitary from a larger molecule called pro-opiomelanocortin, Corticotrophin-
releasing hormone (CRH) also known as Adrenocorticotropic Hormone (ACTH), stimulates the 
adrenal cortical secretion of glucocorticoids so that circulating concentrations of cortisol 
increase.  Surgery is one of the most potent activators of ACTH and cortisol secretion 
(Desborough, 2000). 
 
D) Growth Hormone (GH) 
 
GH is a protein secreted from the anterior pituitary and its release is stimulated by growth 
hormone releasing factor from the hypothalamus.  GH secretion increases in response to 
surgery and trauma according to the severity of the injury (Desborough, 2000).  GH has many 
effects on the metabolism as well as the regulation of growth.  It stimulates protein synthesis 
and inhibits protein breakdown, promotes lipolysis and has an anti-insulin effect.  Therefore, GH 
inhibits glucose uptake and usage by cells.  GH may also stimulate glycogenolysis in the liver 
(Singh et al, 2005). 
 
E) β-Endorphin and Prolactin 
 
The increased, β-Endorphin (opioid peptide) concentrations in the circulation after surgery 
reflects increased pituitary hormone secretion.  It has no key role in metabolic activity.  
Prolactin secretion is increased as part of the stress response to surgery but has little to no 
metabolic effect (Desborough, 2000). 
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F) Cortisol 
 
The increased secretion of ACTH initiates a sudden increase in cortisol levels and its main 
metabolic effect is to overcome the stressful state.  There is a direct feedback mechanism for 
cortisol, to both the hypothalamus and the pituitary gland, to decrease the concentration of 
cortisol in plasma.  Cortisol has a vast number of effects on the metabolism and utilization of 
glucose.  Cortisol causes rapid recruitment of amino acids and fat from cellular stores, making 
them immediately available both for energy and synthesis of other compounds (Singh et al, 
2005).   
 
G) Insulin and Glucagon 
 
Insulin is a very important anabolic hormone (Burton et al., 2004).  Insulin is synthesized and 
secreted by the Beta cells within the pancreas.  Insulin is released when blood glucose and 
amino acid concentrations increase. Insulin ensures the uptake of glucose into muscle and 
adipose tissue as well as the conversion of glucose into glycogen and triglycerides. Usually 
insulin concentrations decrease after the administration of anaesthesia, whilst during surgery 
there is a marked decrease of insulin secretion to match the catabolic, hyperglycemic response. 
In addition, insulin resistance becomes evident during the peri-operative period (Desborough, 
2000).   
 
2.3.3 Metabolic Response to Cardiac Surgery 
 
The metabolic response also forms part of the overall stress response.  The catabolic changes 
that occur result in substrate mobilization, muscle protein loss and sodium and water retention, 
with suppression of anabolic hormones (Burton et al., 2004).  It has been demonstrated that the 
magnitude of the metabolic response is proportional to the severity of the surgical trauma.   
Initiation of the response is with activation of the hypothalamic-pituitary axis and the 
sympathetic nervous system.  The result is failure of the normal feedback mechanism to control 
hormone secretion.  Therefore, the result is an expression of catabolic hormones such as 
catecholamines and pituitary hormones but a suppression of anabolic hormones such as insulin.  
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Insulin is typically secreted in response to hyperglycaemia promoting glucose utilization and 
glycogen synthesis.  Hyperglycaemia is a major attribute of the metabolic response to surgery 
(Burton et al., 2004). 
 
2.3.3.1 Glucose Metabolism during the Stress Response to 
Cardiac Surgery 
 
Glucose metabolism involves complex metabolic reactions to maintain normal glucose levels.  
Exogenous glucose is supplied through dietary intake, whilst endogenous glucose is supplied 
through glycogen stores that release glucose through liver glycogenolysis as well as from non 
carbohydrate precursors (lactate and alanine).  Endogenous glucose is converted to glucose 
through gluconeogenesis mainly in the liver and to a certain degree in the kidneys. During 
normal conditions 50-80% of ingested glucose will be used by glucose dependant tissues.  
Excess glucose is converted to produce energy through glycolysis and is stored as glycogen in 
the liver and skeletal muscles, or converted to fat (Butler et al., 2005).   
Blood glucose levels are regulated by hormonal, neural, as well as hepatic autoregulatory 
mechanisms (McCowen et al., 2001).  The hormonal mechanism involves insulin through its 
anabolic function to increase glucose uptake and storage.  The effect of insulin is also mediated 
by its anti-inflammatory suppression of proinflammatory cytokine production and signalling for 
the reduction in blood glucose levels.  It is accomplished by stimulating glucose uptake and 
glycogen synthesis, and inhibiting glyconeogenesis.  The anabolic effects of insulin are stopped 
by the counter-regulatory hormones such as glucagon, catecholamines, cortisol and growth 
hormone.  These hormones stimulate glycogenolysis and gluconeogenesis and inhibit insulin 
mediated glucose uptake (McCowen et al., 2001). 
The neural mechanisms involve central and peripheral glucosensors that respond to changes in 
blood glucose levels by releasing or inhibiting insulin secretion (McCowen et al., 2001). 
The hepatic mechanism involves a direct response to increased blood glucose levels by 
decreasing its glucose production (McCowen et al., 2001). 
Significant alterations to glucose metabolism occur during conditions of stress such as trauma, 
major surgery, and sepsis (Burton et al., 2004).  Today it is a well known fact that any type of 
prolonged stress or injury leads to insulin resistance, glucose intolerance, and hyperglycaemia.  
These changes follow closely after the increase in catecholamines. Independent of diabetic 
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status, the body experiences cardiac surgery as a dramatic and stressful event and the degree of 
hyperglycaemia depends on the severity, extent and duration of surgery.  The surgical stress 
activates neuro-endocrine pathways, stimulating the adrenergic system and the hypothalamic-
pituitary-adrenal axis (Desborough, 2000).   
There are numerous mechanisms causing a considerable rise in glucose levels.  Firstly, an 
increase in hepatic gluconeogenesis and glycogenolysis due to counter-regulatory hormones 
and the release of epinephrine and norepinephrine, secondly because of decreased glucose 
uptake and clearance due to insulin resistance during surgery. Mechanisms to maintain glucose 
homeostasis become ineffective during surgery.  The hyperglycaemia persists due to catabolic 
hormones promoting glucose production (Desborough, 2000).   
Insulin resistance occurs mostly in the skeletal muscle but other tissue such as adipose and liver 
may also contribute to this phenomenon.  There is also an increased release of proinflammatory 
cytokines and acute phase reactive proteins such as TNF-α, IL-1, IL-6 and C-Reactive Protein 
(CRP) causing further peripheral insulin resistance.  The negative feedback mechanism of 
glucose on gluconeogenesis also fails to continue as normal. Due to the high levels of 
catecholamines, the feedback to stimulate insulin secretion and glucagon inhibition decreases 
significantly.  Lastly, surges in glucose levels may also occur from hyperglycaemia itself, which is 
proinflammatory and perpetuates the glycemic response.  At cellular level, hyperglycaemia 
increases proinflammatory transcription factors, which, induces transcription of 
proinflammatory cytokines (TNF-α, IL-I, IL-6, IL-8 and IL-18) which contributes to more severe 
hyperglycaemia.  It is important to remember, hyperglycaemia leads to inflammation and will, if 
left untreated elevate glucose levels even further, leading to greater oxidative stress and 
increased cytokine production (Shilling et al., 2008).  
 
2.3.3.2 Glucose Levels during Coronary Artery Bypass Graft 
 Surgery 
 
The development of hyperglycaemia during CABG intervention is not unusual irrespective of the 
anaesthetic technique (Doenst et al, 2008).  This is due to a delay in the release of plasma insulin 
relative to the glucose concentration during normo-thermic CABG.  Hyperglycaemia usually 
peaks within the first few minutes of bypass, while the rise in the plasma insulin level is delayed, 
increasing continuously during the CABG procedure.  The relatively slow response to insulin 
with continued hyperglycemic stimulation indicates that the secretory response is inhibited 
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during CABG.  Since the hyperglycaemia is not accompanied by a rise in plasma insulin 
concentration, the failure of an adequate insulin secretory response to noticeable 
hyperglycaemia indicates a secondary complication, the direct inhibition of insulin secretion.  
Evidence is lacking whether either a direct inhibitory effect of hypothermia on intrinsic 
pancreatic beta cell function in vitro or an effect on the ability of the pancreas to secrete insulin 
in vivo during CABG is responsible for this outcome (Desborough, 2000). 
During the re-warming phase of CABG, plasma insulin begins to increase.  At the end of the 
CABG procedure a slow but steady decrease in plasma glucose levels are seen, reaching pre-
anaesthesia levels several hours to several days post-operatively (Gravlee et al., 1993).   
The net effect of the endocrinal response to surgery is an increased secretion of the catabolic 
hormones. Blood glucose concentrations increase with the onset of surgery. Cortisol and 
catecholamines facilitate the production of glucose due to increased hepatic glycogenolysis and 
gluconeogenesis. Mechanisms that maintain glucose homeostasis are ineffective in the peri-
operative period. The risks of prolonged hyperglycaemia are less well established (Desborough 
2000) but it does help to decrease the risk of hyperglycaemia because as this may lead to 
further complications (Marik et al., 2004). 
 
2.3.3.3 Hyperglycaemia, On-Pump vs. Off-Pump CABG Surgery 
 
During cardiac surgery alterations to cardiac output (CO) may occur causing peripheral tissue 
vasoconstriction and as a result decreased peripheral tissue energy production.  It is already 
known that a hypermetabolic response can be seen after cardiac surgery.  It has been 
documented that a hypermetabolic state is present in both on- and off-pump coronary surgery 
as reflected by increased O2 consumption.  However, whole body O2 consumption represents the 
general metabolic behaviour and does not provide any information about peripheral tissue 
metabolism.  A progressive increase in glucose concentration in both the on- and off-pump 
groups can be seen (Cossu et al., 2012). 
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2.3.3.4 Adverse Effects of Hyperglycaemia 
 
The adverse effects of hyperglycaemia include the promotion of oxidative stress, impairment of 
endothelial function, promotion of coagulation, non-enzymatic glycation of platelet 
glycoproteins with abrupt changes in aggregability, amplification of inflammation, suppression 
of immunity and direct toxicity to myocytes and the promotion of apoptosis.  Hyperglycaemia 
may also promote microvascular dysfunction which will lead to poorer clinical outcomes 
(Anantharaman et al., 2009). 
Hyperglycaemia causes a number of damaging effects on the immune defence mechanisms- 
both cellular and humoral.  Alterations include changes in leukocyte function, altered 
microvascular response, and changes in the complement cascade and cytokine network.  
Hyperglycaemia affects leukocyte function in several ways; (1) decreased chemotaxis; (2) 
decreased phagocytosis; (3) decreased adherence; and (4) decreased bacteriocidal activity.  
Hyperglycaemia may also affect leukocyte function through antigen presentation by monocytes.  
Hyperglycaemia causes decreased antigen presentation and clearance which contributes to a 
decrease in infection prevention capabilities (Shilling et al., 2008).   
 
A) Oxidative Stress 
 
Oxidative stress is a well-recognised pathogenic process in the development of atherosclerosis, 
hyperglycaemia, endothelial dysfunction, activation of coagulation (impaired platelet function 
and increased platelet adhesion), and inflammation, suggesting that the action of 
hyperglycaemia is mediated by the production of free radicals (Ceriello, 2004).  
Microvascular and macro-vascular complications are mainly or partly dependant on 
hyperglycaemia.  Hyperglycaemia induced vascular damage may lead to (1) enhanced polyol 
activity, causing fructose accumulation; (2) increased formation of glycation end products (free 
fatty acids); (3) activation of protein kinase C; and (4) increased hexosamine pathway flux.  
Hyperglycemic states trigger all of these damaging metabolic events through the 
overproduction of superoxide radicals through the mitochondrial electron-transport chain 
leading to endothelial dysfunction (Monnier et al., 2006).  
Superoxide over production is accompanied by increased Nitric Oxide (NO) levels, due to 
endothelial NO synthase, favouring the formation of peroxynitrite, which in turn damages DNA.  
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The damaged DNA stimulates the activation of the nuclear enzyme poly (ADP-ribose) 
polymerase.  Poly (ADP-ribose) polymerase diminishes the intracellular levels of its substrate 
NAD+, decreasing the rate of glycolysis, electron transport, and ATP formation.  These processes 
lead to endothelial dysfunction (Ceriello, 2005). 
 
B) Endothelial Dysfunction 
 
It has already been discussed that endothelial cells are extremely sensitive to injurious stimuli.  
Endothelial dysfunction is seen in the earliest stages of arthrosclerosis, even before the 
appearance of plaque (Akbari et al., 1998).  Endothelial cell activation is stimulated by hypoxia, 
exposure to cytokines, endotoxin, and cholesterol, physical injury in the form of surgical 
manipulation or hemodynamic shear stress. In response to stimuli the endothelial cells undergo 
changes that allow them to actively participate in the inflammatory response.  This response 
allows for endothelial-derived factors to disrupt barrier function and enhance vasoconstriction, 
coagulation, leukocyte adhesion, and smooth muscle cell proliferation.  Although these changes 
exist as a protective mechanism this reaction may have serious consequences if the insult is 
severe or continue to spiral out of control (Verrier et al., 1996).  
The end result of the humoral response, leads up to endothelial cell activation, and results in the 
diffuse expression of leukocyte adhesion molecules on surfaces of vascular endothelial cells. 
Once adhering to the endothelium, neutrophils release cytotoxic proteases and oxygen derived 
free radicals that are responsible for organ damage (Boyle et al., 1997). 
 
C) Ischemic Reperfusion Injury (IRI) 
 
IRI is mainly mediated through neutrophil-endothelial interactions.  The ischemic period causes 
high levels of endothelial injury, leading to neutrophil activation and sequestration once 
reperfusion is achieved.  IRI is a manifestation of an acute inflammatory response initiated by 
overlapping cascades of the inflammatory mediators expressed at a local and systemic level.  
Oxygen is vital to cellular aerobic metabolism and the maintenance of high energy stores for 
normal function.  Reintroduction of oxygen to previously hypoxic cells can result in irreversible 
tissue injury and is known as IRI (Boyle et al., 1997).  
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Reperfusion injury results from a number of interdependent mechanisms that are involved in 
the production of reactive oxygen species (ROS). The ROS, formed during oxidative stress, result 
in the oxidation of proteins, lipid peroxidation, inactivation of nitric oxide (NO), and most 
importantly, also causes endothelial injury and microvasculardysfunction (Chandrasena et al., 
2009). 
During cardiac surgery, ischemic/reperfusion injury is initiated during aortic cross-clamping 
where blood supply to the heart and the majority of the lungs is removed.  The heart and lungs 
become ischemic and on release of the clamp they are fully re-perfused.  However, myocardial 
protection extends ischemic tolerance of the myocardium by the reduction of metabolic activity 
but IRI is still exacerbated by increased cross-clamp times (Rao et al., 2001). 
 
2.3.3.5 Hypoglycaemia during Cardiac Surgery 
 
The regular monitoring of glucose levels is important because during the intra-operative period 
insulin resistance increases followed by a rapid decrease post-operatively which could lead to 
severe hypoglycaemia 
Acute hypoglycemia causes distinct physiological responses as a result of autonomic activation, 
principally of the sympatho-adrenal system, and results in end-organ stimulation and a teeming 
release of adrenaline.  This profound autonomic stimulus provokes hemodynamic changes, and 
consequently influences the body’s ability to maintain the supply of glucose to the brain and 
promote the hepatic production of glucose (Cryer, 2004). 
As a consequence of hypoglycaemia the following hemodynamic changes might occur: 
 increased heart rate and peripheral systolic blood pressure, 
 increased blood flow to the myocardium, the splanchnic circulation, and the brain, 
 decreased central blood pressure, 
 decreased peripheral arterial resistance and  
 increased myocardial contractility (Frier et al., 2011). 
The workload of the heart is therefore temporarily, but markedly, increased and may have 
dangerous consequences in older people with coronary heart disease.  
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Hypoglycemia is also known to affect the electrocardiogram (ECG), causing ST wave changes 
with lengthening of the QT interval and cardiac repolarisation. Both induced and spontaneous 
clinical hypoglycaemic episodes prolong cardiac repolarisation.  Changes are reflected by 
changes in the T-wave of the electrocardiogram and may increase the risk of cardiac 
arrhythmia, including ventricular tachycardia and atrial fibrillation (Frier et al., 2011). 
 
2.3.4 The Hemodynamic Response to Cardiac Surgery 
Hemodynamic optimization is a daily occurrence in the hospital environment.  Optimizing tissue 
perfusion is not just the improvement of arterial pressure and CO, but rather the delivery of O2 
from the lungs to the mitochondria in amounts sufficient to sustain required metabolism 
(Mongardon et al., 2009). 
Circulatory abnormalities seen during critical illness lead to an imbalance between systemic 
oxygen delivery and oxygen demand, resulting in global tissue hypoxia or shock. 
At organ level, tissue blood flow and perfusion pressure are controlled by the following extrinsic 
factors: 
 neurological (sympathetic innervations),  
 biochemical (pH, PCO2, and PO2), 
 hormonal (rennin-angiotensin system), 
 vasoactive mediators (NO and prostaglandins) (Mongardon et al., 2009). 
Autoregulation represents intrinsic control and afferent arteriolar tone changes due to 
modifications in perfusion pressure (Mongardon et al., 2009). 
The hemodynamic profile and clinical management of patients are typically characterized in 
terms of global hemodynamic (macro-vascular) parameters, but it remains the responsibility of 
the micro-circulation for delivering blood flow from the cardiovascular system to the tissues.  
With restoration of an acceptable arterial blood pressure, caregivers may be falsely reassured 
that the patient is ‘stable’.  In this case the pathophysiology of events may be described as ‘what 
lies beneath’ in the micro-circulation which may include: global tissue hypoxia, endothelial cell 
injury and the activation of the coagulation cascade and lastly micro-circulatory and 
mitochondrial distress syndrome (MMDS) (Trzeciak et al., 2005; Demers et al., (2000). 
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Profound peripheral vasoconstriction occurs during the initial shock phase of injury where 
blood loss or other causes of hypovolaemia occur.  This leads to renal conservation of water and 
sodium, and the redistribution of circulating blood volume to vital organs.  Early goal directed 
therapy for hypovolaemia is the administration of fluids and vasoactive drugs (Table 2.6).  After 
fluid resuscitation the initial shock phase is followed by a hypermetabolic phase with increased 
O2 consumption and CO2 production.  Due to the increased O2 consumption the body responds 
with actions of vasodilation, increased cardiac output, increased heart rate and increased 
respiratory rate.  The micro-circulation is now compromised in injured tissue due to trauma.  
The body’s effort to provide nutrients to the damaged tissue initiates local vasodilation and 
capillary leakage which leads to local oedema.  Tissue repair occurs within 3-7 days in 
uncomplicated scenarios.  In cases where tissue repair takes longer, postoperative 
complications are most likely to follow (Toft et al., 2008).  
 
Table 2.6  Pharmacological Treatment of Acute Circulatory Failure (adapted from 
 Priebe, 2004). 
DRUG 
MEDIATING 
RECEPTOR(S) 
DOSE 
(µGKG-1 
MIN-1) 
INOTROPIC 
EFFECT 
HR-
EFFECT 
SVR-
EFFECT 
BP-
EFFECT 
Dobutamine β1>β2>α 2–15    HD:  
Dopamine DA>β>α 
Inotropy: 5–
10 
“renal”: 2–5 
SVR: 10–20 
 0,  
 
0 
HD:  
0 
0 
HD:  
Norepinephrine β1>α>β2 
0.01–0.03 
maximal: 0.1 
    
Epinephrine β1=β2>α 
0.01–0.03  
maximal: 0.1–
0.3 
   HD:  0,  
Isoproterenol β1>β2 0.01-0.1     
Phenylephrine Α 0.2-0.3 0 0   
Amrinone PDE Inhibitor 
bolus: 750 (3 
min) infusion: 
2–10 
 0   
=decrease; = increase; 0 = no change; HR = heart rate; SVR = systemic vascular resistance; BP = blood pressure; HD 
= high dose; DA = dopaminergic; PDE = phosphodiesterase (adapted from Priebe, 2004). 
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2.3.4.1 Microvascular and Macrovascular Perfusion 
 
The endothelium regulates the micro-vasculature, reacting to the metabolic needs of tissue.  
Endothelium is important in organ auto regulation and facilitates the response of the 
microvasculature to change local blood flow.  Therefore, it is safe to say that the endothelium 
actively participates in maintaining normal cardiovascular homeostasis (Verrier et al., 1996).  
The micro-circulatory unit consists of the arteriole, the capillary bed, and the post-capillary 
venule, of which the arterioles specifically were of interest where vasoactive mediators exert 
their vasodilatory effects.  Clinically this results in the alteration of the systemic vascular 
resistance (SVR).  During an intense inflammatory response it is in this capillary network where 
endothelial injury and ongoing capillary leakage occur (Trzeciak et al., 2005).  When tissue 
perfusion is continually impaired, cellular dysfunction may become irreversible.   
The causes of impaired tissue perfusion: 
 Low cardiac output, 
 Mal-distribution of blood flow secondary to micro-circulatory dysfunction,   
 Impaired use of substrate due to defects in cellular oxygen utilization (Trzeciak et al., 
2005). 
The clinical signs of hypoperfusion include hypotension, tachycardia, oliguria, cool extremities, 
and metabolic (lactate) acidosis (Trzeciak et al., 2005).  Arterial hypotension itself is not a very 
accurate marker of tissue hypoperfusion because it has been noted from previous studies 
(Rivers et al., 2001; Demers et al., 2000) that tissue hypoperfusion abnormalities, with or 
without impaired cardiac output, can occur long before the appearance of hypotension.  
Therefore, BP parameters are insufficient to identify the need for resuscitation.  Without evident 
hypotension, there appears to be a complex relationship between macro-circulatory 
hemodynamic parameters and micro-circulatory blood flow.  De Backer and co-workers (2002) 
and Sakr et al. (2004) reported that micro-circulatory perfused vessel density was independent 
of arterial blood pressure.  They suggested that micro-circulatory blood flow during severe 
illness is not simply a function of local perfusion pressures but there seems to be a degree of 
disconnection between the macro-circulation and the micro-circulation (Sakr et al., 2004; De 
Backer et al., 2002).   
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During CABG surgery impaired micro-circulation can act as one possible mechanism for the 
development of hyperlactatemia and the other is related to metabolic derangements that reduce 
the prognosis of a patient significantly (Trzeciak et al., 2005).  No matter what the cause, 
unrelenting increased levels of more than 5% of baseline values of lactate can reduce the 
prognosis of a patient significantly (Demers et al., 2000). 
 
A) Oxygen Transport and the Role of the Micro-circulation 
 
The intact micro-circulatory network is a critical intermediate link between the cardiovascular 
system and effective tissue oxygenation, serving as the bridge between the upstream as well as 
the downstream parameters (Figure 2.3).  The Krogh model of micro-circulatory oxygen 
diffusion is a conceptual framework that highlights the significance of the micro-circulation in 
oxygen transport.  When the diffusion distance for oxygen becomes too deep, the anaerobic 
metabolism will most likely take over (Trzeciak et al., 2005; Ranucci et al., 2006).   
Vital information can be retrieved by measuring the mixed venous oxygen saturation (SvO2).  
SvO2 is a global parameter that indicates the oxygen saturation of pooled blood from post-
capillary venules and a low value may indicate anaerobic metabolism; in other words global 
tissue hypoxia (Trzeciak et al., 2005; Ranucci et al., 2006).  Tissue hypoxia has been associated 
with endothelial cell activation, stimulation of systemic inflammation, activation of the 
coagulation cascade as well as multi-organ dysfunction.  Therefore, avoidance of tissue hypoxia 
is an important goal of cardiovascular support (Trzeciak et al., 2005; Ranucci et al., 2006).   
Finding normal or high SvO2 values does not rule out the occurrence of tissue dysoxia. 
Derangements of cellular oxygen utilization may also be playing a significant role.  Cytopathic 
hypoxia is a well recognized mechanism that can cause venous hyperoxia.  An alternative 
explanation may be that micro-circulatory shunting may be the contributing factor.  Blood is 
shunted to open areas of the micro-circulation when weak micro-circulatory units are 
effectively shut down from severe flow impairment.  Shunting results in decreased systemic 
oxygen utilization, venous hyperoxia and also elevated lactate concentrations (Trzeciak et al., 
2005; Ranucci et al., 2006). 
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Figure 2.2 The role of the micro-circulation in goal-directed circulatory support.   
The upstream endpoints of resuscitation are hemodynamic and oxygen-derived variables that can 
be modulated by circulatory support interventions. The downstream variables are markers of 
tissue perfusion and effectiveness of resuscitation. The micro-circulation is the critical 
intermediary that delivers blood flow from the cardiovascular system to the tissues.  [beats per 
minute (BPM);central venous pressure (CVP); oxygen delivery (DO2); heart rate (HR); mean 
arterial pressure (MAP); pulmonary capillary wedge pressure (PCWP);gastric intra-mucosal (pH); 
sublingual pCO2(PsiCO2); systolic blood pressure (SBP);stroke volume (SV); mixed venous oxygen 
saturation (SvO2); systemic vascular resistance (SVR)] (adapted from Trzeciak et al., 2005).  
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2.3.4.2 Hypoperfusion during Cardiac Surgery 
 
When tissues are injured the micro-circulation of the effected tissues are compromised. 
Alterations in microvascular perfusion during cardiac surgery results in various 
pathophysiological changes including the production of vasoactive mediators, activation of 
complement, kinin, cytokine and inflammatory cascades, changes in the endothelial 
permeability, and neutrophil activation. The redistribution of blood flow to maintain perfusion 
of vital organs results in a decreased perfusion to the skeletal muscles, which is an important 
lactate oxidiser, but due to decreased perfusion now becomes a lactate producer (Chiolero, et 
al., 2000).   
The splanchnic circulation may be specifically at risk during the operative period. 
Hypoperfusion of the intestinal mucosa is frequent during major surgery. This results in 
increased permeability to endotoxin, leading to endotoxemia.  Severe stimulation of the 
inflammatory cascade leads to systemic vasodilation with consequent divergence of oxygen 
away from the splanchnic vascular bed. The endotoxins inactivate pyruvate dehydrogenase 
causing an increase in lactate not related to tissue oxygenation. Adrenalin improves cardiac 
output and systemic oxygen delivery, but might also induce anaerobic metabolism, worsen 
tissue hypoxia, leading to lactic acidosis, and decreased splanchnic consumption.  Furthermore, 
glycogenolysis is enhanced resulting in increased pyruvate production. Vasopressin is another 
vasoconstrictor used and is characterized by its potent vasoconstrictive action, especially in 
hemodynamic unstable patients. However, vasopressin compromises splanchnic circulation and 
can lead to excessive lactate production. The hepatic blood flow also decreases, which results in 
a decreased capacity of the liver to use lactate.  During severe splanchnic hypoperfusion, the 
liver now becomes the producer of lactate (Chiolero et al., 2000). 
 
2.3.4.3 Hyperlactatemia during Cardiac Surgery 
 
Hypoperfusion causing increased lactate levels is associated with high postoperative morbidity 
(Ranucci et al., 2006).  Hyperlactatemia may also be due to hemodilution or problematic oxygen 
delivery to various tissues.  Therefore, hyperlactatemia serves as an indicator for circulatory 
failure or insufficiency.   
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Circulatory support therefore involves manipulation of the three determinants of stroke volume 
(preload, taken over by venous return to the pump), myocardial contractility and afterload, 
(taken over by the arterial pump) as well as heart rate (Allsager et al., 2003). 
During CPB systemic microvascular control may deteriorate, inducing peripheral arteriovenous 
shunting that is associated with a rise in lactate levels (Trzeciak et al., 2005; Ranucci et al., 
2006).  
It is important to fulfil the metabolic O2 needs of the patient to avoid hyperlactatemia (acidosis 
Type-A) and to keep maximum flow rates to prevent negative post-operative outcomes (Demers 
et al., 2000). 
The thought of critical O2 delivery is based on the hypothesis that when a patient is perfused 
below maximal flow rates (according to temperature) the oxygen expenditure (Vo2) becomes 
dependent on the oxygen delivery.  Energy production is then to a certain extent supplied by 
anaerobic glycolysis.  Thus when a decrease in peripheral oxygen supply occurs during CABG, an 
increase in lactate production will follow (Ranucci et al., 2006).  
There are three mechanisms that may lead to hyperlactatemia during CABG surgery:  
a) Type A lactic acidosis (Cohen-Woods classification) is caused by poor tissue perfusion, 
shock (hypovolaemic, cardiogenic, haemorrhagic, or septic), acute hypoxaemia or CO2 
poisoning. 
b) Increased lactate production may be stimulated irrespective of tissue dysoxia, as a 
response to inflammatory mediators or through other mechanisms referring to Type-B 
lactic acidosis (Chiolero et al., 2000).   
c) Decreased utilisation of lactate by underperfused liver or muscle cells or glucose failing 
to enter the oxidative pathway and being broken down to lactate by the glycolytic 
pathway (Ranucci et al., 2006).  Tissue dysoxia and inflammatory mediators are a strong 
stimulus for lactate production.  However, hyperglycaemia and increased nonoxidative 
glucose disposal, indicates glucose induced stimulation of tissue glucose uptake and 
glycolysis.  This suggests that hyperglycaemia itself is a large contributor to the 
development of hyperlactatemia (Chiolero et al., 2000). 
Lactate is often used for prediction of clinical outcomes but the question remains if it is 
correctly interpreted in clinical decision-making.  The use of lactate is still controversial because 
of discrepancies regarding reference intervals, cut-off points (Meyer et al., 2013). 
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Changes in lactate level >6mmol/L during cardiopulmonary bypass is an indication that the 
patient is experiencing difficulty and has a significant sensitivity (78%) and specificity (83%) 
for mortality within 3 days (Haterill et al., 1997).   
 
A) Hyperlactatemia: On-pump versus Off-pump 
 
Tissue hypoperfusion is one major risk associated with cardiac surgery.  It is known that CPB 
induces a profound systemic inflammatory response that can alter tissue oxygenation and 
extraction and cause both a decrease in lactate clearance and an increase in lactate production 
(Larmann et al., 2004). 
Hypothermia, re-warming, IRI, and gut-derived endotoxemia are all latent contributors to tissue 
hypoperfusion.  The use of vasoconstrictors may also contribute to tissue hypoperfusion.  
Elevated lactate levels during cardiac surgery may become a unique diagnostic dilemma in the 
sense that increased lactate levels may be secondary to factors inherent to cardiac surgery (CPB 
inflammatory response, and use of vasoconstrictor drugs) or pathological processes (global 
hypoxia, shock, and hypovolemia).  Determining the cause of increased lactate levels may be of 
clinical importance because efforts can then be made to diagnose and treat these pathological 
processes.   
CPB is also a major cause of impaired splanchnic perfusion.  The laminar flow created by CPB 
may cause the release of large amounts of angiotensin II, which is a selective splanchnic 
vasoconstrictor.  Splanchnic ischemia also can increase gut permeability to endotoxin, leading to 
endotoxemia with consequent mismatch of O2 supply and demand and ineffective O2 extraction.  
All of these derangements contribute to the increased risk of increased lactate levels even in the 
presence of normal oxygenation and circulation (Jones et al., 2009; Weissman, 2009). 
Off-pump surgery requires stabilization of the heart and good exposure of the target place of the 
anastomosis.  Altered coronary perfusion by manipulation of the beating heart can lead to 
metabolic changes and electrophysiologic disturbances followed by a reduction in contractility 
which results in an interruption of myocardial oxygen supply (Pojar et al., 2008).  An acute 
deterioration of coronary blood supply can result in a release of ischemic metabolites.  With off-
pump CABG surgery surgical stress is also induced which activates the inflammatory response 
and leads to metabolic changes, and last but not least due to the increased hemodynamic 
instability off-pump patients may need more vasoactive drugs to maintain CO (Stump et al., 
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2001).  This will lead to the same reaction of metabolic changes seen during CPB which in turn 
may lead to increased lactate production.   
Persistent lactate production after reperfusion reflects delayed recovery of aerobic metabolism. 
Hence monitoring of postoperative lactate levels may be useful for assessing the status of 
aerobic metabolism (Chandrasena et al., 2009). 
 
2.4 Metabolic and Hemodynamic Monitoring During 
CABG Surgery 
 
An arterial blood gas (ABG) analysis is performed on arterial blood, drawn from the arterial 
catheter inserted into the radial artery measuring blood pressure.  Table 2.7 represents the 
normal reference ranges for the different ABG variables.  It is important to monitor the 
physiological responses seen during CABG surgery.  This not only allows the assessment of the 
physiological reserve of the patient but will also give a baseline against which the effectiveness 
of any applied treatment can be judged.  Monitoring helps in the early diagnosis of change in 
physiological parameters and provides guidelines towards institution of appropriate therapy.  
There are many physiological variables which can be assessed and these range in complexity as 
well as degrees of invasiveness (Webster, 1999).   
Routine invasive monitoring for all cardiac patients includes arterial cannulation for systolic 
pressure, diastolic pressure and mean arterial pressures (MAP) and routinely central venous 
access to monitor central venous pulmonary artery catheters (PAP) are not used routinely in all 
cardiac patients.  For the purpose of this study pulmonary artery catheter readings were not 
recorded and will not be discussed.  Hemodynamic assessment is important not only to 
establish the patient’s initial profile and risk but also to monitor the efficacy of therapies. 
Routine monitoring provides important clues to possible decompensation, but most resolve 
rapidly during initial therapy (Borst et al., 1999).  Other parameters are also routinely 
measured, but are less invasive in nature, such as temperature, electrocardiogram (ECG) and 
pulse oximetry.   
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2.4.1 Arterial Blood Gas (ABG) 
 
ABG’s are done to determine pH, lactate, partial pressures of oxygen (PaO2) and carbon dioxide 
(PaCO2) as well as the bicarbonate levels (HCO3- std mmol/L) and base excess (BE (B) mmol/L), 
glucose (mmol/L) and lactate (mmol/L).  Other readings include hemoglobin levels and several 
electrolyte balances (Na+ (mmol/L), K+ (mmol/L), Ca++ (mmol/L) and Cl-(mmol/L).  pH 
designates the acid-base balance of arterial blood (Table 2.7).  pH is the units in which the 
relative concentration of hydrogen ions are measured.  The more hydrogen ions in a solution, 
the more acidic the solution is (Kallet et al., 2003).  Normal pH is calculated at 7.45, as long as 
the arterial pH is greater than 7.20, the cardiovascular effects of acidosis are mild because of the 
activity of the compensatory sympathetic nervous system.  The direct depressive effects of 
acidosis on cardiovascular function become more prevalent as the pH falls below 7.20 (Kallet et 
al., 2003). 
Extreme acidosis could potentially lead to increased metabolism, insulin resistance, inhibition of 
anaerobic glycolysis, decreased ATP synthesis, increased protein degradation and 
hyperkaleamia.  It can also cause decreased cardiac contractility, arteriolar dilation, veno-
constriction and centralization of circulating blood volume, as well as increased pulmonary 
vascular resistance.  This may in turn ultimately result in decreased cardiac output and 
decreased arterial blood pressure with reduced renal and hepatic perfusion (Kallet et al., 2003). 
When tissue perfusion is inadequate, serum lactate levels rise due to increased anaerobic 
metabolism.  Inadequate tissue perfusion and oxygenation is manifested by increased lactate 
production and a decrease in pH (Souza et al., 2000). 
Normal arterial pCO2 is maintained between 35 mm Hg and 45 mm Hg.  Arterial pCO2 reflects 
the balance between the production of CO2 and its removal is an independent determinant of pH 
and is produced by cellular metabolism or by the titration of HCO3- by metabolic acids (Davies 
et al., 1997).  According to the Henderson-Hasselbalch (HH) equation an increase in pCO2 will 
result in a decrease in pH and an increase in HCO3- concentration (Kellum, 2005).  The balancing 
component of the respiratory system is the dissolved CO2 that is produced by cellular processes 
and removed by the lungs.  The balancing component of the renal system is the dissolved HCO3 
produced by the kidneys.  The kidneys also help control pH by eliminating hydrogen (H+) ions 
(Kellum, 2005). 
Literature Review                                                                                                                              41 | P a g e  
 
BE (B) (mmol/L), is the measure of metabolic acidosis or alkalosis that is defined as the amount 
of acid or base that must be added to whole blood to restore the pH of the sample to 7.40 while 
the pCO2 is held at 40 mm Hg (Kellum, 2005). 
Potassium (K+) is a critical ion that may present acute changes during cardiac surgery, followed 
by calcium (Ca++).  Other ions such as Cl- and Na+ mmol/L rarely show major changes therefore 
their correction is less demanding.  Hyperkalemia has a prominent effect on cardiac conduction, 
such as a temporary AV block.  With normal renal function, mild hyperkalemia represented by a 
serum level of 6mEq/L will not require special treatment and will resolve spontaneously.  
Hypokalemia on the other hand should be treated to avoid the risks of atrial and ventricular 
arrhythmias (Souza et al., 2000). 
Ca++ levels usually decrease during CPB but appear to recover quickly during the post-operative 
period.  Elevated serum Ca++ levels have been associated with increased peripheral vascular 
resistance and improved coronary, renal and cerebral micro-circulation because of its positive 
inotropic effect.  There is, however, some concern as to the potential role of elevated serum Ca++ 
levels in the aggravation of reperfusion injury (Souza et al., 2000). 
Two sets of information can be obtained from an ABG.  The first is the blood acid-base balance, 
and the second is blood oxygenation.  The measures of blood oxygenation are the oxygen (pO2) 
and the oxygen saturation (O2 sat).  The dissolved oxygen in the blood is called the pO2 and is 
measured in mmHg.  The second measure is the oxygen saturation, which represents the 
amount of hemoglobin sites with attached oxygen.  Oxygen saturation is expressed as a 
percentage of the total sites that have hemoglobin.  The O2 Sat can be continually monitored 
non-invasively with pulse oximetry (Woodruff, 2003). 
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Table 2.7 Reference ranges for Arterial Blood Gas Variables (adapted from Verma et 
al., 2010). 
mmHg= units of measure for pressure;g/dL= gram/decilitre; %= percentage; mmol/L= units of measure for all other 
values. 
 
2.4.2 Temperature 
 
Peripheral temperature (°C) reflects tissue perfusion and is affected by vasoconstriction and 
low cardiac output. There is an increased gradient between core and peripheral temperature in 
shock states (Webster, 1999). 
 
2.4.3 Electrocardiogram (ECG) / Heart Rate (HR) 
 
ECG is a familiar method to monitor cardiac activity, such as ischemic episodes, and may be used 
in the form of continuous bedside monitoring.  ECG is an indispensable part of cardiovascular 
assessment in the significantly ill.  Confirmation of myocardial ischemia, electrolyte imbalance 
and other metabolic disturbances may also be detected.  Patient monitoring such as ECG and 
VARIABLE  NORMAL VALUES UNITS OF MEASURE  
Acid-base Balance 
pH 7.35-7.45  
PaO2 80-100 mmHg 
PaCO2 35-45 mmHg 
HCO3- 22-26 mmol/L 
BE(B)  -2-+2  mmol/L 
Saturation  
Hemoglobin (Hb) 12-14  g/dL 
Saturation >94 % 
Electrolyte Balance 
K+ 3.5-5.0  mmol/L 
Na+ 135-145 mmol/L 
Ca++ 0.9-1.1 mmol/L 
Cl-   
Metabolites 
Glucose 5-7 mmol/L 
Lactate <2 mmol/L 
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hemodynamic monitoring are used but remain restricted in establishing the cause of 
hemodynamic instability (Borst et al., 1999). 
 
2.4.4 Pulse Oximetry 
 
Measurement of the arterial oxygen saturation (SaO2) is essential in the critically ill.  By 
measuring absorption of light at two wavelengths, oxygenated as well as deoxygenated 
haemoglobin can be differentiated, so allowing estimates of arterial saturation (SaO2) to be 
made.  Arterial flow is pulsatile, allowing measurement of the relative percentage of oxygenated 
haemoglobin within arterial blood.  Properly functioning pulse oximetry does reliably reflect 
arterial blood oxihemoglobin saturation.  Pulse rate is also displayed by a pulse oximeter.  Pulse 
oximetry is indicated in any clinical setting where hypoxia may occur (Pearse et al., 2004). 
 
2.4.5 Arterial Blood Pressure  
 
Sudden changes in blood pressure are often associated with cardiac surgery therefore blood 
pressure is continuously monitored.  For this purpose, a cannula is usually inserted 
percutaneously into the radial artery of the left hand. It is inserted under local anaesthetic prior 
to induction of anaesthesia (Schroeder et al., 2007).  The arterial cannula also allows for 
repeated sampling of blood for ABG and acid base analysis.  This is crucial when sudden 
hemodynamic changes are anticipated—for instance, when administering inotropic or 
vasoactive drugs (Hinds et al., 1999). 
Arterial blood pressure is proportional to cardiac output when peripheral resistance is constant.  
Arterial pressure is affected by changes in the volume status of the patient, vasomotor tone and 
cardiac output.  Blood pressure is maintained by physiological compensation in the face of 
changes in blood volume and cardiac output. Indeed, blood pressure may be normal despite 
grossly impaired cardiac function and, therefore, is only a crude indicator of the state of the 
circulation.  However, if blood pressure is inadequate then tissue perfusion will be inadequate.  
Flow to tissues is dependent on mean arterial pressure (MAP).  MAP is not simply an average of 
the systolic and diastolic pressures but is weighted more towards the diastolic pressure - one-
third of the systolic plus twice the diastolic pressure.  Knowledge of the MAP is also required for 
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the calculation of systemic vascular resistance and is often calculated automatically by electrical 
monitors of blood pressure and cardiac output (Webster, 1999). 
The target level of MAP is not necessarily similar in patients.  Even though MAP is usually 
60mmHg, Anderson et al., (2011) suggested that this is not true for all patients.  A MAP of less 
than 60 mmHg could compromise autoregulation in the coronary and renal blood flow in the 
vascular bed of the central nervous system, and blood flow to renal systems.  A number of 
patients, however, do require blood pressures higher than 60 mmHg to maintain adequate 
perfusion (Hinds et al., 1996).  
 
2.4.6 Central Venous Pressure (CVP) 
 
Central venous access is established after induction of anesthesia.  Central venous access is 
primarily required to determine the filling pressure of the right heart (estimation of preload), 
and it also provides, a relatively easy way to determine or monitor intravascular volume status 
(Pearse et al., 2004). 
Normally CVP ranges between 6-12 mmHg.  However, the absolute value is often 
unaccommodating, except in severe cases of hypovolaemia, fluid overload, or heart failure. 
Accurate interpretation requires assessment of the change in central venous pressure in 
response to a fluid challenge in combination with alterations in other monitored variables (such 
as heart rate, blood pressure and urine flow).  CVP monitoring aids in primary resuscitation; 
however, because of the inability to directly assess left ventricular filling pressures and 
volumes, its use is limited by cardiac performance (Hinds et al., 1999). 
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2.5 Post-Operative Clinical Outcomes Associated with 
CABG 
2.5.1 Clinical Outcomes 
 
Morbidity refers to the diseased state of the patient and may often lead to mortality, which is the 
fatal outcome of morbidity.  The long-term outcomes of CABG surgery depend on the intricate 
interaction of patient related and procedure related factors (Laffey et al., 2002).   
Whether OPCAB surgery results in better clinical outcomes when compared to conventional 
CPB with the use of cardioplegic solution (CPS) and an arrested heart remains one of the most 
controversial debated issues in cardiothoracic surgery (Sellke et al., 2005). 
Conventional CABG with the use of CPB still remains the golden standard for revascularisation 
but off-pump coronary artery bypass grafting is used as an alternative technique for 
revascularisation and is said to avoid some of the major side effects of CPB (Pojar et al., 2008).   
Conventional CABG with the use of CPB and CPS assures high quality anastomosis with 
acceptable clinical outcomes (Dybdahl et al., 2004).  Nevertheless, a major complication of on-
pump CABG surgery is the systemic inflammatory response that it provokes which can 
contribute to increased morbidity and mortality rates.   
Evidence exists that OPCAB surgery reduces postoperative morbidity, including myocardial 
injury, renal dysfunction, neurocognitive deficit, and systemic inflammatory response syndrome 
(SIRS).  Despite this the surgical trauma experienced by the patient is similar to that of 
conventional CABG using CPB and OPCAB cardiac surgery (Stump et al., 2001).   
The complications and outcomes often associated with post-operative CABG surgery are 
depicted in Table 2.8.  The STS Adult Cardiac Database: Post-Operative Complications Version 
2.41 was used as a guideline to indicate which complications and clinical outcomes should be 
monitored.   
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Figure 2.3 STS Adult Cardiac Database: Post-operative Complications (adapted from 
 STS Society of thoracic Surgeons, 2008).   
STS Adult Cardiac Database: Post-Operative Complications [Online].  Version 2.41. Available from: 
http://www.ctsnet.org/file/241DataSpecs.pdf [Accessed 22/03/2012]).ICU: intensive care unit, 
[MI: Myocardial Infarction, GIT: Gastro-intestinal tract, SIRS: Systemic Inflammatory Response 
Syndrome]. 
 
2.6 Relevance of the Study 
 
Intra-operative hyperlactatemia and hyperglycaemia are associated with early postoperative 
adverse outcomes in patients undergoing cardiac surgery with CPB. Hypoperfusion during the 
intra-operative period is suggested to be the major cause of increased lactate concentrations 
due to a decreased oxygen supply to tissue resulting in anaerobic metabolism increasing lactate 
production.   
Hence monitoring of postoperative lactate and glucose levels may be useful for assessing the 
status of aerobic metabolism (Chandrasena et al., 2009).   
Hemodynamic instability, resulting in impaired micro-circulation, is one possible mechanism for 
hyperlactatemia and the other is related to metabolic derangements that reduce the prognosis 
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of a patient significantly.  No matter what the cause, uncontrolled levels of lactate >5mmol/L 
can reduce the prognosis of a patient significantly (Trzeciak et al., 2005).   
Literature provides evidence that the degree of hyperglycaemia depends on the severity, extent 
and duration of surgery and mechanisms to maintain glucose homeostasis are ineffective during 
surgery (Desborough, 2000).  The risks of this prolonged hyperglycaemia are less well 
established (Desborough, 2000) but decreasing the risk of hyperglycaemia helps as it has been 
linked to complications associated with SIRS (Marik et al., 2004). 
Due to the fact that metabolic changes are found in both on-pump and off-pump CABG patients 
efforts are made to improve monitoring of both metabolic and clinical changes during CABG 
surgery.   
In this study the value of intra-operative metabolic and clinical monitoring will be assessed by 
evaluating metabolic data and hemodynamic changes, in patients presenting with acute 
coronary syndrome, as a predictor of post-operative clinical outcomes/complications in 
patients that had coronary bypass graft surgery (CABG). 
 
2.6.1 Aim 
 
The aim of the study is to evaluate how metabolic and clinical changes relate to the incidence of 
complications and clinical outcomes in ACS patients undergoing on-pump and off-pump CABG 
surgery  
 
2.6.2 Objectives 
 
 The evaluation and comparison of on-pump vs. off-pump with respect to: 
 Intra-operative metabolic data. 
 Intra-operative hemodynamic data. 
 Post-operative metabolic data. 
 Clinical outcomes and complications. 
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 The evaluation and comparison of lactate <5 mmol/L vs. lactate >5 mmol/L with respect 
to: 
 Intra-operative metabolic data. 
 Intra-operative hemodynamic data. 
 Post-operative metabolic data.  
 Clinical outcomes and complications. 
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Chapter 3 
Methodology 
 
3.1 Study Location 
 
The research study was conducted at Universitas Academic Hospital in the department 
Cardiothoracic Surgery.  Universitas is a state/private hospital located in Bloemfontein, the 
capital city of the Free State, South Africa. 
 
3.2 Study Population 
3.2.1 The Number of Subjects 
 
Sixty patients diagnosed with ACS who received CABG surgery were recruited to participate in 
the research study. The 60 CABG patients were divided into two groups (30 patients who 
received on-pump CABG surgery and 30 patients who received off-pump CABG surgery).   
 
3.2.2 Subject Identification 
 
The patients were selected by either a Cardiologist or a Cardiothoracic Surgeon at the respective 
department situated in UAH. 
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The patients were identified by their hospital number (UM number) therefore preventing 
disclosure of the patient’s personal details and ensuring patient confidentiality. 
 
3.3 Inclusion and Exclusion Criteria 
3.3.1 Inclusion Criteria 
 
 Patients diagnosed with ACS displaying one of the following clinical conditions: 
-   Unstable angina, 
-   ST-elevation myocardial infarction, 
-   Non-ST-elevation myocardial infarction. 
 Patients receiving CABG surgery as method of treatment. 
 Patients able to give informed consent. 
 
3.3.2 Exclusion Criteria 
 
 Patients with existing organ failures other than congestive cardiac failure (CCF). 
 Patients not receiving isolated CABG surgery. 
 
3.4 Study Design 
 
Sixty patients operated in theatre 7 that met the inclusion criteria of the research project was 
selected to form part of this observational analytical cohort study.  Only patients in theatre 7 
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was recruited for the study due to the fact that the Datex hemodynamic monitoring system was 
only available in theatre 7, Universitas Academic Hospital. 
 
3.5 Study Layout 
3.5.1 Phase 1 
 
Phase 1 consisted of 60 patients diagnosed with ACS and received CABG surgery as mode of 
treatment.  The 60 patients were divided into two groups, 30 patients received CABG surgery 
on-pump and 30 patients received CABG surgery off-pump (Figure 3.1a).  Demographic and 
clinical data, intra-operative arterial blood gasses (metabolic data), intra-operative 
hemodynamic data, post-operative arterial blood gasses (metabolic data) and the clinical 
outcomes/complications were recorded and compared between the 2 groups. 
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Figure 3.1.a Schematic Presentation of Study Layout- Phase 1. 
[Acute Coronary Syndrome (ACS); Coronary Artery Bypass Graft surgery (CABG); Arterial Blood Gas (ABG); Central 
Venous Pressure (CVP); Heart Rate (HR); Haemoglobin (Hb); BP (systolic, diastolic and mean arterial blood pressure) 
ECG (Electrocardiograph; ICU (intensive care unit), MI (Myocardial Infarction), GIT (Gastrointestinal Tract)). 
 
60 ACS patients recieving CABG surgery 
30 patients on-pump 
CABG
Demographic & Clinical 
Data
On-Pump CABG 
Surgery
ABG
Baseline 
Intubation
T1-T9 = 15 minute intervals
Hemodynamic Data
Systolic, Diastolic, MAP, CVP, HR and 
Temperature
Post-operative Admission to ICU
ABG
1hr, 2hrs, 4hrs, 8hrs, 12hrs, 24hrs, 48hrs, 72hrs
Clinical Outcomes / 
Complications
(STS Database)
30 patients off-pump 
CABG 
Demographic & Clinical 
Data
Off-Pump CABG 
Surgery
ABG
Baseline
Intubation
T1-T9 = 15 Minute Intervals
Hemodynamic Data
Systolic , Diastolic, MAP, CVP, HR and 
Temperature 
Post-operative Admission to ICU
ABG
1hr, 2hrs, 4hrs, 8hrs, 12hrs, 24hrs, 48hrs, 72hrs
Clinical Outcomes / 
Complications
(STS Database)
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3.5.1.1 Demographic and Clinical Data 
 
Upon admission each patient’s demographic data (EuroSCORE%, ethnicity, gender, age, height, 
weight, body surface area (BSA) and body surface index (BSI)) and clinical data (smoking, 
diabetes, renal complications, neurological complications, pulmonary complications, previous 
non-surgical intervention, dyspnoea, LVEF%, hypertension, ACS and last previous MI) were 
recorded (Figure 3.1a).   
 
3.5.1.2 Metabolic Data 
 
Intra-operative metabolic data were captured for both the on-pump and off-pump CABG 
patients.  Glucose, lactate, pH, PO2, PCO2, HCO3, BE, Hb, Saturation, K+, Ca++, Na+ and Cl- 
concentrations were recorded as part of the ABG.  ABG’s were drawn at baseline and intubation, 
then at 15 minute time intervals after initiation of CBP for the on-pump group, and 15 minute 
time intervals after manipulation of the heart for the off-pump group (for the duration of 
surgery). 
The same metabolic data were captured during the post-operative period at the following time 
intervals: 1 hour, 2 hours, 4 hours, 8 hours, 12 hours, 24 hours, 48 hours and 72 hours after 
admission to the ICU.   
 
3.5.1.3 Hemodynamic Monitoring 
 
Intra-operatively, hemodynamic data were recorded using the Datex Omeda software program.  
The recorded data included; blood pressure (BP) (systolic, diastolic and mean arterial pressure 
(MAP), heart rate (HR), central venous pressure (CVP) and temperature at increments of 1 
minute (Figure 3.1a). 
 
3.5.1.4 Clinical Outcomes/Complications 
 
The clinical outcomes/complications (Figure 3.1a) were recorded using the STS database 
(Appendix E). 
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3.5.2 Phase 2 
 
Irrespective of surgical technique, the 60 patients were divided into those with lactate levels 
<5mmol/L or lactate levels >5mmol/L.  Comparisons between the two groups were made with 
reference to the metabolic data, hemodynamic data and post-operative clinical outcomes 
/complications (Figure 3.1b, refer to section 3.5.1.1, 3.5.1.2 and 3.5.1.3). 
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Figure 3.1.b Schematic Presentation of Study Layout- Phase 2 
[Acute Coronary Syndrome (ACS); Coronary Artery Bypass Graft surgery (CABG); Arterial Blood Gas (ABG); Central 
Venous Pressure (CVP); Heart Rate (HR); Haemoglobin (Hb); BP (systolic, diastolic and mean arterial blood pressure) 
ECG (Electrocardiograph; ICU (intensive care unit), MI (Myocardial Infarction), GIT (Gastrointestinal Tract). 
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3.6 Special Investigations 
3.6.1 Demographic and Clinical Data 
 
The following demographic data were recorded for each patient: 
 Age (years). 
 Gender (M/F). 
 Weight (kg). 
 Height (cm). 
 BMI - Body Mass Index = Weight(kg) / Height(m)2 a measure of body fat based on height 
and weight (Gallagher et al., 1996).  
  BSA – Body Surface Area 0.20247 x height (m)0.725 x weight (kg)0.425 using the Du Bois 
formula (Wang et., 1992). 
 Euroscore calculated using the EuroSCORE II model (Roques et al., 2003).  
 Ethnicity. 
The patient’s pre-operative risk profile was established using the following clinical data (Figure 
3.2). 
 
Figure 3.2 Pre-operative risk profile 
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3.6.2 Arterial Blood Gas Analysis 
3.6.2.1 Sample Collection 
 
For each ABG analysis two millilitres of whole blood was drawn in a pre-heparinised syringe 
(BD Diagnostics) intra-operatively for all patients (Rapidlab 1200, Serial Number 013062).  The 
recorded ABG variables for both groups intra- and post-operatively were pH, pO2, pCO2, during 
HCO3-, BE (B), O2 SAT, Sodium (Na+), Potassium (K+), Calcium (Ca++), Chloride (Cl-), glucose and 
lactate (Table 3.1). 
 
A) On-pump CABG Surgery 
 
During on-pump CABG surgery, arterial blood was drawn for ABG analysis from an indwelling 
radial artery catheter before induction of anaesthesia (baseline) and 5 minutes after intubation.   
Blood was drawn from the sample port of the oxygenator (Sorin Group Italy, Ref: 050239) after 
the initiation of bypass and every 15 minutes until termination of CPB.  
 
B) Off-pump CABG Surgery 
 
During off-pump CABG surgery the arterial blood samples were drawn for ABG analysis from an 
indwelling radial artery catheter before induction of anaesthesia (baseline), 5 minutes after 
intubation and after repositioning of the heart, every 15 minutes until the last anastomosis was 
completed. 
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C) Post-operative ABG Sampling for both On-pump and Off-pump 
Groups 
 
Two millilitre of whole blood was drawn from the patient’s arterial line in a pre-heparinised 
syringe (BD Diagnostics) for an arterial blood gas analysis (Rapidlab 1200, Serial Number 
013062).   
The arterial blood was drawn from the indwelling radial artery catheter during specified time 
intervals scheduled at 1 hour, 2 hours, 4 hours, 8 hours, 12 hours, 24 hours, 48 hours and 72 
hours during the post-operative period in the ICU for both the on- and off-pump groups .  
 
Table 3.1 Metabolic Data and Normal and Abnormal References Ranges 
ARTERIAL BLOOD 
GAS (ABG)  
VARIABLE (UNIT) 
NORMAL 
REFERENCE RANGE 
FOR THE PURPOSE OF THE STUDY 
ABNORMAL VALUES WERE DEFINED 
AS: 
pH 7.35-7.45 <7.2 / 7.5> 
pCO2 (mmHg) 35-45 mmHg  <30mmHg or >46mmHg  
pO2 (mmHg) 100-250 mmHg  <60mmHg 
HCO3- STD (mmol/L) 22-26 mmol/L 
Metabolic Acidosis <22mmol/L;  Metabolic Alkalosis 
>22mmol/L 
BE (B) (mmol/L) -2 mmol/L-+2 mmol/L 
Metabolic Acidosis <-2mmol/L;  Metabolic Alkalosis 
>+2mmol/L 
tHb (g/dL) 12-14 g/dL <8g/dL 
O2 Sat (%) >94% <85% 
Na+ (mmol/L) 135-145 mmol/L >145 mmol/L 
K+ (mmol/L) 3.5-5.0 mmol/L <3mmol/L or >6mmol/L 
Ca++ (mmol/L) 0.9-1.1 mmol/L  >1.1 mmol/L 
Cl- (mmol/L) 104-112 mmol/L >112 mmol/L 
Glucose (mmol/L) 5 mmol/L > 10 mmol/L 
Lactate (mmol/L) <2 mmol/L > 5 mmol/L 
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3.6.3 Hemodynamic Monitoring 
 
Intra-operative hemodynamic data were recorded electronically at 10 second intervals using 
the Datex-Ohmeda S/5TM software program (Datex-Ohmeda S/5™ Collect, GE Healthcare 
software, Ref: L-COLLECT4-01-EN, SN: 6521804, GE Healthcare, Finland).   
The Datex-Ohmeda monitor displays a hemodynamic calculation view where values were 
selected and analysed only at baseline and intubation for both the on-pump and off-pump 
groups and thereafter at 15 minute intervals from onset of CPB for the on-pump group and for 
the off-pump group at 15 minute intervals after manipulation of the heart.  The system collected 
trend waveforms and alarm data directly from a Datex-Ohmeda monitor ((Datex-Ohmeda S/5 ™ 
Cardiovascular Anaesthetic monitor Serial no: 90027365 and 4416799) through a PC serial 
interface cable (RS 232).   
The following hemodynamic parameters were recorded for both the on-pump and off-pump 
groups: 
a) Arterial blood pressure (systolic, diastolic and mean BP via an arterial catheter placed 
into the left radial artery). 
b) Central venous pressure (measured in the SVC with a cannula inserted from either the 
internal jugular or subclavian vein). 
c) Pulse oximetry (probe placed on the patient’s index finger, measured arterial oxygen 
saturation and pulse rate). 
d) Heart rate (recorded via a 3-lead ECG). 
e) Temperature. 
 
Hemodynamic data were collected every minute, but for the purpose of the study, was 
presented at baseline, intubation and 15 minute intervals from onset of CPB for the on-pump 
group.  Hemodynamic data for the off-pump group was presented at baseline, intubation and 15 
minute intervals after manipulation of the heart.   
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3.6.4 Coronary Artery Bypass Graft (CABG) Surgery 
 
The Cardiologist and Cardiothoracic Surgeon made a collaborative decision regarding the 
optimal course of treatment for the patient.   
The study did not influence the surgeon’s decision whether to perform the CABG procedure 
with or without cardiopulmonary bypass. The surgeon selected the method that was most 
suited and beneficial to the patient's condition taking all factors into consideration.  It was the 
surgeon’s decision whether on-pump or off-pump CABG surgery would yield the best possible 
outcome for the patient.  
 
3.6.5 Surgical Techniques 
3.6.5.1 On-pump CABG Surgery 
 
(A) Preparation of the perfusion system in theatre 
 
• The Stöckert S5 System (Cardiopulmonary bypass system, Serial no: 48E00380  and 
48E00381) was routinely used and the bypass circuit setup included: 
• Sorin Biomedica Synthesis oxygenator (Ref: 050239, Sorin Group, Italy). 
• Medtronic adult membrane pack (Ref: M273102E, Medtronic Inc. Minneapolis, USA). 
• Medtronic Myotherm 4:1 (Ref: M999214E, Medtronic Inc. Minneapolis, USA). 
• Medex disposable dome for the Medex transducer (Ref: MX960XYP1, Medex medical 
LTD, Lancashire) (cardioplegia pressure transducer). 
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(B) Prior to CPB the circuit was de-aired using the following 
prime 
 
• 1L Balsol Infusion (Ref: FSB001000, Fresenius Kabi for Bodene Limited trading as 
Intramed, Port Elizabeth, RSA). 
• 12.5g Mannitol (Intramed Mannitol 25% m/v, 12.5g, 50ml, Ref: FSM 250050, Fresenius 
Kabi for Bodene Limited trading as Intramed, Port Elizabeth, RSA). 
• 30mg Heparin, Heparin Sodium-Fresenius 1000 i.u. /ml (Ref: J/8.2/405, Fresenius Kabi 
for Bodene Limited trading as Intramed, Port Elizabeth, RSA). 
• 1g Ranzol (Ranbaxy Ranzol Injection Cefazolin Sodium (Sterile) 1m/Intra Venous (I.V.), 
Ref: 30/20.1.1/0333, Code: MP/DRUGS/28/15/83, Ranbaxy (SA) (Pty) LTD, North 
Centurion, RSA). 
• 500ml Gelofusion (Gelofusion Solution for intra venous (I.V.) infusion, Plasma Substitute 
Ref: 31/8.4/0360, B. Braun Medical (Pty) LTD, Randburg, RSA). 
 
(C) The transducer was prepared for measurement of arterial 
cannula pressure 
 
• Edwards Lifesciences pressure monitoring set (Ref: PX600FP, Edwards Lifesciences, 
Irvine, USA). 
• CritiCare 0.9% Sodium Chloride Injection BP (200ml) (Ref: 32/24/0128, Dismed 
CritiCare (Pty) LTD, Midrand, RSA). 
• 30mg Heparin, Heparin Sodium-Fresenius 1000 i.u/ml (Ref: J/8.2/405, Fresenius Kabi 
for Bodene Limited trading as Intramed, Port Elizabeth, RSA). 
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(D) Cardioplegia 
 
• Two cardioplegic solutions were used at UAH, depending on surgeon’s preference: 
 
(D1) Buckberg solution 
 
• Medsol Cardioplegic Induction Solution (Ref: FSM01850I, Fresenius Kabi for  Bodene 
Limited trading as Intramed, Port Elizabeth, RSA). 
• Medsol Cardioplegic Maintenance Solution (Ref: FSM01850M, Fresenius Kabi for 
Bodene Limited trading as Intramed, Port Elizabeth, RSA). 
• Medsol Cardioplegic Reperfusion Solution (Ref: FSM01850R, Fresenius Kabi for Bodene 
Limited trading as Intramed, Port Elizabeth, RSA). 
• 10ml 50% Dextrose added to each bag of cardioplegic solution (Dextose-Fresenium 50% 
(20ml) (Ref: V/24/222, Fresenius Kabi for Bodene Limited trading as Intramed, Port 
Elizabeth, RSA). 
 
(D2) Modified St Thomas solution 
 
• 1000ml cold Ringer-Lactate (Intramed Ringer-Lactate Solution 1000ml Infusion, Ref: 
FSR001000, Fresenius Kabi for Bodene Limited trading as Intramed, Port Elizabeth, 
RSA). 
• 50ml, 4% Albusol (Human Plasma Albumin, Ref: T/30.3/738, National Bioproducts 
Institute, Pinetown, RSA). 
• 30ml, 8.5% Sodium Bicarbonate (Intramed Sodium Bicarbonate Injection 8.5% (50ml) 
m/v, Ref: FSS850050, Fresenius Kabi for Bodene Limited trading as  Intramed, Port 
Elizabeth, RSA). 
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• 200mg Lignocaine (Lignocaine HCl-Fresenius, Ref: M/4/254, Fresenius Kabi for 
 Bodene Limited trading as Intramed, Port Elizabeth, RSA). 
• 4g Magnesium Sulphate (SABAX Magnesium Sulphate 50% Injection (1g/2ml) iv/imi, 
Pharmacological Classification A.24 (Mineral Substitutes, Electrolytes, Ref: V/24/253, 
ADCOCK Ingram Critical Care (Pty) LTD, Johannesburg, RSA). 
• 30mmol/L Potassium (SABAX Potassium Chloride 15% Injection, Pharmacological 
Classification A.24 (Mineral Substitutes, Electrolytes, Ref: V/24/218, ADCOCK Ingram 
Critical Care (Pty) LTD, Johannesburg, RSA). 
 
(E) Peri-operative management of the patient 
 
 A three point ECG was connected to the patient’s back. 
 Peripheral lines and arterial blood pressure lines were inserted. 
 Anesthesia commenced. 
 Central venous line was inserted. 
 Median sternotomy was performed by the surgeon and saphenous vein grafts were 
harvested from patient’s legs by the assistant.  Internal Mammary Artery  may also 
have been harvested by the surgeon. 
 Full systemic heparinization of the patient was achieved by intravenous administration 
of 4 mg/kg Heparin (Heparin Sodium-Fresenius 1000 i.u/ml, Ref: J/8.2/405, Fresenius 
Kabi for Bodene Limited trading as Intramed, Port  Elizabeth, RSA). 
 5 minutes after heparin administration activated clotting time (ACT) sample was drawn, 
and ACT was measured. 
 The ascending aorta was cannulated and as soon as an ACT of 480 seconds was 
achieved, bypass commenced. 
 Access to the right atrium was established and venous blood was obtained through 
cannulation with a two-stage venous cannula via the right atrial appendage. 
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 Systemic hypothermia of between 28-30⁰C was achieved and the alpha-stat principle 
was applied. 
 An antegrade cardioplegia cannula was placed in the aortic root proximal to the 
arterial cannula. This cannula also served as an aortic vent. 
 The ascending aorta was cross-clamped between the aortic cannula and the antegrade 
cardioplegia cannula. 
 Infusion of cold blood cardioplegia (at ± 20⁰C), antegrade into aortic root via 
cardioplegia cannula and was repeated every 20 minutes. 
 Topical ice slush was applied onto the heart. 
 Distal venous anastomoses were performed on the coronary artery. 
 When last distal anastomosis was performed, rewarming commenced. 
 The aortic root was de-aired through the LV vent cannula. 
 The aorta cross clamp was removed from the distal ascending aorta, when 
normothermia was reached.  
 Oxygenated blood was flowed into the bypassed vessels using a manifold. 
  Proximal anastomosis was performed on the distal ascending aorta utilizing a side-
biting clamp. 
 Cardiopulmonary bypass was weaned and stopped. 
 Protamine was given to reverse Heparin. (Three quarters of heparin dosage = 3mg/kg 
Protamine Sulphate, (Protamine Sulphate), Ref: 4543/0234, CP  Pharmaceuticals 
LTD, Wrexham). 
 Once haemostasis was achieved, mediastinal and pericardial underwater drains were 
inserted. 
 The sternum was wired and the sternotomy closed. 
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3.6.5.2 Off-pump CABG Surgery 
 
 A three point ECG was connected to the patient’s back. 
 Peripheral lines and arterial blood pressure lines were inserted. 
 Anaesthesia commenced. 
 The central venous line was inserted. 
 Patient was draped and autologous cell salvage suction/aspiration line was handed to 
the scrub sister. 
 Surgeon performed median sternotomy and the assistant harvested saphenous veins 
from the patient’s legs. Internal Mammary Artery may also be harvested by surgeon. 
 1mg/kg Heparin was given to the patient to partially heparinize the patient (Heparin 
Sodium-Fresenius 1000 i.u/ml Ref: J/8.2/405, Fresenius Kabi for Bodene Limited 
trading as Intramed, Port Elizabeth, RSA). 
 The distal venous anastomoses onto the coronary artery were performed using one of 3 
stabilizers to stabilize the area. 
- Medtronic Octopus 4 (Ref: 29400, Medtronic Inc. Minneapolis, USA). 
- Medtronic Starfish 2 (Ref: 29800, Medtronic Inc. Minneapolis, USA). 
- Genzyme stabilizer (Ref: TX180010, Thebe Medical, Johannesburg, RSA). 
 A coronary shunt may be used by the surgeon. 
- Medtronic Clear view 1.5mm (Ref: 31150, Medtronic Inc. Minneapolis, USA). 
 A water-filled glove was placed posterior to the heart and steadily inflated in order to 
bring the heart more anterior if necessary or a posterior pericardial stitch and vaginal 
swab could have been used to facilitate better exposure of the coronary arteries. 
 Proximal anastomoses were performed on the ascending aorta utilizing a side-biting 
clamp. 
 Protamine was given to reverse Heparin. (Three quarters of heparin dosage = mg/kg 
Protamine Sulphate dosage).  Prosulf (Protamine Sulphate, Ref: 4543/0234, CP 
Pharmaceuticals LTD,  Wrexham). 
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 Once haemostasis was achieved, mediastinal and pericardial underwater drains were 
inserted. 
 Sternum was wired and the sternotomy was closed. 
 
3.6.6 Post-operative Complications 
 
The surgical data was captured by a cardiothoracic surgeon in a surgical database.  The pre-
operative dataset of the surgical registry was designed in accordance with the Society of 
Cardiothoracic Surgeons of Great Britain and Ireland (SCTS) Adult Cardiac database and the 
post-operative dataset in accordance with the Society of Thoracic Surgeons (STS) Adult Cardiac 
Database.  Details for the pre-operative and post-operative datasets can be viewed in 
Appendices C and D. 
The STS Adult Cardiac Database (Figure 3.3) was used to assess surgical outcome of patients 
included in the study (Adapted from: STS Society of thoracic Surgeons.  2008.  STS Adult Cardiac 
Database: Post-Operative Complications [Online]. Version 2.41. Available from: 
http://www.ctsnet.org [Accessed 20/07/2012]). 
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Figure 3.3 Post-operative Complications Recorded by STS Adult Cardiac 
Database. 
(Adapted from: STS Society of thoracic Surgeons. 2008. STS Adult Cardiac Database: Post-
Operative Complications [Online]. Version 2.41. Available from: 
http://www.ctsnet.org/file/241DataSpecs.pdf [Accessed 20/07/2012]). 
 
3.7 Statistical Analysis 
 
Data was captured on a Microsoft ® Excel spreadsheet.  The statistical analysis was done by a 
qualified biostatistician using SAS Version 9.2.  The data was summarised using descriptive 
statistics, namely percentages and frequencies for categorical data.  Medians and percentiles 
were used to summarize continuous data.   
Analytical statistics compared the frequencies and percentages in different groups by using the 
Chi-square test to calculate p-values.  Medians were compared by using the Kruskal-Wallis test 
to calculate p-values.  Mean values were compared using the Wilcoxon-Mann-Whitney to 
calculate p-values.  Significant differences were noted at p < 0.05.  The hemodynamic and 
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metabolic data were plotted over time, and by analysis group, to provide a visual representation 
of the changes intra- and post-operatively. 
Two separate group analyses were performed when analysing the data.  The on- and off-pump 
patients were compared to assess whether the two groups were comparable regarding 
demographic, risk profiles, intra-and post-operative data and clinical outcomes.  Thereafter the 
data was stratified into two groups, regardless of whether they were operated on- or off-pump, 
according to whether their lactate level ever peaked above 5 mmol/l during surgery or not. The 
same set of analyses were performed as for the on- and off-pump comparisons. 
A power analysis was calculated using G* Power, version 3.1.7 software (Faul, 2013). 
 
3.8 Ethical Aspects 
3.8.1 Ethical Clearance 
 
This study was conducted as part of the project: "Endothelial function as a predictor of post-
intervention outcomes" and was granted ethical clearance by the Ethics Committee of the University 
of the Free State (ETOVS nr 51/07A) (Appendix F).  Approval was also granted by the Clinical Head 
and Director of Finance of Universitas Academic Hospital. 
 
3.9 Safety Variables 
3.9.1 Project and Patient Safety 
 
The research project was safe.  All the procedures were routine procedures for cardiology and 
cardiothoracic surgery and the study did not in any means interfere with the desired treatment 
plan for the patient. 
 Methodology                                                                                                                                        69 | P a g e  
 
 
Patients participating in the study were monitored by doctors in the department of 
cardiothoracic surgery and could discontinue participation at any time without influencing the 
quality of their care/treatment. 
 
3.9.2 Good Clinical Practice (GCP) / Quality Assurance 
 
All clinical work conducted under this research study was subjected to the South African Good 
Clinical Practice guidelines (SA GCP) (The Principles of ICH GCP, 2004). 
The declaration of Helsinki’s basic principle number 3 states that research should be conducted 
only by scientifically qualified people and under the supervision of adequately qualified people 
(World Medical Association, 2002).  Therefore, the research project was administered by 
registered Cardiothoracic Surgeons and Clinical Technologists (Registered with the Health 
Professional Council of South Africa). 
 
3.9.3 Informed Consent and Information Leaflet 
 
Participation was only allowed after informed consent was given.  Each patient received an 
information document that explained the purpose and extent of participation in the research 
study.  Both the informed consent and the information leaflet were approved by the Ethics 
Committee of the University of the Free State. 
 
3.9.4 Confidentiality 
 
The personal details of every patient participating in the study were kept confidential as far as 
possible.  At no time during the research were any of the patients’ identification details made 
known to any person who was not part of the research team.  For the purpose of data collection 
and statistical analysis patients were identified by their hospital number (UM number).  
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3.9.5 Financial Implications to the Patient 
 
The majority of the investigations performed during this study were routine medical practice.  
Financial constraints caused by any additional tests were the responsibility of the Department 
of Cardiothoracic Surgery.  No financial remuneration was claimed or paid to from the patients 
to participate in the study. 
 
3.9.6 Withdrawal Criteria 
 
Participation in the study was voluntary.  Patients had the right to withdraw from the study at 
any time, without stating reason and without influencing the quality of their health care. 
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Chapter 4  
Results 
 
4.1 Introduction 
 
The metabolic and clinical changes of sixty patients diagnosed with ACS undergoing on- and off-
pump CABG surgery were evaluated during the study.  Thirty patients underwent on-pump 
CABG and 30 patients received off-pump CABG surgery.  The sixty patients were then further 
evaluated with respect to lactate levels of <5mmol/L and >5mmol/L.  The objectives for the 
study are defined in Figure 4.1.   
 
 
Figure 4.1 Schematic presentation of research objectives 
 
 
 
 
• The evaluation and comparison of on-pump vs. off-pump CABG surgery with respect
to:
• Intra-operative metabolic data
• Intra-operative hemodynamic data
•Post-operative metabolic data
•Clinical outcomes and complications
Objective 1
• The evaluation and comparison of patients with a lactate <5 mmol/L vs lactate
>5 mmol/L with respect to:
• Intra-operative metabolic data
• Intra-operative hemodynamic data
•Post-operative metabolic data
•Clinical outcomes and complications
Objective 2
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4.2 Study Population 
4.2.1 Demographic Data 
 
Sixty ACS patients receiving CABG surgery (30 patients on-pump and 30 patients off-pump) 
participated in the study.  The on-pump 27 (90%) and off-pump 23 (77%) CABG groups were 
both predominantly male (Figure 4.2) (p >0.05). 
 
 
Figure 4.2 Gender distribution for on-pump and off-pump CABG groups. 
[n=number of patients; % = percentage of patients]. 
 
The majority of patients were Caucasian 50 (83%) followed by Coloured 6 (10%) and Negroid 4 
(7%) (Figure 4.3).  The on-pump and off-pump groups were similar with respect to ethnicity  
(p >0.05). 
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Figure 4.3 Ethnicity distribution for On-pump and Off-pump CABG patients.   
[Caucasian on-pump 24 (80.0%); Caucasian off-pump 26 (86.0%); Coloured on-pump 3 (10%); 
Coloured off-pump 3 (6.0%); Negroid on-pump 3 (10.0%); Negroid off-pump 1 (3.0%); n=number 
of patients; % = percentage of patients.   
 
Although the groups were small they exhibited similar demographic data (Table 4.1).  No 
statistically significant differences (p >0.05) were reported for the EuroSCORE, age, height, 
weight, body surface area (BSA) and body mass index (BMI). 
 
Table 4.1 Demographic Data: On-pump vs. Off-pump CABG Groups 
VARIABLE (UNIT) ON-PUMP OFF-PUMP p-VALUE 
EuroSCORE (%) 
Median 4.0 3.3 
0.19 25th percentile 2.6 1.8 
75th percentile 7.1 6.3 
Age (years) 
Median 58.0 61.0 
0.37 25th percentile 54.0 53.0 
75th percentile 67.0 67.0 
Height (cm) 
Median 177.5 176.0 
0.84 
25th percentile 170.0 170.0 
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VARIABLE (UNIT) ON-PUMP OFF-PUMP p-VALUE 
75th percentile 183.0 184.0 
Weight (kg) 
Median 81.5 90.5 
0.72 25th percentile 75.0 75.0 
75th percentile 96.0 106.0 
BSA (m²) 
Median 1.9 2.0 
0.82 25th percentile 1.8 1.7 
75th percentile 2.1 2.2 
BMI (kg/m²) 
Median 26.5 29.0 
0.34 25th percentile 24.5 25.2 
75th percentile 31.0 32.8 
Significant differences were noted at p < 0.05.  [BSA= Body Surface Area; BMI= Body Mass Index; EuroSCORE: 
calculated using the EuroSCORE II model]. 
 
4.2.2 Pre-operative Clinical Data: On-pump vs.  
   Off-pump CABG Groups 
 
The major pre-operative risk factors recorded for the on- and off-pump CABG groups are 
summarized in Table 4.2.  
The majority of pre-operative risk factors (Table 4.2) showed no statistically significant 
differences between the two groups (p>0.05). 
However, the number of patients that were either smokers or ex-smokers was notable.  In the 
on-pump CABG group 24 (80.0%) of the patients either had a history of smoking or were 
current smokers and in the off-pump CABG group 26 (87.0%) of patients presented as smokers 
or ex-smokers.   
Six (20.0%) patients in both groups had mild COPD, 3 (10.0%) in the off-pump group presented 
with mild COPD and asthma, 1 (3.3%) in the on-pump group had moderate COPD and 1 (3.33%) 
in the off-pump group had severe COPD (Table 4.2).  Most patients had no pre-operative COPD, 
thus, with respect to pulmonary disease the on-pump and off-pump groups were similar.   
ACS was classified as UA, STEMI and NONSTEMI. One patient (3.3%) in the on-pump group and 
5 (16.7%) patients in the off-pump presented with STEMI.  Four patients (13.3%) in the on-
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pump group and 3 (10.0%) patients in the off-pump presented with NONSTEMI.  The majority 
of patients presented with UA, 25 (83.3%) for the on-pump group and 22 (73.3%) for the off-
pump group with no statistically significant difference (p>0.05) between the groups.   
Statistically significant differences between the on-pump and off-pump groups were noted for 
number of previous MI’s (p<0.05) and last previous MI’s upon admission to Cardiology (p<0.05) 
(Table 4.2).  In the case of the off-pump group the last previous MI was unknown for 18 (60%) 
of the patients and thus the difference between the groups may not be notable.   
 
Table 4.2 Pre-operative Clinical Data: On-pump vs. Off-pump Groups 
VARIABLE (UNIT) ON-PUMP 
n (%) 
OFF-PUMP 
n (%) 
p-VALUE 
LVEF % 
Median 51.0 56.5 
0.21 25th percentile 40.0 48.0 
75th percentile 65.0 66.0 
Smoking 
Ex-smoker 6 (20.0%) 12 (40.0%) 
0.27 Never 6 (20.0%) 4 (13.3%) 
Current 18 (60.0%) 14 (46.7%) 
Renal complications 
No 29 (96.7%) 29 (96.7%) 
1.00 
Yes 1 (3.3%) 1 (3.3%) 
Neurological disease 
No 30 (100%) 29 (96.7%) 
0.49 
Yes CVA with full recovery - 1 (3.3%) 
Pulmonary disease 
None 23 (76.7%) 20 (66.7%) 
0.30 
Mild COPD 6 (20.0%) 6 (20.0%) 
Moderate COPD 1 (3.3%) - 
Severe COPD - 1 (3.3%) 
Asthma + Mild COPD - 3 (10.0%) 
Previous non-surgical intervention 
Previous PCI 3 (10.0%) 2 (6.7%) 
0.67 
PCI > 24hrs before surgery 1 (3.3%) - 
Dyspnoea 
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VARIABLE (UNIT) ON-PUMP 
n (%) 
OFF-PUMP 
n (%) 
p-VALUE 
NYHA I 8 (26.7%) 3 (10.0%) 
0.26 
NYHA II 18 (60.0%) 23 (76.7%) 
NYHA III 4 (13.3%) 3 (10.0%) 
NYHA I-IV - 1 (3.3%) 
Diabetes 
None 24 (80.0%) 19 (63.3%) 
0.35 
Diet 1 (3.3%) 5 (16.7%) 
Oral Therapy 3 (10.0%) 4 (13.3%) 
Insulin 2 (6.7%) 2 (6.7%) 
Hypertension 
Treated 19 (63.3%) 20 (66.7%) 0.17 
Acute Coronary Syndrome  
Unstable Angina 25 (83.3%) 22 (73.3%) 
0.18 STEMI 1 (3.3%) 4 (16.7%) 
NONSTEMI 4 (13.3%) 3 (10.0% 
Previous MI 
One 8 (26.7%) 3 (10.0%) 
0.04 
Two or more 14 (46.7%) 12 (40.0%) 
Last previous MI upon admission to Cardiology 
Unknown 10 (33.3%) 18 (60.0%) 
0.03 
< 6 hrs 14 (46.7%) 5 (16.7%) 
6-24 hrs 1 (3.3%) 1 (3.3%) 
1-30 days 5 (16.7%) 4 (13.3%) 
31-90 days - - 
> 90 days - 2 (6.7%) 
Significant differences were noted at p < 0.05. [%= percentage; n= number of patients in each subcategory; LVEF %= 
Left Ventricle Ejection Fraction percentage; BSA= Body Surface Area; BMI= Body Mass Index; STEMI= ST segment 
Elevation Myocardial Infarction; NONSTEMI= Non ST segment Myocardial Infarction; MI= Myocardial Infarction; 
NYHA= New York Heart Association classification; CVA= Cerebrovascular Accident; COPD= Chronic Obstructive 
Pulmonary Disease]. 
 
The data displayed in Table 4.2 indicates that the on- and off-pump CABG groups were mostly 
comparable with respect to pre-operative risk factors and co-morbidities. 
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4.3 Intra-operative Metabolic- and Hemodynamic Data 
for On-pump and Off-pump CABG Groups 
4.3.1 Intra-operative Metabolic Data: On-pump and  
 Off-pump CABG Groups 
 
The metabolic and clinical changes seen in the on- and off-pump CABG groups were compared 
by analysing the patient’s intra-operative arterial blood gasses and hemodynamic profiles.  The 
intra-operative metabolic data for the on-pump CABG group are displayed in Table 4.3 and the 
off-pump CABG group in Table 4.4.  Due to the limited sample size the median, 25th and 75th 
percentiles were calculated.  The median values of metabolic data of both groups were plotted 
on line graphs to compare the two groups and to observe whether any trends could be 
identified (Figure 4.4-4.6).  Metabolic data were recorded intra-operatively at 15 minute time 
intervals.  The baseline ABG represents the first ABG drawn upon the patient's admission to 
theatre.  The second ABG was drawn 5 minutes after intubation.  T1-T9 represents intra-
operative ABG’s that were drawn at 15 minute time intervals from the onset of surgery. 
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Table 4.3 Intra-operative Metabolic Data: On-pump CABG Group 
VARIABLE 
(UNIT) 
B
A
S
E
L
IN
E
 
IN
T
U
B
A
T
IO
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T
1
 
T
2
 
T
3
 
T
4
 
T
5
 
T
6
 
T
7
 
T
8
 
T
9
 
pH 
Median 7.46 7.41 7.42 7.42 7.41 7.41 7.42 7.42 7.40 7.38 7.39 
25th percentile 7.44 7.37 7.36 7.35 7.38 7.37 7.34 7.34 7.33 7.34 7.35 
75th percentile 7.48 7.43 7.46 7.47 7.46 7.46 7.45 7.45 7.45 7.42 7.40 
pCO2 (mmHg) 
Median 34.4 36.7 34.7 34.1 33.9 35.3 41.8 34.3 35.5 37.0 38.1 
25th percentile 31.2 33.9 32.3 32.2 32.5 31.9 32.3 32.3 34.7 35.5 37.6 
75th percentile 35.9 43.4 37.7 37.9 37.1 38.1 42.0 39.7 40.6 40.5 43.1 
pO2 (mmHg) 
Median 71.2 231.0 225.0 205.1 193.0 189.0 188.4 189.0 182.0 203.3 198.0 
25th percentile 66.8 187.1 207.4 184.4 173.4 171.8 157.8 149.0 174.4 144.8 149.1 
75th percentile 84.9 313.8 263.7 245.5 216.3 213.3 215.5 220.1 232.6 220.8 201.0 
HCO3- std (mmol/L) 
Median 24.4 23.5 23.3 22.9 22.6 22.4 24.7 22.5 22.5 22.5 22.7 
25th percentile 24.0 23.0 23.0 22.4 22.3 22.2 22.6 22.2 20.4 20.3 21.1 
75th percentile 25.5 24.9 24.2 23.9 23.5 23.7 25.0 23.6 24.4 23.8 23.3 
BE (B) (mmol/L) 
Median 0.0 -1.1 -1.6 -1.9 -2.3 -2.6 -2.0 -2.3 -2.4 -2.4 -2.1 
25th percentile -1.3 -1.8 -3.6 -4.3 -4.8 -4.4 -5.3 -5.3 -4.9 -5.0 -3.6 
75th percentile 1.3 0.4 -0.4 -0.7 -1.2 -1.0 -1.2 -1.0 -0.6 -0.5 -1.3 
t Hb (g/dL) 
Median 14.5 13.8 9.9 9.9 10.0 9.5 10.4 9.2 9.5 9.4 8.9 
25th percentile 13.8 13.4 9.1 8.9 9.0 8.8 8.4 8.7 8.6 8.3 8.6 
75th percentile 15.4 14.7 11.3 10.8 10.6 10.3 10.9 10.2 10.2 10.0 10.3 
O2 Sat (%) 
Median 95.1 99.5 98.6 98.7 99.1 98.7 98.5 98.4 98.7 99.0 98.5 
25th percentile 94.2 99.3 96.2 97.3 98.2 97.0 97.0 97.0 96.4 97.9 98.0 
75th percentile 96.1 99.7 99.6 99.6 99.5 99.5 99.4 99.5 99.5 99.5 99.4 
Na+ (mmol/L) 
Median 138.0 139.0 136.0 136.0 136.0 136.0 135.0 135.0 136.0 137.0 138.0 
25th percentile 134.2 133.7 134.8 134.1 134.7 134.9 134.0 133.1 134.8 134.5 135.4 
75th percentile 139.7 140.0 137.7 138.0 137.9 137.2 137.8 138.0 138.0 138.3 138.6 
K+ (mmol/L) 
Median 3.9 3.8 3.4 3.6 3.6 3.9 3.9 4.0 4.2 4.1 3.9 
25th percentile 3.4 3.7 3.3 3.4 3.4 3.6 3.7 3.8 3.9 3.7 3.7 
75th percentile 4.1 4.0 3.9 3.7 3.7 4.0 4.0 4.3 4.3 4.2 4.1 
Ca++ (mmol/L) 
Median 1.2 1.1 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 
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VARIABLE 
(UNIT) 
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T
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25th percentile 1.1 1.1 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 
75th percentile 1.2 1.1 1.0 1.1 1.0 1.1 1.1 1.1 1.0 1.0 1.1 
Cl-(mmol/L) 
Median 107.0 109.0 111.0 112.0 112.0 112.0 112.0 112.0 111.0 111.0 112.0 
25th percentile 104.0 101.0 108.0 110.0 104.0 106.0 108.0 107.0 108.0 104.0 105.0 
75th percentile 110.0 111.0 112.0 113.0 113.0 114.0 113.0 113.0 113.0 112.0 113.0 
Glucose (mmol/L) 
Median 5.6 5.6 6.3 6.9 7.5 7.8 7.8 7.8 8.8 9.5 9.5 
25th percentile 4.8 4.9 5.1 5.5 6.1 6.6 6.7 7.1 7.8 7.0 7.5 
75th percentile 6.2 6.3 7.6 8.9 10.0 10.4 10.8 11.2 11.3 11.5 12.8 
Lactate (mmol/L) 
Median 1.2 1.3 2.8 3.6 4.0 4.1 4.1 4.1 3.9 3.8 3.5 
25th percentile 0.9 1.0 2.1 2.6 3.2 2.9 3.2 3.4 3.0 2.6 3.0 
75th percentile 1.4 1.5 4.2 4.7 5.6 5.4 5.6 5.6 6.1 6.5 7.3 
pH= measure of concentration of hydrogen ions, pCO2= Carbon Dioxide, O2= Oxygen, HCO3- & BE (B)= acid-base 
balance, tHb= Haemoglobin, O2 Sat (%)= Saturation, Na+= Sodium, K+= Potassium, Ca++= Calcium and Cl-= Chloride.  
[T1=15 minutes; T2= 30 minutes; T3= 45 minutes; T4= 60 minutes; T5= 75 minutes; T6= 90 minutes; T7= 105 
minutes; T8= 120 minutes; T9= 135 minutes]. 
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Table 4.4 Intra-operative Metabolic Data: Off-pump CABG Group 
VARIABLE 
(UNIT) 
B
A
S
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L
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T
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T
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T
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T
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pH 
Median 7.45 7.41 7.37 7.38 7.38 7.38 7.35 7.38 7.38 7.37 7.37 
25th percentile 7.42 7.38 7.34 7.34 7.35 7.33 7.34 7.32 7.31 7.34 7.32 
75th percentile 7.48 7.45 7.42 7.42 7.41 7.40 7.40 7.40 7.40 7.40 7.41 
pCO2 (mmHg) 
Median 35.9 37.8 37.2 38.0 38.0 39.6 37.6 37.7 37.2 41.8 41.9 
25th percentile 32.3 33.0 35.4 35.2 35.4 36.5 36.5 34.7 35.2 37.7 34.7 
75th percentile 39.1 43.0 40.4 41.8 40.9 41.8 41.4 43.2 44.7 43.8 48.7 
pO2 (mmHg) 
Median 71.7 229.0 151.0 169.0 165.0 143.0 173.0 167.0 157.0 134.0 134.0 
25th percentile 66.1 130.6 113.9 139.0 133.8 118.0 91.9 120.0 82.0 94.4 84.6 
75th percentile 126.1 289.9 189.1 200.8 193.3 177.6 189.5 177.6 184.3 188.7
8 
199.7 
HCO3- std (mmol/L) 
Median 24.6 23.9 21.9 21.5 22.4 22.2 20.3 22.0 21.7 22.2 22.5 
25th percentile 23.7 22.4 20.3 21.0 20.7 20.2 20.0 20.5 21.1 21.5 21.6 
75th percentile 25.5 24.8 24.1 24.7 23.5 23.9 23.4 22.9 23.3 23.7 24.1 
BE (B) (mmol/L) 
Median 0.4 -0.7 -3.2 -3.7 -2.5 -2.8 -3.8 -3.0 -3.2 -2.8 -2.4 
25th percentile -0.9 -2.2 -5.1 -4.2 -4.6 -5.2 -4.0 -4.9 -4.0 -3.6 -3.5 
75th percentile 1.3 0.3 -0.5 0.2 -1.2 -0.7 -1.3 -1.7 -1.5 -0.9 -0.5 
t Hb (g/dL) 
Median 13.2 12.7 11.8 11.4 11.1 11.1 10.8 10.9 11.0 11.9 10.9 
25th percentile 12.3 11.5 10.5 10.4 10.4 10.5 10.3 9.9 9.8 9.6 10.0 
75th percentile 14.9 13.9 13.0 12.4 12.7 12.9 12.9 13.4 13.2 13.0 13.0 
O2 Sat (%) 
Median 95.8 99.5 99.6 98.4 99.7 98.4 98.8 98.6 98.7 99.7 98.7 
25th percentile 93.3 98.1 96.7 97.7 98.1 97.3 97.2 96.7 93.7 96.2 93.8 
75th percentile 96.6 99.7 99.9 99.3 99.8 99.0 99.2 99.2 99.1 99.9 99.2 
Na+ (mmol/L) 
Median 138.0 139.0 139.0 138.0 138.0 138.0 137.0 138.0 138.0 138.0 138.0 
25th percentile 136.0 136.4 135.8 135.7 135.1 136.0 136.0 136.2 135.9 134.2 136.0 
75th percentile 138.9 139.7 140.0 139.2 139.4 139.8 139.7 139.0 139.5 139.1 139.9 
K+ (mmol/L) 
Median 3.8 3.7 3.7 3.9 3.9 3.9 3.9 3.8 3.9 4.1 3.8 
25th percentile 3.7 3.6 3.5 3.4 3.6 3.4 3.9 3.7 3.8 3.7 3.4 
75th percentile 4.0 4.0 4.0 4.0 4.0 4.1 4.3 4.2 4.3 4.4 4.1 
Ca++ (mmol/L) 
Median 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.0 1.0 
25th percentile 1.0 1.0 0.9 1.0 1.0 1.0 0.9 0.9 0.9 1.0 0.9 
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75th percentile 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.1 
Cl-(mmol/L) 
Median 109.0 110.0 112.0 112.0 112.0 112.0 112.0 112.0 112.0 111.0 112.0 
25th percentile 107.0 106.0 110.0 110.0 109.2 110.0 110.0 110.0 109.0 108.0 111.0 
75th percentile 109.1 111.0 113.0 113.0 114.0 113.0 113.0 114.0 112.5 112.0 112.5 
Glucose (mmol/L) 
Median 5.2 5.4 6.5 7.2 7.6 8.1 7.9 7.9 6.8 6.9 7.3 
25th percentile 5.0 5.0 5.0 5.3 5.9 5.7 5.7 5.5 6.1 6.6 5.1 
75th percentile 6.1 6.8 8.9 8.8 8.9 9.8 11.4 11.5 13.4 12.7 11.8 
Lactate (mmol/L) 
Median 1.1 1.2 1.8 2.1 2.3 2.8 2.8 2.9 2.7 2.5 2.8 
25th percentile 0.8 0.9 1.4 1.6 1.8 1.9 1.9 1.8 1.7 2.0 1.8 
75th percentile 1.4 1.6 3.1 3.2 3.6 3.8 4.0 4.5 3.6 3.7 4.2 
pH= measure of concentration of hydrogen ions, pCO2= Carbon Dioxide, O2= Oxygen, HCO3- & BE (B)= acid-base 
balance, tHb= Haemoglobin, O2 Sat (%)= Saturation, Na+= Sodium, K+= Potassium, Ca++= Calcium and Cl-= Chloride.  
[T1= 15 minutes; T2= 30 minutes; T3= 45 minutes; T4= 60 minutes; T5= 75 minutes; T6= 90 minutes; T7= 105 
minutes; T8= 120 minutes; T9= 135 minutes].   
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Figure 4.4 Medians for acid-base balance for the on-pump and off-pump CABG groups.  
[T1=15 minutes; T2=30 minutes; T3= 45 minutes; T4= 60 minutes; T5= 75 minutes; T6= 90 
minutes; T7= 105 minutes; T8= 120 minutes; T9= 135 minutes]. 
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Figure 4.5 Medians for metabolites: saturation (%) and haemoglobin (Hb), glucose 
and lactate for the on-pump and off-pump groups.   
[T1=15 minutes; T2= 30 minutes; T3= 45 minutes; T4= 60 minutes; T5= 75 minutes; T6= 90 
minutes; T7= 105 minutes; T8= 120 minutes; T9= 135 minutes]. 
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Figure 4.6 Medians for Electrolytes: Sodium (Na+), Chloride (Cl-), Potassium (K+) and 
Calcium (Ca++) for the on-pump and off-pump groups.   
[T1=15 minutes; T2= 30 minutes; T3= 45 minutes; T4= 60 minutes; T5= 75 minutes; T6= 90 
minutes; T7= 105 minutes; T8= 120 minutes; T9= 135 minutes]. 
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4.3.1.1 P-values for Intra-operative Metabolic Data: On-
pump vs. Off-pump CABG Groups 
 
There were no statistically significant differences (p>0.05) for the acid-base variables, pH, pO2 
and pCO2 (Table 4.5). 
The other variables for acid-base balance; HCO3- and BE (B), showed statistically significant 
(p<0.05) differences during most of the surgery.   
The metabolites, O2 Sat (%) and glucose showed no statistically significant differences (p>0.05), 
however, tHb (g/dL) and lactate showed statistically significant differences (p<0.05) during 
most of the surgery.   
The electrolytes, K+, Ca++, Na+ and Cl-, indicated no statistically significant differences (p>0.05).   
Overall the groups were comparable with only a few statistically significant differences 
observed between the two groups.   
 
Table 4.5 P-values for Intra-operative Metabolic Data: On-pump vs. Off-pump CABG 
Groups 
VARIABLE 
(UNIT) 
B
A
S
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L
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pH 0.68 0.14 5.15 4.70 6.67 4.52 1.49 0.47 1.34 0.47 0.12 
pCO2 (mmHg) 0.96 0.22 4.72 7.20 9.44 14.7 11.9 0.92 1.65 3.58 0.87 
pO2 (mmHg) 0.63 0.89 17.6 7.80 4.76 11.7 5.19 4.17 12.0 3.34 0.63 
HCO3- STD 
mmol/L) 
0.03 0.19 1.34 0.00 0.00 0.04 0.03 1.11 0.34 0.02 0.40 
BE (B) (mmol/L) 0.10 0.01 0.96 0.00 0.00 0.04 0.02 0.91 0.24 0.00 0.26 
tHb (g/dL) 1.23 1.28 0.00 0.00 0.00 <0.0 <0.0 0.00 0.00 0.00 0.09 
O2 SAT (%) 0.06 1.84 8.37 4.50 1.33 2.32 1.63 7.40 6.03 9.02 1.59 
Na+ (mmol/L) 1.34 1.70 1.00 2.00 1.83 3.00 0.78 0.90 0.49 1.01 1.51 
K+ (mmol/L) 0.63 0.78 0.59 0.74 1.74 1.98 1.00 1.51 1.41 1.52 0.99 
Ca++ (mmol/L) 0.98 1.00 1.55 1.08 1.01 0.88 1.74 2.00 4.79 0.19 0.48 
Cl- (mmol/L) 0.32 0.10 0.66 0.49 0.97 0.53 0.62 0.42 0.88 0.71 0.70 
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Glucose (mmol/L) 0.10 0.11 0.73 0.17 0.06 0.19 0.15 1.13 0.56 0.65 2.32 
VARIABLE 
(UNIT) 
B
A
S
E
L
IN
E
 
IN
T
U
B
A
T
IO
N
 
T
1
 
T
2
 
T
3
 
T
4
 
T
5
 
T
6
 
T
7
 
T
8
 
T
9
 
Lactate (mmol/L) 0.63 0.06 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.11 0.07 
pH= measure of concentration of hydrogen ions, pCO2= Carbon Dioxide, O2= Oxygen, HCO3- & BE (B)= acid-base 
balance, tHb= Haemoglobin, O2 Sat (%)= Saturation, Na+= Sodium, K+= Potassium, Ca++= Calcium and Cl-= Chloride.  
[T1=15 minutes; T2= 30 minutes; T3= 45 minutes; T4= 60 minutes; T5= 75 minutes; T6= 90 minutes; T7= 105 
minutes; T8= 120 minutes; T9= 135 minutes].  The p-values were calculated using the Kruskal–Wallis test for the 
comparison of medians.   
 
4.3.2 Post-hoc Power Analysis: Mean Intra-operative 
and Post-operative Lactate Levels 
 
Table 4.6 summarizes the difference between the on-pump and off-pump groups with respect to 
the mean intra-operative lactate levels and the mean post-operative lactate levels. 
 
Table 4.6 Post-hoc Power Analysis: Mean Intra-operative and Post-operative Lactate 
Levels for On-pump and Off-pump CABG Groups 
VARIABLE (UNIT) ON-PUMP OFF-PUMP 
DIFFERENCE  
(ON-PUMP – 
OFF-PUMP) 
Mean intra-operative lactate level (mmol/L) 3.7 2.4 1.3 (p = 0.00) 
Mean post-operative lactate level (mmol/L) 4.2 2.9 1.3 (p = 0.00) 
p-value was calculated using the Wilcoxon-Mann-Whitney test for the comparison of means. 
 
The differences between the groups, with respect to the mean intra-operative lactate levels and 
the mean post-operative lactate levels, were statistically significant.  The p-values were (p= 0.00 
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and p= 0.00) for the mean intra-operative lactate levels and the mean post-operative lactate 
levels, respectively.   
The usefulness of post hoc power analyses is disputed, however since this was a pilot study a 
post hoc analysis was done, on what was considered to be the primary comparison in the study, 
in order to assess if the study could be considered reasonably powered to show any differences.  
Cohen, 1988 suggests that a minimum power of 80% is needed to speculate whether a study 
carries any statistical value.   
Our study had a modest sample size (n=60), which may have played a role in limiting the 
significance of some of the statistical comparisons conducted.  However, a post-hoc power 
analysis, on the difference between the on-pump and off-pump patients with respect to the 
mean lactate levels during surgery, revealed that this study had a power of more than the 
recommended 80% (d=0.88), indicating that there was a strong probability of detecting an 
effect when it exists in our sample size.   
 
4.3.3 Intra-operative Hemodynamic Data and 
Temperature: On-pump and Off-pump CABG 
Groups 
 
The intra-operative hemodynamic data captured for the on- and off-pump groups are presented 
in Tables 4.7 and 4.8, respectively.   
The median values of hemodynamic data, for the on- and off-pump groups, were plotted on a 
line graph to observe trends between the 2 groups with reference to hemodynamic instability 
(Figure 4.7).  Hemodynamic data were recorded at 5 minute time intervals but for the purpose 
of this study hemodynamic data was only displayed at baseline, intubation and T1-T9 (15 
minute intervals).   
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Table 4.7 Intra-operative Hemodynamic Data and Temperature: On-pump CABG 
Group 
VARIABLE 
(UNIT) 
B
A
S
E
L
IN
E
 
IN
T
U
B
A
T
IO
N
 
T
1
 
T
2
 
T
3
 
T
4
 
T
5
 
T
6
 
T
7
 
T
8
 
T
9
 
Systolic Pressure (mmHg) 
Median 102.6 101.4 124.1 78.4 68.1 66.5 68.9 70.4 68.2 67.9 64.1 
25th percentile 101.4 100.9 95.6 74.6 64.6 65.3 64.2 58.9 58.9 57.0 60.0 
75th percentile 147.7 149.2 124.6 114.0 107.1 108.0 95.2 84.3 98.5 118.0 109.4 
Diastolic Pressure (mmHg) 
Median 52.1 55.9 57.6 50.4 66.6 62.6 64.5 65.2 61.1 64.1 57.8 
25th percentile 50.0 51.5 49.3 50.0 60.1 62.4 63.5 52.9 58.4 57.0 54.0 
75th percentile 56.3 58.0 57.8 66.7 68.0 65.1 66.9 69.9 68.3 68.0 67.9 
Mean Arterial Pressure (mmHg) 
Median 88.3 87.3 95.2 71.8 67.6 63.7 67.9 69.3 59.8 64.1 57.8 
25th percentile 76.3 73.1 69.4 67.4 60.5 54.7 58.6 52.9 54.7 63.3 54.1 
75th percentile 108.8 106.0 96.1.0 87.6 97.0 94.0 78.7 70.9 71.4 81.0 75.5 
CVP (mmHg) 
Median 6.0 6.2 7.4 4.2 3.2 1.6 1.3 1.2 1.3 2.9 2.6 
25th percentile 5.4 5.0 3.2 3.0 1.3 1.3 1.0 1.0 2.0 2.2 2.0 
75th percentile 6.8 7.9 8.0 4.8 4.6 2.7 2.9 2.7 3.1 3.6 3.6 
HR (beats/min) 
Median 67.0 68.0 70.0 71.0 0.0 0.0 0.0 47.0 56.0 40.5 37.0 
25th percentile 64.0 66.0 61.0 0.0 0.0 0.0 0.0 41.0 37.0 31.0 29.0 
75th percentile 69.0 72.0 77.0 72.0 68.0 70.0 71.0 78.0 82.0 81.0 89.0 
Temperature (˚C) 
Median 35.9 35.9 35.8 35.2 32.3 30.1 32.2 32.2 35.4 36.1 34.3 
25th percentile 35.1 35.5 35.1 31.2 29.7 29.5 30.5 30.6 35.0 34.2 34.0 
75th percentile 36.0 36.0 35.8 35.7 33.0 31.1 33.7 35.7 36.3 36.2 36.9 
CVP= central venous pressure, HR= heart rate.  Temperature was measured in degrees Celsius (C).  [T1=15 minutes; 
T2= 30 minutes; T3= 45 minutes; T4= 60 minutes; T5= 75 minutes; T6= 90 minutes; T7= 105 minutes; T8= 120 
minutes; T9= 135 minutes].   
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Table 4.8 Intra-operative Hemodynamic Data and Temperature: Off-pump CABG 
Group 
VARIABLE 
(UNIT) 
B
A
S
E
L
IN
E
 
IN
T
U
B
A
T
IO
N
 
T
1
 
T
2
 
T
3
 
T
4
 
T
5
 
T
6
 
T
7
 
T
8
 
T
9
 
Systolic Pressure (mmHg) 
Median 162.4 170.4 150.0 112.4 107.7 102.4 104.6 96.5 121.5 103.3 115.0 
25th percentile 97.5 101.0 93.9 102.1 106.3 95.5 91.6 96.1 95.7 91.6 77.7 
75th percentile 179.0 183.0 167.0 144.2 139.8 113.0 124.5 111.0 138.2 124.9 124.5 
Diastolic Pressure (mmHg) 
Median 72.0 82.0 68.6 54.8 57.2 56.6 55.2 53.5 55.7 53.1 50.9 
25th percentile 68.4 57.2 54.0 50.7 51.1 50.0 49.1 51.5 49.7 44.2 40.2 
75th percentile 89.1 83.1 75.3 63.0 60.9 64.2 70.2 71.4 60.8 71.2 55.0 
Mean Arterial Pressure (mmHg) 
Median 112.9 116.9 95.4 88.5 80.2 77.8 74.9 67.6 78.2 71.9 75.9 
25th percentile 64.2 76.2 77.9 71.3 67.7 70.9 70.9 64.2 68.3 68.0 65.0 
75th percentile 133.8 117.8 103.4 95.9 95.7 94.3 94.3 86.7 86.9 87.0 81.1 
CVP (mmHg) 
Median 4.0 3.8 2.9 8.9 9.4 9.5 8.5 8.1 7.7 14.4 6.8 
25th percentile 0.7 2.1 2.3 6.7 9.2 8.3 6.8 5.4 4.1 5.5 4.8 
75th percentile 5.0 6.9 11.0 14.2 14.9 12.7 11.4 9.8 13.1 15.7 9.4 
HR (beats/min) 
Median 67.0 68.0 56.0 71.0 62.0 70.0 68.0 74.0 73.0 70.0 57.0 
25th percentile 61.0 62.0 54.0 53.0 58.0 55.0 58.0 65.0 62.0 53.0 55.0 
75th percentile 75.0 74.0 78.0 74.0 80.0 77.0 84.0 81.0 90.0 80.0 75.0 
Temperature (˚C) 
Median 36.7 36.5 36.4 36.1 35.8 35.8 35.9 35.7 35.9 35.7 35.7 
25th percentile 36.3 36.1 35.9 35.5 35.6 35.7 35.3 35.6 35.4 35.4 35.3 
75th percentile 36.9 36.5 36.5 36.1 36.8 36.1 36.2 36.2 36.9 36.7 36.7 
CVP= central venous pressure, HR= heart rate. Temperature was measured in degrees Celsius (C).  [T1=15 minutes; 
T2= 30 minutes; T3= 45 minutes; T4= 60 minutes; T5= 75 minutes; T6= 90 minutes; T7= 105 minutes; T8= 120 
minutes; T9= 135 minutes].   
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Figure 4.7 Medians for hemodynamic data and temperature during on-pump and off-
pump CABG surgery. 
[CVP= central venous pressure, HR= heart rate.  Temperature was measured in degrees Celsius 
(C).  [T1=15 minutes; T2= 30 minutes; T3= 45 minutes; T4= 60 minutes; T5= 75 minutes; T6= 90 
minutes; T7= 105 minutes; T8= 120 minutes; T9= 135 minutes].   
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4.3.3.1 P-values for Intra-operative Hemodynamic Data and 
Temperature: On-pump vs. Off-pump CABG Groups 
 
Statistically significant differences between the on- and off pump groups were noted for systolic 
pressures, diastolic pressures, mean arterial pressures, HR, CVP and body temperature for most 
of the duration of surgery (p<0.05) (Table 4.9).   
 
Table 4.9 P-values for Intra-operative Hemodynamic Data and Temperature:  
On-pump vs. Off-pump Groups 
VARIABLE 
(UNIT) 
B
A
S
E
L
IN
E
 
IN
T
U
B
A
T
IO
N
 
T
1
 
T
2
 
T
3
 
T
4
 
T
5
 
T
6
 
T
7
 
T
8
 
T
9
 
Systolic Pressure (mmHg) 
 0.60 0.40 0.02 <0.01 <0.01 <0.01 <0.01 <0.01 0.00 0.00 0.12 
Diastolic Pressure (mmHg) 
 6.03 10.29 0.01 0.01 0.00 0.00 <0.01 0.02 0.00 <0.01 0.79 
Mean Arterial Pressure (mmHg) 
 0.22 0.10 0.02 0.00 0.01 0.01 0.00 <0.01 0.00 0.00 0.34 
HR (beats/min) 
 0.54 0.20 0.07 0.01 0.00 0.00 0.00 0.01 0.04 0.04 0.66 
CVP (mmHg) 
 0.08 0.86 0.06 0.00 0.02 0.04 <0.01 0.00 <0.01 0.20 0.41 
Temperature (°C) 
 6.21 1.18 0.12 0.02 0.01 0.05 0.03 0.01 0.09 0.49 0.25 
CVP= central venous pressure, HR= heart rate, temperature was measured in degrees Celsius (C).  [T1=15 minutes; 
T2= 30 minutes; T3= 45 minutes; T4= 60 minutes; T5= 75 minutes; T6= 90 minutes; T7= 105 minutes; T8= 120 
minutes; T9= 135 minutes].  The p-values were calculated with the Kruskal-Wallis test where used for the 
comparison of medians.   
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4.4 Post-operative Metabolic Data: On-pump and 
Off-pump CABG Groups 
 4.4.1 Post-operative Metabolic Data: On-pump CABG 
Group 
 
Metabolic changes in the on- and off-pump CABG groups were observed by comparing 
metabolic data during the post-operative period (from 1hr - 72hrs upon admission to ICU) 
(Table 4.10 and Table 4.11).  The ABG’s were drawn post-operatively at specified time intervals; 
1 hr, 2 hrs, 4 hrs, 8 hrs, 12 hrs, 24 hrs, 48 hrs and 72 hrs.   
 
Table 4.10 Post-operative Metabolic Data: On-pump CABG Group 
VARIABLE 
(UNIT) 1
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S
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P
E
R
A
T
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pH 
Median 7.29 7.33 7.33 7.38 7.43 7.47 7.49 7.49 
25th percentile 7.26 7.26 7.31 7.38 7.38 7.45 7.47 7.44 
75th percentile 7.34 7.36 7.39 7.42 7.45 7.49 7.51 7.51 
pCO2 (mmHg) 
Median 42.3 41.0 35.2 34.3 33.9 33.8 33.6 34.8 
25th percentile 39.0 35.7 33.2 31.9 31.8 31.3 30.6 32.5 
75th percentile 46.2 43.4 40.3 38.6 36.6 36.4 39.2 37.4 
pO2(mmHg) 
Median 114.7 97.0 97.1 91.6 85.2 75.7 70.2 69.7 
25th percentile 96.6 88.8 81.8 83.0 81.6 63.5 59.6 46.9 
75th percentile 136.5 117.0 114.6 105.2 106.1 83.9 81.0 82.1 
HCO3- STD (mmol/L) 
Median 19.3 19.8 20.2 21.3 22.7 25.4 26.2 26.2 
25th percentile 17.9 17.7 18.0 19.2 20.3 23.3 25.2 25.4 
75th percentile 21.2 21.5 21.5 22.5 24.6 26.8 27.0 27.2 
BE (B) (mmol/L) 
Median -6.4 -5.7 -5.2 -3.8 -2.2 1.0 1.9 2.0 
25th percentile -8.0 -7.9 -7.9 -6.4 -5.0 -1.3 1.1 1.1 
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VARIABLE 
(UNIT) 1
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75th percentile -3.4 -3.5 -3.6 -2.4 0.2 2.8 2.8 3.2 
tHb (g/dL) 
Median 12.5 14.2 15.0 14.1 12.0 9.7 7.8 7.5 
25th percentile 10.2 11.1 11.0 10.4 10.8 9.3 6.4 6.0 
75th percentile 13.7 15.5 18.8 15.2 13.4 12.6 11.5 12.0 
O2 Sat (%) 
Median 97.8 97.0 96.8 97.1 96.7 95.8 95.0 96.0 
25th percentile 96.2 95.7 95.4 95.6 95.6 93.4 93.5 89.5 
75th percentile 98.2 97.8 97.8 97.5 97.8 96.8 96.6 97.1 
Na+ (mmol/L) 
Median 139.0 138.5 138.3 137.6 138.2 138.1 134.6 133.6 
25th percentile 136.1 137.4 138.0 136.5 138.0 137.1 134.0 133.0 
75th percentile 139.0 139.0 138.6 138.1 138.5 138.7 136.0 135.9 
K+ (mmol/L) 
Median 3.5 3.7 4.3 4.1 4.2 4.1 4.2 4.1 
25th percentile 3.4 3.5 4.0 4.0 4.0 3.5 4.0 4.0 
75th percentile 3.7 3.9 4.3 4.5 4.5 4.3 4.3 4.4 
Ca++ (mmol/L) 
Median 1.0 1.0 1.0 1.0 1.0 1.0 1.1 1.1 
25th percentile 1.0 1.0 1.0 0.9 0.9 1.0 1.0 1.1 
75th percentile 1.0 1.0 1.0 1.0 1.0 1.1 1.1 1.1 
Cl- (mmol/L) 
Median 111.0 110.0 111.0 110.5 111.0 109.5 106.0 105.0 
25th percentile 110.0 109.0 110.0 110.0 110.0 109.0 104.0 104.0 
75th percentile 111.5 111.0 111.5 111.0 112.0 110.0 108.0 108.0 
Glucose (mmol/L) 
Median 11.1 11.7 11.9 11.8 11.5 11.1 10.6 10.6 
25th percentile 10.4 11.5 11.8 11.7 10.9 8.1 6.7 6.1 
75th percentile 15.2 15.8 16.8 15.8 13.4 12.4 10.9 11.1 
Lactate (mmol/L) 
Median 6.3 6.4 6.3 5.9 3.9 1.9 1.5 1.2 
25th percentile 3.0 3.2 3.0 3.0 2.3 1.3 1.0 0.9 
75th percentile 8.6 8.6 8.8 8.3 6.2 2.7 1.7 1.5 
pH= measure of concentration of hydrogen ions, pCO2= Carbon Dioxide, O2= Oxygen, HCO3- & BE (B)= acid-base 
balance, tHb= Haemoglobin, O2 Sat (%)= Saturation, Na+= Sodium, K+= Potassium, Ca++= Calcium and Cl-= Chloride.   
[Data taken at specified times after admission in ICU at 1-, 2-, 4-, 8-, 12-, 24-, 48- and 72 hours during the post-
operative period].  
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Table 4.11 Post-operative Metabolic Data: Off-pump CABG Group 
VARIABLE 
(UNIT)  
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pH 
Median 7.36 7.35 7.38 7.40 7.43 7.47 7.46 7.45 
25th percentile 7.31 7.32 7.35 7.36 7.38 7.43 7.43 7.42 
75th percentile 7.39 7.40 7.42 7.44 7.45 7.48 7.48 7.46 
pCO2 (mmHg) 
Median 40.9 37.7 35.9 33.8 33.1 32.5 33.5 37.8 
25th percentile 35.9 34.2 33.5 31.0 29.6 29.9 31.0 32.0 
75th percentile 43.2 42.4 38.9 37.4 35.6 37.7 37.6 42.7 
pO2 (mmHg) 
Median 120.5 97.5 96.7 91.8 75.1 73.7 74.7 69.7 
25th percentile 86.8 81.9 85.0 71.0 67.9 67.0 64.5 60.8 
75th percentile 140.9 126.4 121.2 111.9 94.0 80.4 88.5 85.5 
HCO3- STD (mmol/L) 
Median 21.9 21.5 21.7 21.6 23.2 23.7 24.7 24.9 
25th percentile 20.2 19.6 20.0 20.4 20.8 22.4 23.5 23.3 
75th percentile 22.6 22.8 23.8 23.9 24.1 25.8 25.9 26.8 
BE (B) (mmol/L) 
Median -2.9 -3.4 -2.7 -2.7 -0.7 -0.3 0.4 1.1 
25th percentile -5.1 -5.7 -5.0 -4.8 -4.2 -1.9 -1.0 -1.4 
75th percentile -1.2 -1.5 -0.1 1.1 1.4 2.2 2.4 3.1 
tHb (g/dL) 
Median 9.4 11.5 12.5 11.2 10.6 8.4 7.6 7.5 
25th percentile 8.0 10.5 11.2 10.1 9.4 7.1 5.5 5.8 
75th percentile 12.9 12.9 12.8 12.5 12.8 12.3 12.5 13.2 
O2 Sat (%) 
Median 97.8 97.3 97.0 96.8 95.7 95.7 96.2 95.2 
25th percentile 96.2 95.6 96.1 95.1 94.0 94.6 93.0 92.6 
75th percentile 98.7 98.3 98.4 98.0 97.7 97.5 97.0 96.7 
Na+ (mmol/L) 
Median 138.7 138.8 137.9 137.2 137.6 136.9 135.7 135.0 
25th percentile 134.8 134.7 137.7 134.9 133.7 135.0 135.2 134.8 
75th percentile 139.2 139.0 138.0 138.2 138.0 137.4 136.7 136.8 
K+ (mmol/L) 
Median 3.8 4.0 4.2 4.1 4.2 4.2 4.2 4.2 
25th percentile 3.5 3.6 4.0 3.0 3.0 4.1 4.0 4.0 
75th percentile 3.9 4.2 4.2 4.1 4.3 4.4 4.4 4.8 
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Ca++ (mmol/L) 
Median 1.0 1.0 1.0 1.0 1.0 1.1 1.1 1.1 
25th percentile 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.1 
75th percentile 1.1 1.1 1.1 1.0 1.1 1.1 1.1 1.1 
Cl- (mmol/L) 
Median 110.0 110.0 109.0 111.0 110.0 109.5 107.0 106.5 
25th percentile 109.0 109.0 107.0 110.0 108.0 108.0 106.0 106.0 
75th percentile 111.0 111.0 110.0 112.0 111.0 111.0 111.0 112.0 
Glucose (mmol/L) 
Median 11.9 11.9 11.9 11.6 11.7 11.6 11.5 12.1 
25th percentile 7.5 8.3 9.6 9.3 8.7 7.2 7.1 6.3 
75th percentile 12.5 13.3 14.6 12.9 12.8 12.3 13.4 12.9 
Lactate (mmol/L) 
Median 2.7 2.8 2.8 2.6 2.1 1.6 1.3 1.2 
25th percentile 1.6 1.9 1.8 1.6 1.3 1.3 1.0 0.9 
75th percentile 5.5 4.8 5.7 4.9 4.8 2.5 1.7 1.5 
pH= measure of concentration of hydrogen ions, pCO2= Carbon Dioxide, O2= Oxygen, HCO3- & BE (B)= acid-base 
balance, tHb= Haemoglobin, O2 Sat (%)= Saturation, Na+= Sodium, K+= Potassium, Ca++= Calcium and Cl-= Chloride.  
[Data taken at specified times after admission in ICU at 1-, 2-, 4-, 8-, 12-, 24-, 48- and 72 hours during the post-
operative period].  
 
The medians of post-operative metabolic data for the on-pump and off-pump groups were 
plotted on line graphs to observe whether any trends could be identified in the 2 groups (Figure 
4.8 - 4.10).   
Figure 4.8 depicts the trends that were seen for all acid-base values during the first 72 hours 
post-operatively.   
The trends in the on-pump and off-pump groups with respect to metabolites; saturation (%) 
and haemoglobin (Hb) are illustrated in Figure 4.9, followed by the electrolyte levels in Figure 
4.10.   
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Figure 4.8 Medians for acid-base balance for on-pump and off-pump CABG groups 
during the first 72 hours post-operatively.  
[T1=15 minutes; T2=30 minutes; T3= 45 minutes; T4= 60 minutes; T5= 75 minutes; T6= 
90minutes; T7= 105 minutes; T8= 120 minutes; T9= 135 minutes]. 
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Figure 4.9 Medians for metabolites, saturation (%) and haemoglobin (Hb) for on-
pump and off-pump groups during the first 72 hours post-operatively. 
[T1=15 minutes; T2=30 minutes; T3= 45 minutes; T4= 60 minutes; T5= 75 minutes; T6= 90 
minutes; T7= 105 minutes; T8= 120 minutes; T9= 135 minutes].  
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Figure 4.10 Medians for electrolytes, Sodium (Na+), Potassium (K+), Calcium (Ca++) and 
chloride (Cl-) for on-pump and off-pump group up to 72 hours post-
operatively.   
[T1=15 minutes; T2=30 minutes; T3= 45 minutes; T4= 60 minutes; T5= 75 minutes; T6= 
90minutes; T7= 105 minutes; T8= 120 minutes; T9= 135 minutes]. 
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 4.4.2 P-values for Post-operative Metabolic Data: On-
pump vs. Off-pump CABG Groups 
 
Post-operative metabolic data were summarised up to 72 hrs after admission to ICU for the on-
pump vs. off-pump surgery group in Table 4.12.   
Variables for the acid-base balance, pO2 and pCO2, showed no statistically significant (p>0.05) 
differences between the two groups.  Other variables for acid-base balance, pH, HCO3- and BE 
(B), (p<0.05), showed statistically significant differences (p<0.05) from admission to ICU until 4 
hours post-operatively.   
The metabolites O2 SAT% and tHb (g/dL) showed no statistically significant differences 
(p>0.05).  However, glucose levels and lactate levels showed statistically significant differences 
(p<0.05) from admission to ICU until 12 hours post-operatively.   
The electrolytes K+, Ca++, Na+ and Cl- indicated no statistically significant differences (p>0.05).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Results                                                                                                                                                 100 | P a g e  
 
Table 4.12 P-values for Post-operative Metabolic Data: On-pump vs. Off-pump CABG 
Group 
VARIABLE (UNIT) 
1
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pH 0.00 0.04 0.01 0.10 0.08 0.09 0.06 0.14 
pCO2 (mmHg) 0.16 0.26 0.68 0.24 0.48 0.61 0.91 0.31 
pO2 (mmHg) 0.72 0.90 0.67 0.86 0.07 0.86 0.20 0.90 
HCO3- STD (mmol/L) 0.00 0.03 0.02 0.34 0.09 0.05 0.30 0.06 
BE (B) (mmol/L) 0.00 0.00 0.00 0.09 0.23 0.42 0.07 0.07 
tHb (g/dL) 0.12 0.78 0.98 0.58 0.48 0.42 0.09 0.10 
O2 SAT (%) 0.57 0.68 0.26 0.72 0.14 0.74 0.64 0.58 
Na+ (mmol/L) 1.74 1.50 1.04 1.0 1.31 2.0 0.81 0.60 
K+ (mmol/L) 0.63 0.78 0.59 0.74 1.74 1.98 1.0 1.51 
Ca++ (mmol/L) 0.98 1.0 1.27 1.48 1.71 0.58 1.44 1.0 
Cl- (mmol/L) 0.28 0.70 0.98 1.0 0.76 0.93 0.72 0.54 
Glucose (mmol/L) 0.00 0.00 0.00 0.00 0.02 0.14 0.93 0.39 
Lactate (mmol/L) 0.00 0.00 0.00 0.00 0.04 0.40 0.88 0.84 
pH= measure of concentration of hydrogen ions, pCO2= Carbon Dioxide, O2= Oxygen, HCO3- & BE (B)= acid-base 
balance, tHb= Haemoglobin, O2 Sat (%)= Saturation, Na+= Sodium, K+= Potassium, Ca++= Calcium and Cl-= Chloride.  
The p-values were calculated with the Kruskal-Wallis test for the comparison of medians.  [Data taken at specified 
times after admission in ICU at 1-, 2-, 4-, 8-, 12-, 24-, 48- and 72 hours during the post-operative period].  
 
 4.4.3 The Clinical Outcomes/Complications: On-pump 
and Off-pump CABG Groups 
 
Post-operative clinical outcomes and complications were summarised for the on-pump and off-
pump surgery group in Table 4.13.   
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The on-pump group had none of the following clinical outcomes or complications: mortality, 
return to ICU, post-operative MI, neurological complications, renal complications, multi organ 
failure, post-operative dissection of major arteries, acute limb ischemia, heart block, cardiac 
arrest, anticoagulant complications or tamponade.   
Clinical outcomes noted for the on-pump group were as follow: re-intubation 1 (3.3%), re-
operation 1 (3.3%), pulmonary complications 1 (3.3%), GIT complications 1 (3.3%), AF 1 
(3.3%), sternal wound infection 1 (3.3%) and septicaemia 1 (3.3%).   
The off-pump group had none of the following clinical outcomes or complications: re-intubation, 
post-operative MI, neurological complications, dissection of major arteries, acute limb ischemia 
heart block, cardiac arrest, anticoagulant complications, tamponade or sternal wound infection.   
For the off-pump group 2 (7.0%) patients died, 1 (3.3%) patient was returned to the ICU, re-
operation 1 (3.3%), pulmonary complication 1 (3.3%), renal complication 1 (3.3%), GIT 
complication, multi organ failure 1 (3.3%), AF 1 (3.3%) and septicaemia 1 (3.3%).   
Length of hospital stay and length of ICU stay indicated no statistically significant difference 
(p>0.05), however, a statistically significant difference was noted for ventilation time of p<0.05.   
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Table 4.13 Clinical Outcomes/Complications: On-pump vs. Off-pump CABG Group 
VARIABLES (UNITS) 
ON-PUMP 
n (%) 
OFF-PUMP 
n (%) 
p-VALUES 
Mortality 
Yes - 2 (7.0%) 
- 
No 30 (100.0%) 28 (93.0%) 
Return to ICU 
Yes - 1 (3.3%) 
- 
No 30 (100.0%) 29 (96.7%) 
Re-intubation 
Yes 1 (3.3%) - 
- 
No 29 (96.7%) 30 (100.0%) 
Re-operation 
Yes 1 (3.3%) 1 (3.3%) 
- 
No 29 (96.7%) 29 (96.7%) 
Post-operative MI 
Yes - - 
- 
No 30 (100.0%) 30 (100.0%) 
Pulmonary complications 
Yes 1 (3.3%) 1 (3.3%) 
- 
No 29 (96.7%) 29 (96.7%) 
Neurological complications 
Yes - - 
- 
No 30 (100%) 30 (100.0%) 
Renal complications 
Yes - 1 (3.3%) 
- 
N 30 (100.0%) 29 (96.7%) 
GIT complications 
Yes 1 (3.3%) 1 (3.3%) 
- 
No 29 (96.7%) 29 (96.7%) 
Multi organ failure 
Yes - 1 (3.3%) 
- 
No 30 (100.0%) 29 (96.7%) 
Post-operative dissection of major arteries 
Yes - - 
- 
No 30 (100.0%) 30 (100.0%) 
Acute limb ischemia 
Yes - - 
- 
No 30 (100.0%) 30 (100.0%) 
Heart block 
Yes - - 
- 
No 30 (100.0%) 30 (100.0%) 
Atrial fibrillation 
Yes 1 (3.3%) 1 (3.3%) 
- 
No 29 (96.7%) 29 (96.7%) 
Cardiac arrest 
Yes - - 
- 
No 30 (100.0%) 30 (100.0%) 
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Anticoagulant complications 
Yes - - 
- 
No 30 (100.0%) 30 (100.0%) 
Tamponade 
Yes - - 
- 
No 30 (100.0%) 30 (100.0%) 
Sternal wound infection 
Yes 1 (3.0%) - 
- 
No 29 (96.7%) 30 (100.0%) 
Septicaemia 
Yes 1 (3.3.0%) 1 (3.3%) 
- 
No 29 (96.7%) 29 (96.7%) 
Post-operative blood transfusion 
Yes 15 (50.0%) 8 (26.0%) 
- 
No 15 (50.0%) 22 (73%) 
Length of hospital stay (days) 
Median 8.65 7.46 
0.29 25th percentile 5.41 6.21 
75th percentile 13.79 11.31 
Length of ICU stay (days) 
Median 3.18 3.67 
0.82 25th percentile 2.64 2.52 
75th percentile 6.72 7.35 
Ventilation time (hours) 
Median 13.07 10.45 
0.03 25th percentile 6.00 7.46 
75th percentile 30.04 20.27 
ICU= Intensive Care Unit; MI= Myocardial Infarction; GIT= Gastrointestinal Tract.  P-values were calculated using the 
Kruskal-Wallis test for the comparison of medians.   
 
4.5 Data for the Lactate <5 mmol/L Group and Lactate 
>5 mmol/L Group 
 
4.5.1 Division of Lactate <5 mmol/L Group and Lactate 
>5mmol/L Group 
 
The sixty recruited patients were divided into two groups according to peri-operative and post-
operative lactate values irrespective of surgical technique.   
If a patient’s lactate level remained <5mmol/L intra- and post-operatively the patient fell in the 
lactate group 1 (lactate <5mmol/L).  If a patient’s lactate level increased >5mmol/L at any time 
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intra- or post-operatively the patient fell in the lactate group 2 (lactate >5mmol/L) (Figure 
4.11). 
 
 
Figure 4.11 Lactate<5 mmol/L and Lactate >5mmol/L irrespective of surgical 
  technique.  
[n= number of patients]. 
 
4.5.1.1 Association between Lactate Group and Surgical 
Technique 
 
This evaluation was done to determine whether the odds of a certain event or outcome will be 
the same for the 2 lactate groups.  In this case, whether the odds of a lactate levels of >5mmol/L 
will be the same for both the on-pump and off-pump group.  This test indicated a likelihood of 
the on-pump group having lactate of >5mmol/L was 2.3 times more likely than the off-pump 
group.  However, this difference was not statistically significant (Table 4.14).   
 
 
Lactate <5mmol/L (n=43) Lactate >5mmol/L (n=17)
24
6
19
11
Population Lactate <5mml/L vs. 
Lactate >5mmol/L
On-pump
Off-pump
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Table 4.14 Odds Ratio for Lactate Group vs. Surgical Technique 
LACTATE GROUP AND SURGICAL TECHNIQUE ODDS RATIO p-VALUE 
Surgical 
Technique 
Lactate < 5 
mmol/L 
Frequency (%) 
Lactate > 5 
mmol/L 
Frequency (%) 
Total 
  
Off-pump CABG 24 (40.0) 6 (10.0) 30(50.0) 
On-pump CABG 19 (31.7) 11 (18.3) 30 (50.0) 
Total 43 (71.7) 17 (28.3) 60 (100.0) 2.3 0.15 
p-values were calculated using the Chi-square test for the difference in proportions between the lactate groups. 
 
4.5.2 Demographic and Clinical Data for Lactate <5 
mmol/L and Lactate >5mmol/L 
 
The demographic data revealed no statistically significant differences between the lactate <5 
mmol/L group and lactate >5mmol/L group.  Although the groups were unbalanced in size, the 
groups were comparable with respect to demographic and baseline clinical data (Table 4.15).   
 
Table 4.15 Demographic Data: Lactate <5 mmol/L and Lactate >5mmol/L 
VARIABLE (UNIT) 
LACTATE 
<5mmol/L 
LACTATE 
>5mmol/L 
p-VALUE 
EuroSCORE (%) 
Median 4.0 4.0 
0.19 25th percentile 1.6 2.6 
75th percentile 7.5 6.3 
Age (years) 
Median 62.0 57.0 
0.37 25th percentile 53.0 54.0 
75th percentile 68.0 64.0 
Height (cm) 
Median 175.0 178.0 
0.84 25th percentile 169.0 171.0 
75th percentile 184.0 184.0 
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VARIABLE (UNIT) 
LACTATE 
<5mmol/L 
LACTATE 
>5mmol/L 
p-VALUE 
Weight (kg) 
Median 82.0 96.0 
0.72 25th percentile 72.0 83.0 
75th percentile 102.0 106.0 
BSA (m²) 
Median 1.9 2.0 
0.82 25th percentile 1.8 1.7 
75th percentile 2.2 2.1 
BMI (kg/m²) 
Median 27.5 31.0 
0.34 25th percentile 24.1 25.6 
75th percentile 30.4 32.8 
Significant differences were noted at p < 0.05. [BSA= Body Surface Area; BMI= Body Mass Index; EuroSCORE = 
calculated using the EuroSCORE II model].  p-values were calculated using the Kruskal-Wallis test for the comparison 
of medians. 
 
4.5.3 Pre-operative Clinical Data: Lactate <5mmol/L vs. 
Lactate >5mmol/L 
 
Pre-operative risk factors were summarized by lactate group in Table 4.16.  Pre-operative risk 
factors such as; LVEF%, renal complications, neurological complications, pulmonary 
complications, previous non-surgical intervention, dyspnoea, diabetes, hypertension and ACS 
showed no significant differences between the two groups (p>0.05).   
There was a statistically significant difference between the lactate groups with respect to the 
number of previous MI’s.  Last previous MI data showed statistically significance (p<0.05), 
however much of the data was not available for the lactate <5mmol/L group. 
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Table 4.16 Pre-operative Clinical Data: Lactate <5mmol/L vs. Lactate >5mmol/L 
VARIABLE (UNIT) 
LACTATE 
<5 mmol/L 
n (%) 
LACTATE  
>5 mmol/L 
n (%) 
p-VALUE 
LVEF % 
Median 53.0 53.0 
0.15 25th percentile 45.0 48.0 
75th percentile 66.0 60.0 
Renal complications 
No 41(95.0%) 17(100.0%) 
1.00 
Yes 2(4.0%) - 
Neurological disease 
No 43(100.0%) 17(100.0%) 
0.98 
Yes CVA with full recovery - - 
Pulmonary disease 
Mild COPD 4(9.0%) 3(17.0%) 
2.72 
Moderate COPD 1(2.0%) - 
Previous Non-Surgical Intervention 
Previous PCI 2 (4.0%) 2 (11.0%) 
0.82 
PCI > 24hrs before surgery 1(2.0%) - 
Dyspnoea 
NYHA I 8 (18.0%) 1 (5.0%) 
0.56 
NYHA II 19 (44.0%) 11 (64.6%) 
NYHA III 4 (9.0%) 3 (17.0%) 
NYHA VI - 1 (5.0%) 
Diabetes 
None 31(72.0%) 12(70.0%) 
0.56 
Diet 
 
5 (12.0%) 1 (6.0%) 
Oral therapy 4 (9.0%) 3 (18.0%) 
Insulin 3 (7.0%) 1 (6.0%) 
Hypertension 
Treated 18 (60.0%) 20 (66.67%) 0.74 
Acute Coronary Syndrome 
Unstable Angina 17 (39.0%) 5 (29.0%) 
0.48 STEMI 11 (25.0%) 4 (23.0%) 
NONSTEMI 14 (32.0%) 8 (47.0%) 
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VARIABLE (UNIT) 
LACTATE 
<5 mmol/L 
n (%) 
LACTATE  
>5 mmol/L 
n (%) 
p-VALUE 
Previous MI 
One 8 (18.0%) 3 (17.0%) 
0.05 
Two or more 14 (32.0%) 12 (70.00%) 
Last Previous MI Upon Admission To Cardiology 
Unknown 18(41.0%) 3 (18.0%) 
0.01 
< 6hrs 16 (37.0%) 5 (29.0%) 
6 – 24hrs 4 (9.0%) 3 (18.0%) 
1 – 30 days 5 (11.0%) 4 (23.0%) 
31 – 90 days - - 
> 90 days - 2 (12.0%) 
Significant differences were noted at p < 0.05. [LVEF %= Left Ventricle Ejection Fraction percentage; STEMI= ST 
segment Elevation Myocardial Infarction; NONSTEMI= Non ST segment Myocardial Infarction; MI= Myocardial 
Infarction; CVA= Cerebrovascular Accident; COPD= Chronic Obstructive Pulmonary Disease].  p-values for the 
comparison of categorical data was calculated using the Chi-square. 
 
4.5.4 Intra-operative Metabolic Data: Lactate  
<5 mmol/L and Lactate >5mmol/L 
 
The metabolic changes seen in lactate <5mmol/L and lactate >5mmol/L were compared by 
analysing the patient’s intra-operative metabolic data and hemodynamic profiles.  The intra-
operative metabolic data were displayed in Table 4.17 and Table 4.18 for lactate <5mmol/L and 
lactate >5mmol/L respectively.   
The metabolic data were recorded intra-operatively at baseline, intubation and at 15 minute 
time intervals thereafter.  The baseline ABG represents the first ABG drawn upon the patient's 
admission to theatre.  The second ABG was drawn 5 minutes after intubation.  T1-T9 represents 
intra-operative ABG’s that were drawn at 15 minute intervals from the onset of surgery.   
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Table 4.17 Intra-operative Metabolic Data: Lactate <5 mmol/L 
VARIABLE 
(UNIT) 
B
A
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T
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T
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T
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T
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pH 
Median 7.45 7.41 7.41 7.42 7.41 7.40 7.39 7.39 7.39 7.38 7.40 
25th percentile 7.43 7.39 7.36 7.36 7.37 7.37 7.37 7.36 7.36 7.36 7.35 
75th percentile 7.47 7.45 7.45 7.45 7.44 7.43 7.45 7.41 7.42 7.41 7.41 
pCO2 (mmHg) 
Median 34.8 36.5 36.3 36.8 36.5 36.6 39.5 39.2 35.7 36.7 36.8 
25th percentile 31.8 33.0 33.0 32.7 34.2 32.6 35.8 35.3 35.1 34.5 34.3 
75th percentile 37.8 43.0 39.8 39.5 40.6 40.3 39.8 37.8 39.6 41.8 41.9 
pO2 (mmHg) 
Median 73.5 163.2 251.3 188.1 195.0 186.4 175.8 175.0 175.7 196.8 172.1 
25th percentile 66.8 126.4 129.2 157.4 154.7 143.1 143.7 154.0 145.3 122.4 116.3 
75th percentile 126.1 297.0 297.5 229.7 212.6 209.4 198.2 215.0 200.8 213.7 213.3 
HCO3- std (mmol/L) 
Median 24.7 23.9 22.9 23.4 23.3 22.9 23.1 22.6 22.9 22.8 23.2 
25th percentile 23.5 22.5 21.5 21.1 21.4 21.8 22.1 22.0 22.3 22.0 21.8 
75th percentile 25.5 25.0 24.3 24.5 24.0 24.0 23.7 24.2 24.1 24.1 23.6 
BE (B) (mmol/L) 
Median 0.1 -0.7 -1.9 -1.4 -1.4 -2.0 -1.7 -2.3 -2.0 -2.1 -1.6 
25th percentile -1.1 -2.2 -3.4 -3.6 -4.0 -3.7 -3.2 -2.9 -3.0 -2.7 -2.9 
75th percentile 1.3 0.5 -0.4 -0.2 0.0 -0.6 -0.6 -0.9 -0.5 -6.2 -6.2 
t Hb (g/dL) 
Median 13.2 11.6 11.3 10.7 10.5 10.5 10.4 10.1 10.1 9.5 9.1 
25th percentile 12.4 11.2 9.9 9.9 9.5 9.3 8.9 8.8 9.0 8.7 8.5 
75th percentile 14.6 13.9 12.4 11.4 11.4 11.3 11.1 10.8 11.6 10.6 10.3 
O2 Sat (%) 
Median 95.3 99.5 98.9 99.3 99.3 99.2 99.2 99.2 99.2 99.3 99.0 
25th percentile 94.2 99.1 98.2 98.3 98.7 98.6 98.2 98.4 98.6 98.5 96.5 
75th percentile 97.1 99.7 99.3 99.5 99.5 99.4 99.4 99.4 99.4 99.4 99.4 
Na+ (mmol/L) 
Median 138.0 139.7 137.3 137.2 137.9 136.4 136.7 136.8 136.7 136.9 137.1 
25th percentile 136.0 136.2 135.1 135.8 136.0 134.2 135.7 135.9 136.0 136.4 136.7 
75th percentile 139.0 139.8 139.7 139.5 
139.7
616 
140.0 139.2 139.2 139.7 139.1 140.9 
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VARIABLE 
(UNIT) 
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K+ (mmol/L) 
Median 3.8 3.7 3.6 3.7 3.9 3.9 4.0 4.1 4.2 4.3 4.2 
25th percentile 3.1 3.7 3.4 3.3 3.5 3.9 3.8 3.2 3.9 3.6 3.7 
75th percentile 4.2 4.7 4.5 4.6 4.4 4.4 4.5 4.5 4.34 4.4 4.4 
Ca++ (mmol/L) 
Median 1.2 1.1 1.1 1.1 1.0 1.0 1.0 1.0 1.0 1.0 1.0 
25th percentile 1.0 0.9 1.0 0.9 1.0 0.9 0.9 0.9 0.9 1.0 1.0 
75th percentile 1.2 1.2 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.1 
Cl- (mmol/L) 
Median 107.0 110.0 111.0 111.0 112.0 112.0 112.0 112.0 111.0 112.0 110.5 
25th percentile 96.0 98.0 99.0 101.0 101.0 101.0 104.0 104.0 105.0 104.0 114.0 
75th percentile 115.0 124.0 124.0 125.0 120.0 118.0 121.0 117.0 115.0 112.0 115.0 
Glucose (mmol/L) 
Median 5.2 5.4 5.6 5.7 6.7 7.0 6.9 7.2 7.0 8.0 8.2 
25th percentile 4.9 4.9 4.8 4.5 5.8 5.9 5.8 5.8 6.2 6.6 6.1 
75th percentile 6.1 6.4 7.9 8.0 8.2 8.8 9.0 9.7 10.3 10.3 9.6 
Lactate (mmol/L) 
Median 1.2 1.6 1.9 2.2 2.5 2.8 3.0 2.9 2.8 2.8 2.8 
25th percentile 0.9 1.1 1.4 1.6 1.77 1.9 2.2 2.0 2.0 2.0 2.2 
75th percentile 1.5 2.4 2.8 3.2 3.4 3.5 3.8 3.5 3.6 3.5 3.8 
pH= measure of concentration of hydrogen ions, pCO2= Carbon Dioxide, O2= Oxygen, HCO3- & BE (B)= acid-base 
balance, tHb= Haemoglobin, O2 Sat (%)= Saturation, Na+= Sodium, K+= Potassium, Ca++= Calcium and Cl-= Chloride.  
[T1=15 minutes; T2= 30 minutes; T3= 45 minutes; T4= 60 minutes; T5= 75 minutes; T6= 90 minutes; T7= 105 
minutes; T8= 120 minutes; T9= 135 minutes].   
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Table 4.18 Intra-operative Metabolic Data: Lactate >5 mmol/L 
VARIABLE 
(UNIT) 
B
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T
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T
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pH 
Median 7.45 7.39 7.36 7.36 7.34 7.37 7.32 7.33 7.33 7.33 7.33 
25th percentile 7.43 7.36 7.33 7.30 7.31 7.31 7.29 7.29 7.30 7.27 7.24 
75th percentile 7.47 7.41 7.41 7.45 7.38 7.38 7.38 7.36 7.35 7.37 7.36 
pCO2 (mmHg) 
Median 34.0 37.3 38.0 36.2 36.7 35.3 38.5 36.1 35.4 38.9 39.1 
25th percentile 32.2 35.8 33.6 35.5 33.5 34.3 33.5 32.5 34.1 37.2 36.4 
75th percentile 39.3 46.0 41.6 38.3 40.1 39.3 41.3 45.4 44.9 44.8 48.4 
pO2 (mmHg) 
Median 69.8 190.0 203.0 214.0 203.0 173.0 172.0 175.0 151.0 173.0 164.0 
25th percentile 61.3 154.6 179.1 160.5 136.0 142.0 131.5 110.7 105.5 158.2 125.0 
75th percentile 72.7 190.1 263.7 241.2 213.9 193.9 217.8 196.1 227.4 216.8 172.0 
HCO3- std (mmol/L) 
Median 24.6 23.4 21.8 21.0 20.3 20.5 20.1 19.8 20.0 20.3 20.9 
25th percentile 23.9 22.9 20.6 19.0 19.0 18.8 18.7 18.3 19.4 18.9 18.7 
75th percentile 25.6 24.2 22.9 21.3 22.4 22.0 21.9 21.7 22.2 21.8 21.7 
BE (B) (mmol/L) 
Median 0.2 -1.3 -3.3 -4.2 -5.0 -4.8 -5.2 -5.7 -5.4 -5.1 -4.4 
25th percentile -1.0 -1.9 -5.1 -6.8 -6.6 -7.0 -6.9 -7.5 -6.1 -6.7 -6.0 
75th percentile 1.4 -0.4 -2.5 -3.8 -2.5 -3.0 -3.0 -3.4 -2.8 -3.2 -3.9 
t Hb (g/dL) 
Median 15.2 14.7 11.9 10.4 10.4 10.4 10.2 10.1 10.0 10.0 9.7 
25th percentile 14.5 13.4 9.7 9.3 9.2 8.5 9.0 9.1 8.4 7.9 8.1 
75th percentile 16.2 15.4 12.0 12.0 11.0 10.4 10.4 10.4 11.0 14.7 11.1 
O2 Sat (%) 
Median 94.9 99.4 99.3 99.4 99.5 99.2 99.1 99.2 98.8 99.1 99.0 
25th percentile 92.9 98.9 98.6 98.4 98.6 98.3 97.2 97.4 97.2 95.3 96.3 
75th percentile 99.7 99.6 99.5 99.4 99.5 99.4 99.4 99.4 99.3 99.4 99.5 
Na+ (mmol/L) 
Median 138.5 138.0 137.3 137.1 137.3 137.0 137.0 137.4 137.6 137.1 138.0 
25th percentile 134.3 133.1 127.9 129.7 129.3 126.8 125.7 125.6 127.2 128.6 132.0 
75th percentile 142.2 143.2 139.5 142.3 141.2 144.2 142.8 142.8 145.3 144.5 145.5 
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VARIABLE 
(UNIT) 
B
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T
6
 
T
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T
8
 
T
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K+ (mmol/L) 
Median 4.0 3.8 3.4 3.0 3.4 3.5 3.5 3.7 3.9 3.8 3.2 
25th percentile 3.0 2.2 2.8 2.3 2.4 2.2 2.9 2.7 2.9 3.2 2.9 
75th percentile 4.5 4.6 4.4 5.5 5.3 5.7 6.1 6.1 5.2 5.1 4.3 
Ca++ (mmol/L) 
Median 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.0 1.1 1.0 
25th percentile 1.0 0.9 0.8 0.9 0.9 0.9 0.8 0.8 0.7 0.8 0.9 
75th percentile 1.2 1.2 1.2 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.0 
Cl- (mmol/L) 
Median 109.0 110.0 112.0 112.0 112.0 112.0 112.0 112.0 112.0 111.5 111.5 
25th percentile 92.0 93.0 99.0 98.0 107.0 99.0 98.0 98.0 97.0 107.0 105.0 
75th percentile 118.0 118.0 115.0 117.0 117.0 116.0 118.0 116.0 116.0 115.0 113.0 
Glucose (mmol/L) 
Median 5.8 5.7 6.8 8.7 10.1 10.9 10.4 11.5 12.2 13.1 12.7 
25th percentile 5.0 5.2 6.2 6.2 7.6 8.2 8.8 8.6 10.0 9.6 9.6 
75th percentile 6.2 6.2 8.8 11.2 12.5 13.6 14.6 14.8 16.1 16.6 16.5 
Lactate (mmol/L) 
Median 1.2 1.4 2.9 4.7 5.2 5.7 5.7 5.7 5.8 6.1 6.5 
25th percentile 1.0 1.0 2.6 3.4 4.2 4.5 4.4 4.9 5.2 5.3 5.9 
75th percentile 1.4 1.7 5.7 6.0 6.9 6.8 7.1 8.4 9.7 10.4 10.5 
pH= measure of concentration of hydrogen ions, pCO2= Carbon Dioxide, O2= Oxygen, HCO3- & BE (B)= acid-base 
balance, tHb= Haemoglobin, O2 Sat (%)= Saturation, Na+= Sodium, K+= Potassium, Ca++= Calcium and Cl-= Chloride.  
[T1=15 minutes; T2= 30 minutes; T3= 45 minutes; T4= 60 minutes; T5= 75 minutes; T6= 90 minutes; T7= 105 
minutes; T8= 120 minutes; T9= 135 minutes].   
 
Due to the limited sample size the median, 25th and 75th percentile were calculated and the 
median values of metabolic data were plotted to observe whether any trends could be observed 
in lactate <5 mmol/L and lactate > 5 mmol/L (Figure 4.12-4.14).   
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Figure 4.12 Medians for acid-base balance during the intra-operative period for lactate 
<5mmol/l and lactate >5mmol/L groups.   
[pCO2= Carbon Dioxide, O2= Oxygen, pH= measure of concentration of hydrogen ions and BE (B)= 
acid-base balance.  [T1=15 minutes; T2= 30 minutes; T3= 45 minutes; T4= 60 minutes; T5= 75 
minutes; T6= 90 minutes; T7= 105 minutes; T8= 120 minutes; T9= 135 minutes].   
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Figure 4.13 Medians for metabolites, saturation (%) and haemoglobin (tHb) during the 
intra-operative period for both lactate <5mmol/l and lactate >5mmol/L 
groups.   
[T1=15 minutes; T2= 30 minutes; T3= 45 minutes; T4= 60 minutes; T5= 75 minutes; T6= 90 
minutes; T7= 105  minutes; T8= 120 minutes; T9= 135 minutes].   
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Figure 4.14  Medians for electrolytes: Sodium (Na+), Potassium (K+), Calcium (Ca++) and 
Chloride (Cl-) during the Intra-operative period for both lactate <5mmol/l 
and lactate >5mmol/L groups.   
[T1=15 minutes; T2= 30 minutes; T3= 45 minutes; T4= 60 minutes; T5= 75 minutes; T6= 90 
minutes; T7= 105 minutes; T8= 120 minutes; T9= 135 minutes]. 
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4.5.5 P-values for Intra-operative Metabolic Data: 
Lactate <5 mmol/L vs. Lactate >5 mmol/L 
 
At various time points during surgery, statistically significant differences (p<0.05) were noted 
between lactate <5 mmol/L and lactate > 5 mmol/L (Table 4.19). 
 
Variables for the acid-base balance, pO2 and pCO2, showed no statistically significant (p>0.05) 
differences between the two groups (Table 4.19).   
Other variables for acid-base balance, pH, HCO3- and BE (B), showed statistically significant 
(p<0.05) differences for most of the surgery duration.   
The metabolites O2 Sat (%) showed no statistically significant differences (p>0.05), however, 
tHb (g/dL), glucose levels and lactate levels showed statistically significant differences (p<0.05) 
for most of the surgery duration.   
The electrolytes K+, Ca++, Na+ and Cl- indicated no statistically significant differences (p>0.05).   
Groups were comparable with only a few statistically significant differences observed between 
the two groups.   
 
Table 4.19 P-values for Intra-operative Metabolic Data: Lactate <5 mmol/L vs. Lactate 
>5 mmol/L  
VARIABLE 
(UNIT) 
B
A
S
E
L
IN
E
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T
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B
A
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T
1
 
T
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T
3
 
T
4
 
T
5
 
T
6
 
T
7
 
T
8
 
T
9
 
pH 0.01 0.02 0.03 0.02 0.00 0.01 0.00 0.00 0.01 0.00 0.04 
pCO2 (mmHg) 0.78 0.13 0.26 0.58 0.78 0.88 0.68 0.41 0.61 0.78 0.34 
pO2 (mmHg) 0.07 0.39 0.57 0.25 0.85 0.60 0.80 0.87 0.23 0.29 0.85 
HCO3- STD 
(mmol/L) 
0.95 0.35 0.05 0.02 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
BE (B) (mmol/L) 0.98 0.28 0.05 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
tHb (g/dL) 0.01 0.00 0.32 0.36 0.88 0.71 0.26 0.33 0.95 0.30 0.86 
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O2 SAT (%) 0.35 0.79 0.33 0.33 0.54 0.98 0.89 0.77 0.46 0.49 0.97 
Na+ (mmol/L) 0.87 0.45 0.96 0.52 0.74 0.64 0.63 0.99 1.0 0.71 0.21 
K+ (mmol/L) 1.0 0.85 0.19 0.43 1.0 0.78 0.61 0.13 0.67 0.31 0.47 
Ca++ (mmol/L) 1.0 2.0 1.64 1.53 1.74 1.41 1.78 1.54 1.92 0.76 0.57 
Cl- (mmol/L) 0.41 0.19 0.78 0.49 0.74 0.42 0.68 0.78 0.61 0.52 0.75 
Glucose (mmol/L) 0.49 0.39 0.08 0.00 0.00 0.00 0.00 0.00 <0.0 0.00 0.00 
Lactate (mmol/L) 0.38 0.39 0.00 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 
pH= measure of concentration of hydrogen ions, pCO2= Carbon Dioxide, O2= Oxygen, HCO3- & BE (B)= acid-base 
balance, tHb= Haemoglobin, O2 Sat (%)= Saturation, Na+= Sodium, K+= Potassium, Ca++= Calcium and Cl-= Chloride.  
[T1=15 minutes; T2= 30 minutes; T3= 45 minutes; T4= 60 minutes; T5= 75 minutes; T6= 90 minutes; T7= 105 
minutes; T8= 120 minutes; T9= 135 minutes].  The p-values were calculated using the Kruskal-Wallis test for the 
comparison of medians.   
 
4.5.6 Intra-operative Hemodynamic Data and 
Temperature: Lactate <5mmol/L and Lactate 
>5mmol/L 
 
The intra-operative hemodynamic data included systolic pressure, diastolic pressure, MAP, CVP 
and HR and were compared between lactate <5 mmol/L group and lactate > 5 mmol/L group to 
investigate the impact of the hemodynamic instability on metabolic changes. 
Table 4.20 and Table 4.21 present the intra-operative hemodynamic data for the lactate <5 
mmol/L group and the lactate > 5 mmol/L group, respectively.  Line graphs were drawn (Figure 
4.15), using the median values of the lactate groups to display possible trends observed in the 
two groups.   
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Table 4.20 Intra-operative Hemodynamic Data and Temperature: Lactate <5 mmol/L 
VARIABLE 
(UNIT) 
B
A
S
E
L
IN
E
 
IN
T
U
B
A
T
IO
N
 
T
1
 
T
2
 
T
3
 
T
4
 
T
5
 
T
6
 
T
7
 
T
8
 
T
9
 
Systolic Pressure (mmHg) 
Median 123.0 122.0 122.0 124.0 119.0 113.0 110.0 114.0 111.0 109.0 112.0 
25th percentile 67.9 77.9 87.0 77.1 99.2 81.0 73.0 71.0 83.0 69.8 74.0 
75th percentile 143.0 130.0 128.0 128.0 133.0 124.0 120.0 131.0 122.0 128.0 136.0 
Diastolic Pressure (mmHg) 
Median 92.7 92.3 91.3 84.3 82.4 90.3 85.5 82.9 82.6 79.6 78.0 
25th percentile 82.0 77.0 68.0 67.0 80.3 64.0 62.0 71.0 75.0 62.0 59.3 
75th percentile 102.6 110.0 117.0 
124.0
0 
119.7 110.0 109.7 104.2 100.0 103.8 107.2 
Mean Arterial Pressure (mmHg) 
Median 92.7 92.3 91.3 84.3 82.4 90.3 85.5 82.9 78.0 75.4 78.6 
25th percentile 67.8 68.5 69.2 71.5 72.6 74.0 68.7 63.8 62.1 64.9 60.7 
75th percentile 98.4 97.3 99.4 100.0 101.7 103.8 109.5 95.7 97.4 91.3 90.2 
HR (beats/min) 
Median 68.0 68.0 67.0 67.0 64.0 71.0 64.0 61.0 58.0 61.0 60.5 
25th percentile 58.0 62.0 64.0 56.0 63.0 57.0 58.0 42.0 53.0 51.0 55.0 
75th percentile 70.0 74.0 71.0 82.0 75.0 73.0 70.0 68.0 69.0 67.0 62.0 
CVP (mmHg) 
Median 5.3 6.1 4.1 4.2 5.4 4.5 4.3 4.6 5.8 4.8 4.2 
25th percentile 4.2 5.4 3.8 3.1 4.8 4.0 4.0 3.7 4.2 4.3 3.1 
75th percentile 7.5 8.7 9.3 9.7 8.2 9.3 6.7 5.5 5.9 8.5 5.5 
Temperature (°C) 
Median 36.0 36.0 35.8 33.4 32.1 32.2 32.7 32.6 32.5 33.8 34.4 
25th percentile 32.2 32.0 31.8 30.3 30.4 32.0 31.6 31.6 30.3 31.1 32.0 
75th percentile 36.5 36.1 36.6 36.2 36.6 36.3 36.1 36.4 36.4 36.1 36.4 
CVP= central venous pressure, HR=heart rate. C= degrees Celsius.  [T1-9: time intervals of 15 minutes] 
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Table 4.21 Intra-operative Hemodynamic Data and Temperature: Lactate >5mmol/L 
VARIABLE 
(UNIT) 
B
A
S
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L
IN
E
 
IN
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U
B
A
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T
1
 
T
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T
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T
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T
5
 
T
6
 
T
7
 
T
8
 
T
9
 
Systolic Pressure (mmHg) 
Median 118.3 130.0 112.0 70.0 63.4 74.1 78.1 79.5 84.0 86.2 88.8 
25th percentile 111.0 110.6 110.5 58.0 55.7 57.3 56.4 59.7 74.5 81.4 86.8 
75th percentile 128.4 137.3 117.3 116.4 110.2 94.2 110.0 125.3 106.7 110.0 113.1 
Diastolic Pressure (mmHg) 
Median 63.1 68.3 47.8 52.4 52.5 53.9 56.2 54.7 45.3 54.4 57.9 
25th percentile 37.5 41.0 37.9 40.1 37.1 39.1 38.7 36.8 40.2 37.2 45.4 
75th percentile 86.1 73.9 79.4 70.5 70.5 66.2 63.9 58.4 60.4 60.8 62.1 
Mean Arterial Pressure (mmHg) 
Median 80.5 72.3 71.4 70.5 67.9 64.9 68.6 67.2 60.8 64.3 56.7 
25th percentile 62.5 57.8 62.2 60.3 51.8 61.1 55.8 57.3 50.1 46.9 50.3 
75th percentile 113.6 76.7 115.0 92.8 107.6 77.2 73.9 71.1 72.7 74.7 68.0 
HR (beats/min) 
Median 67.0 66.0 74.0 73.0 69.0 75.0 69.0 67.0 62.0 64.0 64.0 
25th percentile 53.0 61.0 62.0 53.0 53.0 53.0 52.0 54.0 57.0 53.0 53.0 
75th percentile 83.0 82.0 80.0 78.0 77.0 76.0 84.0 80.0 81.0 84.0 77.0 
Temperature (°C) 
Median 36.1 36.4 36.0 33.9 32.4 32.4 32.1 32.4 32.6 33.9 35.1 
25th percentile 34.9 34.5 32.5 31.4 30.7 30.1 29.7 29.3 29.0 28.8 30.7 
75th percentile 36.3 36.5 36.3 36.3 36.2 36.2 36.1 36.1 36.1 36.0 36.1 
CVP (mmHg) 
Median 4.8 5.0 5.1 4.9 4.8 4.5 4.5 4.4 4.8 5.8 5.0 
25th percentile 3.5 2.0 2.6 2.6 3.2 3.1 3.3 3.2 3.2 3.8 3.9 
75th percentile 7.5 6.5 6.9 5.9 5.3 5.2 5.7 4.8 7.7 7.1 5.3 
CVP= central venous pressure, HR=heart rate, C= degrees Celsius.  [T1-9: time intervals of 15 minutes]. 
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Figure 4.15 Medians for hemodynamics for both lactate <5mmol/L and lactate 
>5mmol/L during CABG surgery.  
[CVP= central venous pressure, HR= heart rate.  Temperature was measured in degrees Celsius 
(C).  [T1=15 minutes; T2= 30 minutes; T3= 45 minutes; T4= 60 minutes; T5= 75 minutes; T6= 90 
minutes; T7= 105 minutes; T8= 120 minutes; T9= 135 minutes]. 
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4.5.7 Intra-operative Hemodynamic Data and 
Temperature: Lactate <5mmol/L vs. Lactate 
>5mmol/L 
 
Statistically significant differences between the lactate <5 mmol/L group and lactate > 5 
mmol/L group were noted for the systolic pressures, diastolic pressures and mean arterial 
blood pressure data (Table 4.22) for most part of the surgery.  No statistically significant 
differences between the two groups were noted for HR, CVP and temperature (p>0.05).   
 
Table 4.22 Intra-operative Hemodynamic Data and Temperature: Lactate < 5mmol/L 
vs. Lactate > 5mmol/L 
VARIABLE 
(UNIT) 
B
A
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T
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T
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T
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T
6
 
T
7
 
T
8
 
T
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Systolic Pressure (mmHg) 
 0.32 0.70 0.93 0.03 0.00 0.05 0.00 0.01 0.01 0.27 0.31 
Diastolic Pressure (mmHg) 
 0.25 0.62 0.19 0.00 0.01 0.04 0.03 0.03 0.00 0.04 0.14 
Mean Arterial Pressure (mmHg) 
 0.15 0.10 0.98 0.04 0.05 0.03 0.02 0.04 0.00 0.02 0.28 
HR (beats/min) 
 0.41 0.81 0.80 0.32 0.85 0.16 0.19 0.16 0.34 0.31 0.09 
CVP (mmHg) 
 0.15 0.99 0.33 0.54 0.14 0.38 0.80 0.39 0.18 0.88 0.72 
Temperature (°C) 
 0.69 0.95 0.18 0.70 0.27 0.35 0.72 0.64 0.68 0.78 0.61 
CVP= central venous pressure, HR= heart rate. C= Temperature was measured in degrees Celsius.  [T1-9: time 
intervals of 15 minutes].  The p-values were calculated using the Kruskal-Wallis test for the comparison of medians.   
 
4.5.8 Post-operative Metabolic Data: Lactate <5mmol/L 
and Lactate >5mmol/L 
 
Post-operative metabolic data for the lactate <5 mmol/L group and the lactate > 5 mmol/L 
group were displayed in Table 4.23 and Table 4.24, respectively.  The median values of the 
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metabolic data were plotted against each other at specific time intervals to look for trends in the 
2 groups (Figure 4.16 - 4.18). 
 
Table 4.23 Post-operative Metabolic Data: Lactate <5 mmol/L 
VARIABLE 
(UNIT) 1
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pH 
Median 7.34 7.34 7.37 7.40 7.43 7.47 7.47 7.46 
25th percentile 7.29 7.30 7.32 7.37 7.38 7.44 7.44 7.43 
75th percentile 7.38 7.40 7.42 7.43 7.45 7.49 7.49 7.49 
pCO2 (mmHg) 
Median 43.2 41.0 35.6 33.8 34.1 33.5 34.0 35.6 
25th percentile 35.9 34.3 33.4 31.0 29.6 30.9 31.0 32.0 
75th percentile 43.4 43.2 40.0 37.6 35.6 36.3 36.4 40.3 
pO2 (mmHg) 
Median 116.5 98.5 97.6 92.5 82.9 75.7 74.7 69.4 
25th percentile 94.4 82.0 85.0 78.3 71.0 63.1 64.5 60.6 
75th percentile 146.0 122.6 121.2 108.5 99.2 84.5 87.0 82.5 
HCO3- STD (mmol/L) 
Median 21.2 20.7 21.1 21.5 23.0 24.3 25.3 25.6 
25th percentile 18.8 18.7 20.0 20.4 20.7 22.6 23.7 23.7 
75th percentile 22.4 22.6 23.1 23.4 24.1 26.2 26.5 26.9 
BE (B) (mmol/L) 
Median -3.4 -3.8 -3.4 -2.9 -1.8 0.6 1.0 1.7 
25th percentile -6.4 -6.6 -5.1 -4.8 -4.2 -1.7 -0.4 -0.6 
75th percentile -1.4 -1.9 -0.6 -0.7 1.1 2.4 2.5 3.0 
tHb (g/dL) 
Median 12.6 14.6 15.6 13.0 11.8 9.8 7.3 7.8 
25th percentile 10.6 10.9 11.1 10.2 10.7 9.0 6.5 6.0 
75th percentile 12.8 15.2 15.8 14.7 12.6 12.35 12.2 12.4 
O2 Sat (%) 
Median 97.9 97.2 96.9 97.0 96.6 95.9 96.1 95.2 
25th percentile 96.9 96.0 95.9 95.2 94.2 93.7 93.9 92.6 
75th percentile 98.7 98.1 98.3 98.0 97.7 97.4 96.8 96.7 
Na+ (mmol/L) 
Median 138.6 138.0 137.5 137.1 136..6 136.4 135.5 135.0 
25th percentile 129.3 131.9 131.0 131.8 131.6 129.3 127.1 127.2 
75th percentile 149.4 147.3 148.4 148.8 147.5 144.7 141.4 141.6 
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VARIABLE 
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K+ (mmol/L) 
Median 4.1 4.2 4.6 4.5 4.5 4.3 4.3 4.2 
25th percentile 2.8 2.8 3.1 2.7 3.3 2.7 3.5 2.6 
75th percentile 6.0 5.0 5.3 5.1 5.9 6.5 4.8 5.0 
Ca++ (mmol/L) 
Median 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.1 
25th percentile 0.9 0.8 0.9 0.8 0.7 0.9 0.7 0.9 
75th percentile 1.3 1.1 1.1 1.1 1.2 1.1 1.1 1.2 
Cl- (mmol/L) 
Median 108.0 108.5 108.0 109.0 108.0 108.0 105.0 105.0 
25th percentile 100.0 101.0 101.0 101.0 102.0 101.0 95.0 98.0 
75th percentile 118.0 119.0 119.0 122.0 117.0 123.0 118.0 117.0 
Glucose (mmol/L) 
Median 12.0 11.7 11.9 11.6 11.5 11.1 10.6 11.3 
25th percentile 8.6 9.7 11.0 10.3 9.9 7.2 6.8 6.3 
75th percentile 12.7 13.6 15.5 14.8 13.0 12.9 11.3 12.6 
Lactate (mmol/L) 
Median 3.0 3.1 3.8 3.1 2.4 1.6 1.2 1.1 
25th percentile 1.9 2.8 3.2 3.0 2.0 1.2 1.0 1.0 
75th percentile 3.5 3.1 3.8 3.2 3.7 3.1 2.4 2.6 
pH= measure of concentration of hydrogen ions, pCO2= Carbon Dioxide, O2= Oxygen, HCO3- & BE (B)= acid-base 
balance, tHb= Haemoglobin, O2 Sat (%)= Saturation, Na+= Sodium, K+= Potassium, Ca++= Calcium and Cl-= Chloride.  
[Data taken at specified times after admission in ICU at 1-, 2-, 4-, 8-, 12-, 24-, 48- and 72 hours during the post-
operative period].  
 
 
 
 
 
 
 
 
 
 
 
Results                                                                                                                                                 124 | P a g e  
 
Table 4.24 Post-operative Metabolic Data: Lactate >5 mmol/L 
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pH 
Median 7.28 7.32 7.33 7.36 7.42 7.46 7.47 7.46 
25th percentile 7.24 7.27 7.31 7.34 7.38 7.45 7.47 7.45 
75th percentile 7.32 7.34 7.38 7.45 7.51 7.50 7.50 7.50 
pCO2 (mmHg) 
Median 40.7 37.7 35.6 34.3 33.1 33.2 33.0 36.6 
25th percentile 40.4 35.7 33.9 33.5 32.5 30.5 30.4 33.1 
75th percentile 46.2 43.1 38.1 37.0 36.9 37.3 40.5 42.4 
pO2 (mmHg) 
Median 113.8 93.8 94.4 90.7 82.9 73.5 66.2 74.7 
25th percentile 95.0 88.8 84.8 74.3 73.5 67.7 54.2 50.0 
75th percentile 121.7 108.5 111.3 107.3 105.5 81.5 87.0 81.2 
HCO3- STD (mmol/L) 
Median 19.3 19.9 19.3 20.5 22.8 25.0 25.9 26.5 
25th percentile 17.9 18.4 17.8 18.8 20.9 23.1 25.2 25.3 
75th percentile 20.4 21.6 21.5 21.8 24.6 26.6 27.8 28.4 
BE (B) (mmol/L) 
Median -6.3 -5.6 -6.3 -4.8 -2.1 0.5 2.2 2.8 
25th percentile -8.2 -7.3 -8.2 -6.9 -4.2 -1.6 1.2 1.1 
75th percentile -4.9 -3.4 -3.6 -3.1 0.2 2.5 3.9 4.4 
tHb (g/dL) 
Median 10.5 11.9 12.9 12.7 11.4 8.5 7.7 7.1 
25th percentile 10.0 11.1 11.0 10.7 11.3 8.0 6.9 6.6 
75th percentile 13.0 13.2 13.0 13.6 12.7 12.0 12.0 13.0 
O2 Sat (%) 
Median 97.3 96.9 96.9 96.7 96.3 95.7 94.5 96.1 
25th percentile 95.0 95.5 95.0 95.2 95.2 94.9 93.7 91.7 
75th percentile 98.0 97.7 97.6 97.5 97.8 97.2 96.3 97.2 
Na+ (mmol/L) 
Median 140.0 140.3 140.7 139.8 141.1 139.8 135.5 133.3 
25th percentile 131.7 131.9 133.4 131.2 134.9 135.0 134.4 130.1 
75th percentile 142.4 144.9 145.0 145.4 146.0 139.8 137.6 134.0 
K+ (mmol/L) 
Median 3.4 3.5 3.7 4.0 4.1 4.1 4.2 4.1 
25th percentile 2.6 2.7 3.4 3.0 2.9 3.7 3.5 3.9 
75th percentile 4.3 4.1 4.6 4.8 4.9 4.1 4.4 4.7 
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Ca++ (mmol/L) 
Median 1.0 1.0 1.0 1.0 1.0 1.0 1.1 1.1 
25th percentile 0.9 0.9 0.9 1.0 1.0 1.0 1.0 1.1 
75th percentile 1.0 1.1 1.1 1.1 1.1 1.0 1.1 1.2 
Cl- (mmol/L) 
Median 111.0 111.0 111.0 113.0 113.0 111.0 107.0 104.0 
25th percentile 107.0 108.0 110.0 111.0 110.0 109.0 103.2 102.0 
75th percentile 111.0 111.0 111.5 114.4 114.9 114.0 109.0 107.0 
Glucose (mmol/L) 
Median 11.7 11.9 11.9 11.6 11.6 11.3 11.4 11.4 
25th percentile 9.8 11.4 11.1 11.0 10.9 7.8 6.5 6.3 
75th percentile 15.4 16.2 16.3 14.7 13.7 12.5 12.0 12.1 
Lactate (mmol/L) 
Median 7.9 8.3 8.3 7.3 4.1 2.1 1.7 1.2 
25th percentile 6.5 5.0 5.5 3.4 3.1 1.5 1.5 1.0 
75th percentile 9.1 10.5 10.7 9.9 6.7 3.8 1.8 1.3 
pH= measure of concentration of hydrogen ions, pCO2= Carbon Dioxide, O2= Oxygen, HCO3- & BE (B)= acid-base 
balance, tHb= Haemoglobin, O2 Sat (%)= Saturation, Na+= Sodium, K+= Potassium, Ca++= Calcium and Cl-= Chloride.  
[Data taken at specified times after admission in ICU at 1-, 2-, 4-, 8-, 12-, 24-, 48- and 72 hours during the post-
operative period].  
 
Results                                                                                                                                                 126 | P a g e  
 
 
Figure 4.16 Medians of acid-base balance during the first 72 hours post-operatively 
following CABG surgery for both lactate <5mmol/L and lactate >5mmol/L.  
[T1=15 minutes; T2= 30 minutes; T3= 45 minutes; T4= 60 minutes; T5= 75 minutes; T6= 90 
minutes; T7= 105 minutes; T8= 120 minutes; T9= 135 minutes]. 
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Figure 4.17 Medians for metabolites, saturation (%) and haemoglobin (Hb) the first 
72hour post-operative period following CABG surgery for both lactate 
<5mmol/L and lactate >5mmol/L.   
[T1=15 minutes; T2= 30 minutes; T3= 45 minutes; T4= 60 minutes; T5= 75 minutes; T6= 90 
minutes; T7= 105 minutes; T8= 120 minutes; T9= 135 minutes]. 
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Figure 4.18 Medians for electrolytes, Sodium (Na+), Potassium (K+), Calcium (Ca++) and 
Chloride (Cl-) following CABG surgery for both lactate <5mmol/L and 
lactate >5mmol/L.   
[T1=15 minutes; T2= 30 minutes; T3= 45 minutes; T4= 60 minutes; T5= 75 minutes; T6= 90 
minutes; T7= 105 minutes; T8= 120 minutes; T9= 135 minutes]. 
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4.5.9 P-values for Post-operative Metabolic Data: 
Lactate <5 mmol/L vs. Lactate >5 mmol/L 
 
Variables for the acid-base balance, pO2 and pCO2, showed no statistically significant (p>0.05) 
differences between the two groups (Table 4.25). 
pH showed statistically significant (p<0.05) differences only during the 1st hour post-
operatively.  HCO3- and BE (B) showed statistically significant (p<0.05) differences only during 
the 1st hour and during the 4th hour post-operatively.   
The metabolites O2 SAT% and tHb (g/dL) showed no statistically significant differences 
(p>0.05).  Glucose levels showed statistically significant (p<0.05) differences only during the 4th 
hour post-operatively.  Lactate exhibited a statistically significant difference between the groups 
from the immediate post-operative period (p<0.05) until the 12th hour post-operatively, this 
was expected since we stratified on this variable.   
The electrolytes K+, Ca++, Na+ and Cl- indicated no statistically significant differences (p>0.05).   
 
Table 4.25 P-values for Post-operative Metabolic Data: Lactate <5mmol/L vs. Lactate 
>mmol/L 
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pH 0.00 0.14 0.06 0.08 0.76 0.99 0.84 0.63 
pCO2 (mmHg) 0.08 0.50 0.72 0.33 0.28 0.77 0.24 0.48 
pO2 (mmHg) 0.22 0.45 0.51 0.62 0.68 0.99 0.05 0.52 
HCO3- STD 
(mmol/L) 
0.03 0.28 0.02 0.19 0.72 0.53 0.13 0.11 
BE (B) (mmol/L) 0.01 0.13 0.01 0.08 0.72 0.93 0.10 0.13 
tHb (g/dL) 0.49 0.64 0.89 0.95 0.60 0.71 0.12 0.45 
O2 Sat (%) 0.20 0.40 0.37 0.51 0.89 0.71 0.27 0.66 
Na+ (mmol/L) 0.85 0.87 0.78 0.49 0.42 1.0 1.92 0.64 
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K+ (mmol/L) 0.52 0.19 0.31 0.47 1.41 0.76 0.61 0.45 
Ca++ (mmol/L) 0.19 1.78 1.54 0.13 0.41 0.75 0.78 1.0 
Cl- (mmol/L) 0.78 1.0 0.67 1.74 0.74 0.68 0.24 1.64 
Glucose (mmol/L) 0.08 0.04 0.21 0.67 0.36 0.18 0.37 0.48 
Lactate (mmol/L) <0.00 0.00 0.00 0.03 0.05 0.07 0.06 0.59 
pH= measure of concentration of hydrogen ions, pCO2= Carbon Dioxide, O2= Oxygen, HCO3- & BE (B)= acid-base 
balance, tHb= Haemoglobin, O2 Sat (%)= Saturation, Na+= Sodium, K+= Potassium, Ca++= Calcium and Cl-= Chloride.  
The p-values were calculated using the Kruskal-Wallis test for the comparison of medians.  [Data taken at specified 
times after admission in ICU at 1-, 2-, 4-, 8-, 12-, 24-, 48- and 72 hours during the post-operative period].   
 
4.5.10 Clinical Outcomes/Complications: Lactate 
<5mmol/L vs. Lactate >mmol/L 
 
All 60 patients were divided into one of two groups, regardless of the type of coronary artery 
revascularization according to their peak lactate levels (lactate <5 mmol/L or lactate >5 
mmol/L).  Lactate >5 mmol/L is considered high (presents an increased risk for post-operative 
complications).  Groups were compared according to post-operative clinical outcomes and 
complications Table 4.26.  
Table 4.26 Clinical Outcomes/Complications between Lactate <5mmol/L vs. Lactate  
  >5 mmol/ L 
VARIABLES (UNITS) 
LACTATE 
<5 mmol/L 
n (%) 
LACTATE 
>5mmol/L  
n (%) 
p-VALUE 
Mortality 
Yes 2 (5.0%) - 
- 
No 41 (95.0%) 30 (100.0%) 
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VARIABLES (UNITS) 
LACTATE 
<5 mmol/L 
n (%) 
LACTATE 
>5mmol/L  
n (%) 
p-VALUE 
Return to ICU 
Yes - - 
 
No 43 (100.0%) 17 (100.0%) 
Re-intubation 
Yes - 1 (6.0%) 
- 
No 43 (100.0%) 16 (94.0%) 
Re-operation 
Yes 1 (2.0%) 1 (6.0%) 
- 
No 42 (98.0%) 16 (94.0%) 
Post-operative MI 
Yes - - 
- 
No 43 (100.0%) 17 (100.0%) 
Pulmonary complications 
Yes 1 (2.0%) 1 (6.0%) 
- 
No 42 (98.0%) 16 (94.0%) 
Neurological complications 
Yes - - 
- 
No 43 (100.0%) 17 (100.0%) 
Renal complications 
Yes 1 (2.0%) 1 (6.0%) 
- 
No 42 (98.0%) 16 (94.0%) 
GIT complications 
Yes - 2 (12.0%) 
- 
No 43 (100.0%) 15 (88.0%) 
Multi system failure 
Yes 1 (2.0%) - 
- 
No 42 (98.0%) 17 (100.0%) 
Post-operative dissection of major arteries 
Yes - - 
- 
No 43 (100.0%) 17 (100.0%) 
Acute limb ischemia 
Yes - - 
- 
No 43 (100.0%) 17 (100.0%) 
Heart block 
Yes - - 
- 
No 43 (100.0%) 17 (100.0%) 
Atrial fibrillation 
Yes - 2 (12.0%) 
- 
No 43 (100.0%) 15 (88.0%) 
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VARIABLES (UNITS) 
LACTATE 
<5 mmol/L 
n (%) 
LACTATE 
>5mmol/L  
n (%) 
p-VALUE 
Cardiac arrest 
Yes - - 
- 
No 43 (100.0%) 17 (100.0%) 
Anticoagulant complications 
Yes - - 
- 
No 43 (100.0%) 17 (100.0%) 
Tamponade 
Yes - - 
 
No 43 (100.0%) 17 (100.0%) 
Sternal wound infection 
Yes 1 (2.0%) - 
- 
No 42 (98.0%) 17 (100.0%) 
Septicaemia 
Yes 1 (2.0%) 1 (6.0%) 
- 
No 42 (98.0%) 16 (94.0%) 
Post-operative blood transfusions 
Yes 14 (33.0%) 9 (53.0%) 
- 
No 29 (67.0%) 8 (47.0%) 
Length of hospital stay (days) 
Median 8.0 7.0 
0.50 25th percentile 5.0 5.0 
75th percentile 18.0 20.0 
Length of ICU stay (days) 
Median 3.0 3.0 
0.53 25th percentile 1.0 2.0 
75th percentile 6.0 6.0 
Ventilation time (hours) 
Median 12.0 12.0 
0.33 25th percentile 4.0 6.0 
75th percentile 36.0 55.0 
ICU= Intensive Care Unit; MI= Myocardial Infarction; GIT= Gastrointestinal Tract.  P-value was calculated using the 
Kruskal-Wallis test for the comparison of medians.   
 
Post-operative clinical outcomes and complications were summarised for the lactate <5mmol/L 
group and the lactate >5mmol/L group in Table 4.26.   
The lactate <5mmol/L group had none of the following clinical outcomes or complications: 
return to ICU, re-intubation, post-operative MI, neurological complications, GIT complications, 
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post-operative dissection, acute limb ischemia, heart block, AF, cardiac arrest, anticoagulant 
complications or tamponade was noted for the on-pump group.   
Clinical outcomes that were noted for the lactate <5mmol/L group were as follow: mortality 2 
(5.0%), re-operation 1 (2.0%), pulmonary complications 1 (2.0%), renal complications 1 
(2.0%), multi organ failure 1 (2.0%), sternal wound infection 1 (2.0%), septicaemia 1 (2.0%) 
The lactate >5mmol/L group had none of the following clinical outcomes or complications: 
mortality, return to ICU, post-operative MI, neurological complications, multi organ failure, 
acute limb ischemia heart block, cardiac arrest, anticoagulant complications, tamponade or 
sternal wound infection.   
For the lactate >5mmol/L group 1 (6.0%) patient was re-intubated, re-operation 1 (6.0%), 
pulmonary complication 1 (6.0%), renal complication 1 (6.0%), GIT complication 2 (12.0%), AF 
2 (6.0%) and septicaemia 1 (6.0%).   
Length of hospital stay length, ICU stay and ventilation time indicated non-statistically 
significant differences (p>0.05).   
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Chapter 5 
Discussion 
 
5.1 Introduction 
 
Takala et al., (1996) and Lindsay et al., (2013) found increases in lactate concentrations occur 
frequently in cardiac surgery and reflect the changes in oxygen delivery and consumption of the 
patient.  Previous studies (Basaran et al., 2006; Munoz et al., 2000 and Meyer et al., 2013) have 
noted an association between hyperlactatemia on admission to ICU, and morbidity and mortality.  
This study investigated the metabolic and hemodynamic changes that occur during coronary 
artery bypass surgery in patients that presented with acute coronary syndrome.   
Despite the fact that elevated lactate levels have been described to be associated with adverse 
outcomes in paediatric cardiac surgery (McLean et al., 2007), as well as in general intensive care 
admission (e.g. sepsis), no specific lactate level has been identified as a reliable indicator of 
adverse outcomes in adult coronary artery bypass surgery.   
Firstly, elevated lactate levels are associated with anaerobic metabolism during conditions with 
impaired O2 delivery to the microcirculation, and thus elevated lactate levels could be associated 
with adverse outcomes.  If a perfusion difference at microcirculatory level exists between on- and 
off-pump CABG techniques, this might be detected by elevated lactate levels in the affected group. 
In the debate about advantages of either technique, this might be important in selecting a specific 
approach for a specific individual. 
Secondly, increased lactate production may be stimulated irrespective of tissue oxygenation, as a 
response to inflammatory mediators or through other mechanisms related to metabolic 
derangements.   
Thirdly, when pulsatile flow is converted to laminar flow in patients during CPB, a redistribution 
of blood flow occurs to maintain perfusion of vital organs.  Therefore, consequent mismatch of O2 
supply and demand and ineffective O2 extraction occurs due to the alterations of blood flow.  
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Redistribution of blood flow can also alter regional metabolic pathways resulting in muscle tissue 
becoming a lactate producer.  This might have an impact on patient outcomes. 
After reviewing the literature, a number of assumptions were made: 
1. Post-operative lactate levels and rate of clearance may be associated with morbidity and 
mortality as was seen by Lindsay et al., (2013) and Yilmaz et al., (2011). 
2. Mean lactate levels during the first 6-12 hours of ICU admission may have a predictive 
ability as was found by Hajjar et al., (2013) and McNelis et al., (2001). 
3. A lactate value >5 mmol/l may provide clinicians with an early indication of a patient’s 
likelihood of experiencing various post-operative complications as was found by Munoz 
et al., (2000) and Hajjar et al., (2013). 
 
This study was divided into two sections: 
1. Is there a difference in perfusion detectable by elevated circulating lactate between on 
and off pump coronary artery bypass surgery in comparable groups of patients? 
2. Can an intra-operative peak value of lactate (in our case >5mmol/L) predict a higher 
incidence of complications and adverse outcomes in CABG patients (irrespective of 
whether the patient was done on- or off-pump)?   
 
5.2 On-Pump vs. Off-Pump CABG 
5.2.1 Pre-operative Demographic and Clinical Data 
 
Sixty patients (median age on-pump group 58 years and off-pump group, 61 years) met the 
inclusion criteria of the study and were divided into two groups (30 patients’ on-pump and 30 
patients’ off-pump).  Both groups were predominantly male [on-pump 27 (90%) and off-pump 
23 (77%)] as is seen in most CAD studies (Konety, et al., 2005) (Figure 4.2).  The patients in the 
on-pump and off-pump groups were considered similar regarding risk factors and co-morbidities 
with EuroSCOREs of 7.1 for the on-pump group and 6.3 for the off-pump group.  On-pump patients 
had a BMI of 31.0 kg/m2 compared to the off-pump patients with a BMI of 32.8 kg/m2 but this 
difference was not statistically significant (p>0.05) (Table 4.1).   
There was a difference between the groups with respect to the number of pre-operative acute 
MI’s (p <0.05) and last previous MI upon admission to Cardiology (p <0.05) (Table 4.2).  In the 
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on-pump CABG group 14 (47%) of patients had a MI less than 6 hours prior to admission to 
Cardiology compared to the 5 (17%) in the off-pump CABG group.  A large number of last previous 
MI was unknown and thus the difference between the groups may not be that notable.  Secondly, 
this data was only for admission prior to cardiology and cardiac surgery was done at a later stage.  
Thus, pre-operative MI may have little impact on late survival.   
Essentially, the study groups were considered similar in nature for the purpose of the study.   
 
5.2.2 Intra-operative Metabolic Data: On-pump vs. Off-
pump 
 
The metabolic and clinical changes observed in the on- and off-pump CABG groups were 
compared by reviewing the patients’ intra-operative metabolic data reflected in Table 4.3 and 4.4.  
The difference noted for pO2 and pCO2, between the on-pump group and off-pump group, was to 
be expected due to the O2 concentrations obtained with routine CPB (Figure 4.4).  Compared to 
mechanical ventilation, at 40% O2, during off-pump CABG surgery.   
pH in the off-pump group was lower throughout a large part of surgery and correlates with HCO3- 
and BE also being lower in the off-pump group (Figure 4.4), but pH, HCO3- and BE did not correlate 
with the lactate data for the off-pump group.   
Statistically significant differences between the on-pump and off-pump group for HCO3- and  
BE (B) were shown in (Table 4.5).  Although values for acid-base variables were lower in the on-
pump group they still remained within normal reference ranges.   
Hemoglobin was lower in the on-pump group compared to the off-pump group (Figure 4.5).  
However, this is ascribed to the hemodilution seen during the on-pump surgical technique used.   
Electrolyte data and glucose did not reveal any trends or statistically significant differences 
between the two groups.  The electrolyte data (Table 4.5 and Figure 4.6) remained within normal 
reference ranges as was found by Maasoumi et al., (2013).   
12 patients in the on-pump group and 11 patients in the off-pump group had intra-operative 
lactate levels >5 mmol/L.  With respect to number of patients with lactate >5mmol/L, no 
difference could be demonstrated between the on-pump and off-pump groups.  However, the 
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median values of lactate between the on-pump and off-pump group did show that the lactate 
levels were higher in the on-pump group with a statistical significant differences (p<0.05).   
In order to understand the statistical differences seen for the on-pump group we need to look at 
the following literature:   
 During on pump cardiac surgery, pulsatile flow is changed to a relative laminar pattern.  
This causes peripheral vasoconstriction and decreased peripheral tissue energy 
production (Pojar et al., 2008).  Further, hypoperfusion of the intestinal mucosa also 
stimulates divergence of oxygen away from the splanchnic vascular bed, and results in a 
raised hepatic lactate production (Chiolero et al., 2000). 
 In addition, peripheral vasoconstriction associated with CPB causes a redistribution of 
circulating blood volume to vital organs compromising the microcirculation.  This 
phenomenon is associated with peripheral arteriovenous shunting (Trzeciak et al., 2005), 
resulting in decreased perfusion to skeletal muscles, which are an important lactate 
oxidizer.  Further, decreased perfusion of skeletal muscle might even result in lactate 
production (Chiolero et al., 2000).   
 Hemodilution during CPB reduces perfusion pressure and reduces the oxygen carrying 
capacity of blood.  In combination with the leftward shift of oxygen hemoglobin 
dissociation induced by hypothermia, this might limit oxygen delivery to cells (Scaravilli 
et al., 2012).   
 Hypothermia contributes to vasoconstriction leading to further hypo-perfusion at 
microcirculatory level and decreased splanchnic perfusion.   
 
All of these derangements contribute to increased lactate levels seen in the on-pump group even 
in the presence of normal oxygenation and circulation as seen from the data collected as was seen 
by Jones et al., (2009).   
Hypothetically, pulsatile flow, regional blood flow autoregulation and oxygen delivery remain 
“intact” during off-pump CABG and thus lactate levels are normal, or are at least, less affected by 
the surgical trauma.   
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5.2.3 Intra-operative Hemodynamic Data: On-pump vs. 
Off-pump GABG Groups 
 
During both on-pump and off-pump CABG surgery hemodynamic changes were seen with 
statistically significant differences (Table 4.9) noted for systolic pressures, diastolic pressures 
and mean arterial pressures (p<0.05) for most of the surgery duration.  Figure 4.7 indicates a 
trend where hemodynamic variables were lower in the on-pump group which would be expected 
considering the surgical technique used (on-pump non-pulsatile flow versus off-pump with 
maintained pulsatile flow). 
The hemodynamic differences between the on-pump and off-pump groups merely reflect the 
nature of CPB flow versus pulsatile flow.   
 
5.2.4 Post-operative Metabolic Data: On-pump vs. Off-
pump CABG Groups 
 
Post-operative metabolic data were summarized for up to 72 hrs after admission to the ICU for 
the on-pump and off-pump surgery groups in Table 4.10 and Table 4.11, respectively.   
There were no statistically significant (p>0.05) differences or trends for pO2 and pCO2, between 
the two groups (Figure 4.8 and Table 4.12).  pH, HCO3- and BE (B), were lower in the on-pump 
group (Figure 4.8) and showed statistically significant differences (p<0.05) between the on-pump 
and off-pump CABG groups from admission to ICU until 4 hours post-operatively (Table 4.12).   
O2 Sat (%) and tHb, showed no statistically significant differences (p>0.05).   
The median tHb was lower for the off-pump group than for the on-pump group (Figure 4.9).  This 
could be attributed to the autotransfused blood or donor blood given to the on-pump patients 
after termination of CPB.   
Electrolytes, K+, Ca++, Na+ and Cl-, indicated no statistically significant differences (p>0.05) nor any 
differing trends (Figure 4.10 and Table 4.12).   
Glucose levels and lactate levels showed statistically significant differences (p<0.05) from 
admission to ICU up to 12 hours post-operatively (Table 4.12).  The lactate values for the on-
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pump group were significantly higher than the off-pump lactate values during the immediate 
post-operative period (p<0.05) (Table 4.12).   
According to literature patients not recovering to a lactate level of <2mmol/L within 24 hours 
post-operatively are associated with increased 60-day mortality as confirmed by van Beest et al., 
(2013).  Both groups recovered to <2mmol/L by the 24th hour post-operatively.  No other 
discrepancies were seen in the remaining metabolic data.   
As is discussed in literature, pulsatile flow is converted to laminar flow during on-pump CABG.  
This allows for vasoconstriction and a redistribution of blood flow away from the peripheral 
tissue and the splanchnic circulation.  Hypothermia during CPB further contributes to 
vasoconstriction.   
We postulate that, with decreased splanchnic circulation and peripheral tissue/muscle perfusion, 
a buildup of lactate in the tissue occurs.  During the post-operative period the on-pump group 
tends to have a washout of lactate.  Post-operatively all of the factors contributing to decreased 
blood flow to non-vital organs are eliminated as the patient is returned to normo-thermic 
temperatures and pulsatile flow is returned, which allows for peripheral tissue and the gut 
mucosa to be perfused again.  Therefore, a washout of lactate from previously hypo-perfused 
tissues is seen with the return of pulsatile flow.   
As expected, increased glucose levels were evident during the post-operative period in both 
groups which correlates with increased lactate levels due to the metabolic response to surgery 
and confirmed by Burton et al., (2004).  Increased levels of glucose may serve as an early warning 
sign of metabolic imbalances that may arise due to surgery or due to post-operative complications 
(Anderson et al., 2011). 
 
5.2.5 Clinical Outcomes/Complications 
 
One patient in the off-pump group presented with renal complications.  Blood transfusions were 
more frequent in the on-pump group, as published in several studies, (El Naggar et al., 2012 and 
Sellke et al., 2005) this is ascribed to the different surgical techniques that were used.   
The length of hospital stay and ventilation time were longer in the on-pump group but time spent 
in ICU was longer for the off-pump group (Table 4.13).  The shorter mechanical ventilation in off-
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pump patients was caused, at least partially, by differences in anesthetic technique as seen by van 
Dijk et al., (2001).   
Two patients from the off-pump group died and none from the on-pump group.  Both patients 
died due to sepsis.  The groups were similar with respect to pulmonary complications, atrial 
fibrillation and neurological complications.   
The overall peri-operative complication rate as well as the number of patients, in both on-pump 
and off-pump groups were low for patients undergoing CABG surgery.  Therefore, to make a 
distinct analysis, between the on-pump and off-pump groups, would be difficult.  The present 
study did not indicate whether or not off-pump CABG surgery could be preferred to on-pump 
CABG surgery.   
 
5.3 Lactate <5mmol/L vs. Lactate >5mmol/L 
5.3.1 Demographic and Clinical Data 
 
Sixty patients (median age 62 years for the lactate <5mmol/L and 57 years for the lactate 
>5mmol/L) were divided into two groups (lactate <5mmol/L vs. lactate >5mmol/L).  The patients 
in the lactate <5mmol/L vs. Lactate >5mmol/L groups were considered similar with respect to 
risk factors and co-morbidities with a EuroSCORE of 3.95 placing both groups in a medium risk 
group (EuroSCORE 3-5) for early mortality.   
The BMI was higher in the lactate >5mmol/L (Table 4.15) which may imply that overweight 
patients may have a bigger risk of hyperlactatemia.  Levy et al. (2005) stated that coronary flow 
is significantly lower in obese patients, and capillary recruitment is reduced in non-diabetic obese 
individuals compared with lean control subjects.  Obesity also appears to have an independent 
effect on microvascular function.  Several mechanisms have been identified by which obesity 
could cause microvascular abnormalities.  Amongst other mechanisms, deposits of fat around 
arterioles may be involved in local TNF-α signaling, resulting in impaired perfusion and insulin 
resistance.  The association between the perfusion of fatty tissue during CPB and a lactate 
washout seen during the return of pulsatile flow suggests that it remains more difficult to perfuse 
fatty tissue.   
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Clinical data were similar and comparable for the lactate <5mmol/L group and the lactate 
>5mmol/L group (Table 4.16)  
 
5.3.2 Intra-operative Metabolic Data: Lactate <5mmol/L 
vs. Lactate >5mmol/L 
 
Haterill et al. (1997), demonstrated patients with a lactate levels >6mmol/L during 
cardiopulmonary bypass had a significant sensitivity (78%) and specificity (83%) for mortality 
within 3 days.  Therefore, we decided to use a lactate value of 5mmol/L as the cut-off reference 
value.  Group 1 consisted of patients with lactate levels <5mmol/L irrespective of surgical 
technique and group 2 consisted of patients whose lactate levels were raised above 5mmol/L at 
any time during the intra- or post-operative period, irrespective of surgical technique used.   
The only statistical difference (p<0.05) in intra-operative metabolic data was for tHb at baseline 
and intubation (Table 4.19).  There was no difference in for the trends of haemoglobin and O2 Sat 
(%) levels between the two groups (Figure 4.13) suggesting a different mechanism to stimulate 
increased aerobic glucose metabolism in order to increase lactate levels in the absence of tissue 
hypoxia.   
Studies done by Levy et al. (2005) have shown that the activity of the Na+/K+ pump system, which 
requires significant amounts of ATP for its function, is related to increased lactate, in the absence 
of tissue hypoxia.  Such enhanced glycolysis can be triggered by cytokine-mediated uptake of 
glucose or catecholamine-stimulated increased Na-K-pump activity (Bakker et al., 2013) and 
according to literature we know that surgical patients have increased release of cytokines and 
catecholamine as an early response to tissue injury (Toft et al.,  2008).  Therefore, this 
phenomenon may be the trigger for increased levels of lactate, and it applies to both on and off 
pump surgical groups. 
All patients undergoing CABG surgery showed increased levels of glucose, and they were 
consistently and statistically significantly higher in the lactate >5mmol/L (Figure 4.13).  The 
difference in glucose levels for the two groups was also statistically significant (p<0.05) for most 
of the surgery (Table 4.19) and this difference correlates to the findings of a study done by Yilmaz 
et al. (2011).  Hyperlactatemia invariably accompanied hyperglycaemia due to the metabolic 
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response to surgical trauma, where the extra glucose fails to enter the oxidative metabolic 
pathway and is degraded to lactate.   
Data also indicated lower pH, HCO3-STD and BE(B) levels in the lactate >5mmol/L and these 
levels correlate to the trends and statistical significance (p<0.05) seen for lactate and glucose 
(Figure 4.12 and Table 4.18).  We postulate, that the increased lactate levels were not from 
respiratory acidosis, partly because metabolic data for pCO2 and pO2 were not only comparable 
for both groups but remained within normal reference ranges throughout the duration of hospital 
stay.  Confirming, indirectly, that hyperlactatemia may be caused by the metabolic response to 
surgery as well as changes in whole body perfusion.   
The trends for the electrolyte data were similar and the levels remained within normal reference 
ranges (Figure 4.14, Table 4.17 and Table 4.18), with no statistically significant differences 
observed (p>0.05) and correlates to the findings of a study done by Maasoumi et al., (2013).   
 
5.3.3 Intra-operative Hemodynamic Data: Lactate 
<5mmol/L vs. Lactate >5mmol/L 
 
Although the trends for systolic pressure, diastolic pressure and MAP (Figure 4.15), in the lactate 
<5mmol/L and lactate >5mmol/L were similar, statistically significant differences were noted 
(p<0.05) for all these variables throughout most of the surgery duration (Table 4.22).   
The statistically significant differences (p<0.05) in systolic pressures, diastolic pressures and 
MAP between the lactate <5mmol/L group and lactate >5mmol/L group could be due to the 
surgical technique used because a larger number patients from the on-pump group 11 (37.0%) 
had a lactate level of >5mmol/L vs. off-pump 6 (20.0%).   
Even though generally believed to be inadequate, MAP is frequently used as an important 
diagnostic tool for goal oriented therapy in patients with hemodynamic instability.  Low MAP 
leads to inadequate systemic perfusion and as a result depletion of high energy phosphates, 
cellular dysfunction and finally accumulation of waste products including lactate (Basaran et al., 
2006).   
CVP, HR and temperature were comparable for the groups and showed no statistical significance 
(p>0.05).   
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5.3.4 Post-operative Metabolic Data: Lactate <5mmol/L 
vs. Lactate >5mmol/L 
 
The metabolic data during the post-operative period (Figure 4.16) indicated a similar trends for 
the lactate groups with respect to all the acid-base variables and returned to normal reference 
ranges within the first 12 hours post-operatively and correlates to the findings of a study done by 
Munoz et al., (2000).   
Data indicated a lower HCO3-STD and BE (B) for the lactate >5mmol/L group which correlates to 
the increased lactate levels seen in this group.  As was previously mentioned, we speculate this 
correlation is due to the hyperchloremic acidosis and not due to alterations of O2 delivery and 
extraction at cellular level (Table 4.23 and Table 4.24).   
Although, lactate was statistically significantly higher (p<0.05) in the lactate >5mmol/L (Table 
4.25) it nonetheless returned to within normal reference values of <2mmol/L, by 24 hours post-
operatively (Figure 4.17) as was seen by McNelis et al., (2001).   
However, dynamic indices of lactate homeostasis, which describe not only magnitude but also 
duration and trend over time, may be even more useful in predicting outcome. 
The trends for both groups with respect to electrolytes were similar and remained within normal 
reference ranges (Figure 4.18), with no statistically significant differences (p>0.05) (Table 4.25) 
and correlates to the findings of a study done by Maasoumi et al., (2013).   
 
5.3.5 Clinical Outcomes / Complications: Lactate 
<5mmol/L vs. Lactate >5mmol/L 
 
From clinical data that was collected (Table 4.26) it was noted that two patients died in the lactate 
<5mmol/L group.  The proportions of other clinical outcomes such as re-operation due to post-
operative bleeding and pulmonary complications were similar for both groups.  None of the 
patients with a lactate of >5mmol/L had neurological- or renal complications.  There were two 
patients with a lactate of >5mmol/L that presented with atrial fibrillation and GIT complications.  
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There were no significant differences between the two groups with respect to ventilation time, 
hospital stay and ICU stay; therefore lactate concentrations do not seem to be of clinical use when 
predicting length of stay as was found by Lindsay et al., (2013) 
Two patients returned to theatre, one patient from each group.  Only one patient with a lactate of 
>5mmol/L was re-intubated.  One patient from each lactate group had pulmonary complications.   
In our study population, a value of >5mmol/L was not significantly related to more adverse events 
or complications.   
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Chapter 6  
Conclusion 
 
6.1 General 
 
Although the study population was relatively small, on-pump patients showed a tendency 
towards higher median lactate values.  This is in keeping with Pojar et al. (2008).  Lower, tHb.  
HCO3- and BE (B) values showed statistically significant differences between the on-pump 
(group 1) and off-pump groups and, according to Montassier et al. (2012), these variables are an 
accurate marker for the prediction of elevated lactate levels.  However, this phenomenon was 
not observed during this study.   
The absolute values for metabolic variables generally remained within normal reference ranges 
during the study for all patients.  Except for lactate values, which were elevated during on-pump 
and off-pump CABG surgery, and returned to within the normal range of <2mmol/L within 24 
hours post-operatively.   
A peak lactate levels >6 mmol/L is associated with mortality within 3 days with a sensitivity 
78% and specificity 83% (Haterill et al., 1997).  Therefore, we postulate that our peak lactate 
value of 5mmol/L is too low to see a correlation with clinical outcomes.   
Firstly, increased lactate levels could be due to type A lactic acidosis: 
Type A- results from an imbalance between tissue oxygen supply and demand due to ischemia, 
global hypoxia, respiratory failure, regional hypoperfusion and limb/mesenteric ischemia.  
Lactate production results from cellular metabolism of pyruvate into lactate under anaerobic 
conditions.  Therefore, type A is related to total O2 debt and the magnitude of tissue 
hypoperfusion.   
Cardiac surgery is characterised by dramatic changes in microvascular control with profound 
changes in cardiac output distribution.  This results in a redistribution of perfusion, with some 
tissues experiencing substantial decreased O2 transport while others are being over-perfused.  
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Therefore, an increase or change in lactate levels during the on-pump CABG surgery may be a 
marker of regional hypoperfusion due to the redistribution of blood flow.  This might be as a 
result of manipulation of the heart during off-pump surgery or due to the effect of CPB.   
Secondly, increased lactate levels could be due to type B lactic acidosis  
Type B lactic acidosis is due to delayed clearance of lactate, renal dysfunction, catecholamine 
release and accelerated aerobic glycolysis.  The metabolic response to surgery itself may impair 
oxygen delivery and extraction at cellular level.   
Assessing lactate levels at a single point in time did not correlate with clinical outcomes.  A cut-
off value of 5mmol/L for lactate levels is probably too low to show the association of 
hyperlactatemia as a predictor for clinical outcomes in this study.   
The duration and the time spent with elevated lactate levels are related to both morbidity and 
mortality (Bakker et al., 2013).  In this study, the time of exposure to high lactate levels, was not 
sustained for an extensive period.  In our practice, persistent increases in lactate levels 
>2.0mmol/L prompted perfusion and anaesthetic interventions.  These interventions limited 
the time spent at an elevated lactate level and may have been a limitation of the study.   
Coronary artery bypass surgery remains an established form of treatment for coronary artery 
disease.  According to the Hawkes et al. (2006) the overall mortality rate of coronary artery 
surgery is low, at around 2%–3%, although this benefit is offset by a complication rate of 20%–
30%.  Data obtained from the study indicated that our results lead to similar clinical outcomes, 
even in the group of patients that did spent some time, however limited, with lactate levels 
>5mmol/L.   
We conclude that the study showed a significant difference between the on-pump and off-pump 
group with respect to lactate levels.  The cut-off peak lactate level of >5mmol/L was too low to 
show a positive correlation with clinical outcomes.  A recovery period which describes not only 
magnitude but also duration and trend over time, may be even more useful in predicting 
outcome.   
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6.1.1 Limitations 
 
1. Prospective analytical cohort study. 
2. Small sample size. 
3. Insufficient number of patients with extended periods of impaired 
flow. 
4. Insufficient number of patients with complications. 
5. Non- standardization of cardioplegia solutions used during surgery.   
 
6.1.2 Recommendations 
 
1. Randomized trial. 
2. Increase study population. 
3. Increase peak lactate level to >10mmol/L. 
4. The evaluation and comparison of lactate levels over time by use of 
an “area under the curve” to summarize lactate exposure in patients. 
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Appendix A  
Informed Consent Forms 
 
AN EVALUATION AND COMPARISON OF METABOLIC AND CLINICAL CHANGES IN 
PATIENTS WITH ACCUTE CORONARY SYNDROMES UNDERGOING ON-PUMP AND OFF-
PUMP CORONARY ARTERY BYPASS SURGERY 
 
      Date: _____________________ 
 
CONSENT TO PARTICIPATE IN RESEARCH 
 
You have been asked to participate in a research study.  
 
You have been informed about the study by ………………………………………. .  
You received an information sheet which is a written summary of the research. 
 
You have been informed about any available compensation or medical treatment if injury occurs 
as a result of study-related procedures.  You may contact Prof FE Smit (082 774 1087) and Prof 
WMJ van Den Heever-Kriek (082 770 5356) at any time if you have questions about the 
research or if you are injured as a result of the research. 
 
You may contact the Secretariat of the Ethics Committee of the Faculty of Health Sciences, UFS at 
telephone number (051) 4052812 if you have questions about your rights as a research subject.  
Your participation in this research is voluntary, and you will not be penalized or lose benefits if 
you refuse to participate or decide to terminate participation.   
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If you agree to participate, you will be given a signed copy of this document. 
 
It has been explained to you, that by participating in this study, there is no additional medical 
risk to you other than those of the intervention which has been discussed with you by your 
Cardiologist or Cardiothoracic Surgeon. 
 
The research study (summarised for you in the information sheet), including the above 
information has also been verbally described to me.  I understand what my involvement in the 
study means and I voluntarily agree to participate.  
 
_____________________   __________________ 
Signature of Participant   Date 
 
 
_____________________   __________________ 
Signature of Witness    Date 
(Where applicable) 
 
 
_____________________   __________________ 
Signature of Translator   Date 
(Where applicable) 
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EVALIASIE EN VERGELYKING VAN METABOLIESE EN KLINIESE VERANDERINGE TUSSEN 
OP-POMP EN AF-POMP KORONêRE VAT OMLEIDINGS CHIRURGIE IN PATIENTE MET 
AKUTE KORONêRE SINDROOM. 
 
        Datum: _______________ 
 
TOESTEMMING TOT DEELNAME AAN NAVORSING 
 
U is versoek om aan ‘n navorsingsstudie deel te neem. 
 
U is oor die studie ingelig deur……………………………………………………….............. 
 
U het ‘n inligtingsdokument wat ‘n geskrewe opsomming van die navorsing is ontvang. 
 
U is ingelig oor die moontlike kompensasie en mediese behandeling wat sal intree indien 
komplikasies van u deelname aan die studie intree; 
 
U kan Prof FE Smit (082 774 1087 ) / Prof WMJ van Den Heever-Kriek  (082 770 5356) enige 
tyd kontak indien u vrae oor die navorsing het of as gevolg van die navorsing beseer is. 
 
U kan die Sekretariaat van die Etiekkomitee van die Fakulteit Gesondheidswetenskappe, UV by 
telefoonnommer (051) 405 2812 kontak indien u enige vrae het oor u regte as ‘n proefpersoon. 
 
U deelname aan hierdie navorsing is vrywillig, en u sal nie gepenaliseer word of voordele 
verbeur as u weier om deel te neem of besluit om deelname te staak nie. 
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As u instem om deel te neem, sal ‘n ondertekende kopie van hierdie dokument aan u gegee 
word. 
 
Dit is aan u verduidelik dat u deelname aan hierdie studie, buite die risiko’s van die chirurgiese 
intervensie soos bespreek met u deur u Kardioloog of Kardiotoraks-chirurg, geen addisionele 
mediese risiko’s inhou nie. 
Die navorsingstudie (opgesom in die inligtingsdokument), insluitende die bogenoemde inligting 
is ook verbaal aan my beskryf.  Ek begryp wat my betrokkenheid by die studie beteken.   
 
Ek verstaan ook dat my pasiënt inligting konfidensieel hanteer sal word en dat my deelname 
vrywillig is en ek teen enige tyd kan onttrek. 
 
_____________________________    _____________________ 
Handtekening van deelnemer     Datum 
 
_____________________________    _____________________ 
Getuie        Datum 
(Indien van toepassing) 
 
_____________________________    _____________________ 
Hantekening van Vertaler      Datum 
(Indien van toepassing) 
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Letsatsi: ____________ 
 
TUMELLO YA HO NKA KAROLO DIPATLISISONG 
 
O kopilwe ho nka karolo thutong ya dipatlisiso. 
 
O ile wa tsebiswa ka thuto ena ke ………………………………………………………………….. 
 
O ka nna wa ikopanya le Prof FE Smit (082 774 1087 ) / Prof WMJ van Den Heever-Kriek  (082 
770 5356) nako e nngwe le e nngwe ebang o nale dipotso mabapi le dipatlisiso kapa ebang o ka 
tswa kotsi ka baka la dipatlisiso. 
 
O ka nna wa ikopanya le Mongodi wa Ethics Committee ya Faculty of Health Sciences, UFS 
nomorong ya mohala ya (051) 4052812 ebang o nale dipotso ka ditokelo tsa hao jwaloka eo ho 
etswang dipatlisiso ka yena. 
 
Ho nka karolo ha hao dipatlisisong tsena ke boithaopong ba hao, mme o keke wa fumantshwa 
kotlo kapa wa lahlehelwa ke menyetla ya hao ebang o ka hana kapa wa nka qeto ya ho kgaotsa 
ka ho nka karolo. 
 
Ha o dumela ho nka karolo, o tla nehwa khopi e saennweng ya tokomane ena hammoho le 
leqhephe la ba nkang karolo e leng le ngotsweng kgutsufatso ya dipatlisiso. 
 
Thuto ya dipatlisiso ho kenyellwa lesedi le ngotsweng ka hodimo, di ile tsa hlaloswa ho nna ka 
molomo. 
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Ke utlwisisa hore ho nka karolo ha ka thutong ena ho bolelang.  Ke boetse ke utlwisisa hore 
tlhahiso leseding e mabapi le dintlha tse amang botho ba ka, e tla nkwa e le sephiri le hore ho 
nka karolo ha ka ke boithaopo le hore nka nna ka ikgula nako e nngwe le e nngwe. 
 
____________________     __________________ 
Tshaeno ya motho ya     Letsatsinkang karolo 
 
_____________________     __________________ 
Tshaeno ya mofetoledi    Letsats 
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Appendix B  
Information Leaflets 
 
AN EVALUATION AND COMPARISON OF METABOLIC AND CLINICAL CHANGES IN 
PATIENTS WITH ACUTE CORONARY SYNDROMES UNDERGOING ON-PUMP AND OFF-PUMP 
CORONARY ARTERY BYPASS SURGERY. (This master’s thesis was only a subsection of a 
research project, therefore the information leaflet contain all the information required for the 
parent study.) 
 
Dear Patient 
 
We, the department of Cardiothoracic Surgery and Cardiology, are doing research on 
endothelial function as a predictor of post intervention outcomes.  Research is just the process 
to learn the answer to a question.  In this study we want to learn if there is a difference in 
outcomes in patients presenting with acute coronary syndrome and those with worsening or 
chronic stable angina? 
 
Invitation to participate 
 
We are asking/inviting you to participate in a research study.  If you grant us permission you 
have to sign an informed consent form so that we have evidence that you were willing to 
participate in the research project. 
 
What is involved in the study? 
This is an uncontrolled longitudinal study.  Sixty patients with acute coronary syndrome (ACS) 
will be recruited from the Cardiology clinic for participation. This study will commence on the 
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18th of June 2007 and is expected to continue until the 31st of July 2008. Due to the fact that 
every test performed except the oximetry and atherosclerotic measurements is routine practice 
for a patient with ACS the patient won’t be subjected to numerous amounts of tests. 
The following tests will be performed: 
A) Physical Examination 
After a confirmed diagnosis of acute coronary syndrome and granted consent a complete 
medical history and physical examination will be performed by a qualified medical doctor 
located at cardiothoracic surgery (Routine practice for ACS). 
B) Cardiology evaluation 
The patient will be submitted for a cardiac echocardiogram and an angiogram at the catheter 
lab on the second floor, Universitas Hospital.  (Routine practice for ACS). 
C) Arterial blood gas analysis  
Arterial blood gas analysis will be performed by sampling whole blood in a pre-heparanized 
syringe from an indwelling radial artery catheter before induction of anaesthesia. (Routine 
practice for ACS). 
D) Oximetry measurements 
The oximetry measurements are non-invasive measurements of regional oxygen saturation 
in the blood.  These measurements will be taken either in the catheter lab or in theatre during 
the surgical procedures and the patients will therefore not experience any discomfort.  
SomaSensors (small round stickers) will be placed on the forehead and on the back of the 
patient to detect the oxygen saturation.  The SomaSensors is linked to an electronic machine 
which will register the readings. 
 
Risks 
 
The research project is very safe.  All the procedures are non-invasive and no adverse effects are 
predicted.  Patients participating in this study will be well monitored and can at any time 
discontinue participation in the study.  The study will be discontinued prematurely if the 
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researcher or any of the study leaders feels that a patient’s confidentiality might be breached or 
if any unethical procedures occur. 
Benefits 
 
We know that SIRS mediators are activated in the endothelium and that this response can be 
abnormal in atherosclerosis.  It is also known that medical treatment with statins and ACE 
inhibitors modifies this response and can improve or normalise endothelial function. SIRS 
occurs more often post –intervention in some patients (e.g. metabolic syndrome, patients with 
pre-op elevated TNF, microalbuminuria). Outcomes in inflammatory markers and clinical SIRS 
might differ between on-pump and off-pump CABG. 
If we can correlate the pre-intervention endothelial function to outcomes in two different 
settings (stable angina and acute coronary syndrome) we might be able to develop a rational 
approach to intervention and choice of intervention. 
Your participation will enable us to attempt to try and identify a relationship between clinical 
data, blood tests and endothelial function/atherosclerosis load will be made. 
 
Participation is voluntary 
 
Refusal to participate will involve no penalty or loss of benefits to which the subject is otherwise 
entitled; the subject may discontinue participation at any time without penalty or loss of 
benefits to which the subject is otherwise entitled.  
 
Confidentiality 
 
Efforts will be made to keep personal information confidential.  Absolute confidentiality cannot 
be guaranteed.  Personal information may be disclosed if required by law.  Organizations that 
may inspect and/or copy your research records for quality assurance and data analysis include 
groups such as the Ethics Committee for Medical Research and the Medicines Control Council. 
If results are published, this may lead to individual/cohort identification.  
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Contact details of researcher(s) – for further information/reporting of study-related adverse 
events. 
 
a) Prof FE Smit 
 Head:  Department Cardiothoracic Surgery 
 UFS 
 Cell: 082 774 1087 
 
b) Prof WMJ van den Heever-Kriek 
 Associate Professor 
 CUT 
 Cell: 082 770 5356 
 
Contact details of REC Secretariat and Chair – for reporting of complaints/problems. 
 
a) Prof BB Hoek 
 Chairman:  Ethical Committee 
 UFS 
 Phone:  051 405 3177 
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INLIGTINGSDOKUMENT 
 
EVALIASIE EN VERGELYKING VAN METABOLIESE EN KLINIESE VERANDERINGE TUSSEN 
OP-POMP EN AF-POMP KORONêRE VAT OMLEIDINGS CHIRURGIE IN PATIENTE MET 
AKUTE KORONêRE SINDROOM. 
 
Beste Pasiënt 
 
Ons, die Departement Kardiotorakschirurgie, is besig om navorsing oor endoteel funksie as ‘n 
voorspeller van post intervensie uitkomste in koronêre siekte te doen.  Navorsing is slegs die 
proses waardeur die antwoord op ‘n vraagstuk verkry word.  In hierdie studie wil ons leer of 
daar `n verskil is in die uitkomste van pasiënte wat presenteer met akute koronêre sindroom en 
die met verskwakkende of chroniese stabiele angina? 
 
Uitnodiging om deel te neem 
 
Ons versoek/nooi u uit om aan die navorsingstudie deel te neem.  Indien u aan ons toestemming 
verleen moet u `n toestemmingsvorm teken sodat ons `n bewys het dat u gewillig was om aan 
die studie deel te neem. 
 
Wat behels die studie 
 
Hierdie in `n ongekontrolleerde longitudinale studie.  Sestig pasiënte met akute koronêre 
sindroom (AKS) sal gewerf word vanaf die Kardiologie kliniek vir deelname aan die studie.  
Hierdie studie sal begin op die 18de Junie 2007 en word verwag om voort te gaan tot op die 
31ste Julie 2008.  Al die toeste wat gedoen word, behalwe vir die aterosklerotiese evaluasie en 
oksimetrie lesings, is roetiene toetse vir `n pasiënte met AKS.  Die pasiënt sal dus nie 
onderworpe wees aan groot hoeveelhede toetse nie. 
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Die volgende toetse sal uitgevoer word: 
A) Fisiese ondersoek 
 
Nadat `n bevestigde diagnose van akute koronêre sindroom en toestemming van die die pasiënt 
sal `n volledige mediese geskiedenis en fisiese ondersoek gedoen word deur `n gekwalifiseerde 
mediese dokter by kardiotorakschirurgie.  (Roetiene prakryk vir AKS). 
B) Kardiologie evaluasie 
 
`n Kardiale echokardiogram en angiogram sal van die pasiënt geneem word in die kateter lab op 
die tweede vloer in Universitas Hospitaal.  (Roetiene prakryk vir AKS). 
C) Arterial blood gas analysis  
 
Arterial blood gas analysis will be performed by sampling whole blood in a pre-heparanized 
syringe from an indwelling radial artery catheter before induction of anaesthesia. (Routine 
practice for ACS). 
D) Oksimetrie metings 
 
Die oksimetrie metings is nie-indringende metings van suurstof saturasie in die bloed.    
Hierdie meetings sal in die kateter laboratorium of in die teater gedurende die chirurgiese 
prosedures geneem word en die pasiënt sal dus geen ongerief/ongemak ervaar nie.  
SomaSensors (klein ronde plakkertjies) word of die voorkop en die rug van die pasiënt geplak 
om die suurstof saturasievlakke te meet.  Hierdie plakkers is gekoppel aan ‘n elektronies 
masjien wat die lesings registreer.   
 
Risiko’s  
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Hierdie projek is baie veilig.  Al die prosedures is nie-indringend en geen nadelige gevolge word 
voorspel nie.  Pasiënte wat aan die studie deelneem sal gemonitor word en kan enige tyd 
onttrek vanuit die studie.  Die studie sal onmiddellik gestaak word indien die navorser of enige 
ander studieleier voel dat `n pasiënt se konfidensialiteit gebreek word of enige onetiese 
gebeurtenisse plaasvind. 
 
Voordele 
 
Ons weet dat SIRS middellaars geaktiveer word in die endoteel en dat hierdie respons 
abnormaal kan wees met aterosklerose.  Dit is ook bekend dat mediese behandeling met 
statiene en ACE inhibitors hierdie respons verander en dat dit endoteel funksie kan verbeter of 
normaliseer.  In sommige pasiënte vind SIRS meestal post-intervensie plaas (bv.  metaboliese 
sindroom, pasiënte met pre-operatiewe verhoogde TNF en mikroalbumienurie waardes).  Die 
kliniese uitkomste van SIRS gebasseer op inflammatoriese merkers mag verskil tussen KVO 
(met gebruik van die hart-long apparaat en daarsonder) en perkutane koronêre ingreep.  Indien 
`n korrelasie tussen pre-intervensie endoteel funksie en uitkomste in twee verskillende gevalle 
(stabiele angina en akute koronêre sindroom) getref kan word, kan dit ons instaat stel om `n 
rasionale benadering tot intervensie en keuse van intervensie te maak.   
U deelname sal ons instaat stel om te poog om die verhouding tussen kliniese data, bloedtoetse 
en endoteel funksie/aterosklerose lading te identifiseer. 
 
Deelname is vrywillig 
 
Weiering om deel te neem sal geen boete of verlies van voordele waarop die deelnemer 
andersins geregtig is behels nie; die proefpersoon kan te eniger tyd aan deelname onttrek 
sonder boete of verlies van voordele waarop die proefpersoon andersins geregtig is. 
 
Vertroulikheid 
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Daar sal gepoog word om persoonlike inligting vertroulik te hou.  Volkome vertroulikheid kan 
nie gewaarborg word nie.  Persoonlike inligting kan bekend gemaak word as die wet dit vereis.  
Organisasies wat u navorsingsrekords mag ondersoek en/of kopieer vir kwaliteitsversekering 
en data-analise sluit groepe soos die Etiekkomitee vir Mediese Navorsing en die 
Medisynebeheerraad in.  As resultate gepubliseer word kan dit lei tot 
individuele/groepsidentifikasie. 
 
Kontakbesonderhede van navorser(s)  
Vir verdere inligting/rapportering van studieverwante newe-effekte. 
 
a) Prof FE Smit 
 Hoof:  Departement Kardiotorakschirurgie 
 UV 
 Sel: 082 774 1087 
 
b) Prof WMJ van den Heever-Kriek 
 Mede-Professor 
 SUT 
 Sel: 082 770 5356 
 
Kontakbesonderhede van REC Voorsitter 
Vir raportering van klagtes/probleme 
 
a) Prof BB Hoek 
 Voorsitter:  Etiek komitee 
 UV 
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 Telefoon: 051 405 317 
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Appendix C  
Example of Data Collection Forms 
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Appendix D  
Adult STS Database 
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Appendix E  
STS Database Format 
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Appendix F 
Ethical Clearance 
 
 
